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Abstract
Amyloid-β (Aβ) metal interactions promote aggregation and produce reactive oxy-
gen species, hallmarks of Alzheimer’s disease (AD). Oligomerisation of Aβ has been
proposed to be modulated by copper and zinc ions. In environments of fast mo-
lecular turnover, such as the synaptic cleft, the kinetics of molecular interactions
are important. To assess the roles of Cu2+ and Zn2+ in the early molecular events
of AD, the kinetics of Aβ binding to both ions were determined. Metal binding
was monitored using the quenching of a fluorescent dye covalently linked to Aβ
by Cu2+, enabling measurements to be performed at physiologically relevant Aβ
concentrations.
The binding of monomeric Aβ to Cu2+ was nearly diffusion limited with a
lifetime of a few seconds. Two forms of Aβ ·Cu were found that interconverted,
and at least two further Cu2+ ions could bind. The protonated form of Aβ ·Cu was
capable of dimerisation. Cu2+ assisted dimerisation is two orders of magnitude
faster than without Cu2+. A metric was devised to measure the effectiveness of
the removal of Cu2+ from Aβ ·Cu by a ligand. The kinetics of Cu2+ binding to Aβ
pre-bound to GM1 micelles were similar to unbound Aβ, however GM1 micelles
protected the Aβ complex from Cu2+ binding ligands. Zn2+ binding to Aβ was two
orders of magnitude slower than Cu2+, with a lifetime of tens of milliseconds. The
binding of Zn2+ to Aβ ·Cu, was a further three orders of magnitude slower.
A reaction-diffusion simulation of the repeated release of neurometals into a
synaptic cleft suggested that Aβ ·Cu is two orders of magnitude more likely to form
than Aβ ·Zn under physiological conditions. This suggests that Cu2+ rather than
Zn2+ is responsible for the dimerisation of Aβ in the synaptic cleft.
The methodology applied here is applicable to determine the Cu2+ binding
kinetics of other peptides or proteins.
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Chapter 1
Introduction
Dementia is a decline in cognitive ability such that it interferes with daily life and a
growing global problem. The number of people worldwide estimated to be living
with dementia is 45 million people, and it is expected to increase to over 130 million
by 2050 [1]. In 2010 the cost of care was estimated to be USD 604 billion [2].
Of the dementias, Alzheimer’s disease is the most common form, making up
60 % to 80 % of cases [3] and is associated with being of older age [4]. In older adults,
dementia is the second most prevalent disease in contributing significantly to death
(13.6 %) [5]. Alzheimer’s disease begins 10 to 15 years before the symptoms become
apparent, and is characterised by abnormal levels of senile plaques and neurofib-
rillary tangles. Although there are drugs available that reduce the apparent effects
of Alzheimer’s disease, none exist that combat the cause, neither preventing nor
slowing continued progression of Alzheimer’s disease. The difficulty in developing
effective therapeutics comes in part from a lack of understanding of the disease
mechanism at a molecular scale and thus finding targets with which drugs can
interfere.
Currently the main hypothesis for the cause of Alzheimer’s disease is the amyloid
cascade hypothesis [6;7] (see Fig. 1.1). Central to the cascade is the thought that the
peptide known as Amyloid-β (Aβ), which is the main component in senile plaques,
is thought to be the main culprit in Alzheimer’s disease. However, monomeric Aβ
and Aβ in fibrils are not thought to be the cause of the neurotoxicity. Studies suggest
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Figure 1.1: The amyloid cascade hypothesis: APP (amyloid precursor protein)
is cleaved forming Amyloid-β (Aβ). Increase in the concentration of Aβ or an
increase in its rate of aggregation promotes aggregation to form plaques and soluble
oligomers. These are thought to result in synaptotoxicity and neurotoxicity stressing
the cell, resulting in dysfunction and death. Once enough of the brain’s neuronal
network is damaged, the patient exhibits dementia. Based upon [7].
that it is instead the small Aβ oligomers that are toxic [8]. Isolating the mechanism
of oligomer formation and the structure of toxic aggregates would provide targets
for drug development.
One explanation for the cause of the amyloid cascade hypothesis is the amyloid-
metal hypothesis. Metal ions are found at high concentrations in senile plaques, so
it is thought that metal ions bind to Aβ promoting oligomerisation and aggregation.
The binding of metal ions to Aβ may also produce reactive oxygen species, damaging
Aβ, proteins or lipids nearby.
This thesis investigates the amyloid-metal hypothesis, that neurometal ions
mediate the aggregation and toxicity in Alzheimer’s disease [9], by elucidating the
kinetic mechanism of the binding of metals to Aβ. Understanding the kinetics
of Aβ-metal interactions allows for the lifetime and formation of complexes to be
predicted in vivo. This can then be used to determine the probability of oligomers
forming and gives a basis system for their study.
1.1 Alzheimer’s disease
Alzheimer’s disease was first reported by Alois Alzheimer in 1907, when a patient
showed the characteristic symptoms of memory loss, neurofibrillary tangles (formed
from hyperphosphorylated tau protein) and miliary foci (senile plaques formed
from Aβ) [10;11], shown in figure 1.2.
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[12]
Figure 1.2: Tissue from the hippocampal region of the brain, stained brown for
tau protein. The triangular-like structures are neurofibrillary tangles, formed from
the tau protein, inside neurons. The large less dense roundish structures are senile
plaques formed from Aβ. Reproduced with permission from Prof. Nigel J. Cairns,
Washington University School of Medicine [12].
The criteria for the clinical diagnosis of Alzheimer’s disease were established in
1984 [13] and have since been updated in 2011 [14]. The main issue in the diagnosis
of Alzheimer’s disease is differentiating it from other forms of dementia, which have
similar symptoms, but a different underlying biological cause.
The progression of Alzheimer’s disease is separated into three phases: preclinical,
mild cognitive impairment (MCI), and full Alzheimer’s disease. However, these are
part of a continuum and not clear cut.
The preclinical stage (before apparent symptoms) is thought to begin one to
two decades before the diagnosis of Alzheimer’s disease [15;16]. This is because the
characteristic features of Alzheimer’s disease, such as memory loss, only occur once
sufficient neuronal matter is destroyed by the disease. This complicates drug trials
for a cure for Alzheimer’s disease, as once it is diagnosed it may already be too
late to reverse the changes, i.e. the irreversibly damaged neurons. It is therefore
important to understand the initial stages of Alzheimer’s disease, so that effective
therapeutics can be developed.
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1.1.1 Diagnosis and Symptoms
For a diagnosis of Alzheimer’s disease [14] the clinical criteria of ‘all-cause dementia’
must be met, with a set of further criteria for the three classifications of dementia
caused by Alzheimer’s disease. They are (1) Probable Alzheimer’s disease dementia,
(2) Possible Alzheimer’s disease dementia, and (3) Probable or possible Alzhei-
mer’s disease dementia with evidence of the Alzheimer’s disease pathophysiological
process∗.
All-cause dementia A summary of the criteria for diagnosis are:
1. Interference with function at work or usual activities.
2. A decline from previous performance levels and function.
3. When not explained by delirium or major psychiatric disorder.
4. A detectable and diagnosed cognitive impairment.
5. A cognitive or behavioral impairment of at least two of:
(a) Acquiring and remembering new information.
(b) Reasoning and handling of complex tasks.
(c) Visuospatial abilities.
(d) Language functions.
(e) Changes in personality or behavior.
For the exact criteria, see reference [14].
Probable Alzheimer’s disease Here all the ‘all-cause dementia’ criteria are met
with, and the following criteria (summary):
1. Gradual onset over months to years.
2. Clear cut history of worsening cognition.
3. The first and most prominent deficits are of either category:
(a) Amnestic presentation: Impairment in learning and recall of recently
learned information. With further evidence of cognitive dysfunction in
at least one other cognitive domain.
∗The third classification is only for research purposes, not clinical diagnosis.
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(b) Nonamnestic presentations: Deficits in one of the following, with further
deficits in other cognitive domains:
• Language
• Visuospatial
• Executive
4. Diagnosis should not be applied when there is evidence of:
(a) Cognitive impairment from a cerebrovascular disease, such as a stroke.
(b) Features of Lewy body dementia (excluding dementia itself).
(c) Features of frontotemporal dementia.
(d) Prominent features of semantic or nonfluent/agrammatic variants of
primary progressive aphasia.
(e) Evidence of another disease or medication that could substantially effect
cognition.
The diagnosis can be made with increased certainty when there is evidence of
a causative genetic mutation (i.e. in amyloid precursor protein, presenilin-1, or
presenilin-2).
Carrying the ϵ4 allele of the apolipoprotein E gene, was explicitly excluded from
this list as it was not sufficiently specific [17]. For the exact criteria, see reference [14].
Possible Alzheimer’s disease The diagnosis is made if the disease follows an
atypical course, or there is mixed aetiology.
For a definitive diagnosis of Alzheimer’s disease, a histopathological examination
is required [18].
1.1.2 Treatments for the Symptoms of Alzheimer’s Disease
There are currently four∗ drugs approved in the US to temporarily slow the worsen-
ing of the symptoms of Alzheimer’s disease thus improving the quality of life. There
are three cholinesterase inhibitors (donepezil, galantamine and rivastigmine), and
∗The drug tacrine, a cholinesterase inhibitor, has been discontinued.
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one NMDA (N-methyl-D-aspartate) receptor antagonist (memantine) [19]. Both these
categories affect the communication between neurons via synaptic proteins.
Cholinesterase inhibitors Acetylcholine (ACh) is a neurotransmitter, released
into the synaptic cleft during neurotransmission. In Alzheimer’s disease its receptors
(alpha-4 beta-2 nicotinic receptors), which has been implicated in learning [20], are
impaired [21]. The cholinesterase enzymes in the synapse break down the ACh.
The method of action of the drug is to inhibit the enzymes that break down ACh,
increasing the activity of the ACh receptors.
NMDA receptor antagonists NMDA receptors are activated by the neurotrans-
mitter glutamate. However, in Alzheimer’s disease abnormally prolonged release of
glutamate causes excitotoxicity, resulting in the death of neurons [22]. Unlike ACh,
there are no enzymes in the synapse to degrade glutamate [23]. Thus the mechanism
of action of NMDA receptor antagonists is thought to be to protect neurons from
damage, by inhibiting the response of NMDA receptors.
1.1.3 Progression of Alzheimer’s Disease Pathology
Alzheimer’s disease is thought to begin one to two decades before cognitive impair-
ment shows [15]. There are five well established biomarkers for Alzheimer’s disease:
1. Decrease in CSF (cerebrospinal fluid) Aβ42 concentration.
2. Increase in PET (positron emission tomography) imaging of amyloid.
3. Increased CSF concentrations of tau and phosphorylated tau.
4. Hypometabolism on fluorodeoxyglucose (a fluorescent glucose analog).
5. Atrophy on structural MRI, showing large scale neuronal loss.
This list also corresponds to the hypothesised temporal ordering of biomarkers in
patients [24] (see Fig. 1.3). This suggests that in order to understand the cause of
Alzheimer’s disease, the cause of the decrease in Aβ42 and increase in larger amyloid
structures should be investigated from their formation as small oligomers.
The second category of biomarker change is the increase in tau proteins. The Aβ
and tau proteins are the basis for the two main hypotheses for Alzheimer’s disease.
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Figure 1.3: Model of the dynamics of biomarkers in the Alzheimer’s disease patho-
logical cascade. Reprinted from The Lancet, 12, Clifford R Jack, et al., Tracking
pathophysiological processes in Alzheimer’s disease: an updated hypothetical model
of dynamic biomarkers, 207-216, 2013, with permission from Elsevier. [24]
1.1.4 Alzheimer’s Disease Hypotheses
Alzheimer’s disease is caused by the atrophy of neuronal matter. Once sufficient
matter is destroyed, then the clinical symptoms occur. However, the underlying
disease mechanism of the atrophy is unknown. The hypotheses fall broadly into two
main categories, the amyloid hypothesis (related to the aggregation of Aβ) and the
tau hypothesis (related to the aggregation of tau proteins). Better understanding of
the cause of aggregation may allow the underlying cause of Alzheimer’s disease to
be determined and for the development of therapeutics to combat it. [25]
Tau Hypothesis
The purpose of tau proteins in healthy cells are to stabilise microtubules which form
the cell’s cytoskeleton. The binding of tau to microtubules is controlled in the cell
by their phosphorilation state. Phosphorilation of tau causes decreased association
with the microtubules. There is redundancy in this stabilisation mechanism, in that
two other proteins are known to also stabilise microtubules (MAP1 & MAP2). In
Alzheimer’s disease, the tau proteins become hyperphosphorylated, becoming less
soluble and aggregate forming neurofibrillary tangles within cells. [26] It is thought
that tau oligomers are more toxic than the tau in filaments. Filaments themselves
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may be considered protective, as they sequester tau oligomers. However, the loss in
microtubules independently burdens the cell. [26;27] It has been proposed that the
tau mediates Aβ toxicity [28] and vice versa [29].
Amyloid Hypothesis
The amyloid cascade hypothesis [6;30–32] is a sequence of events in the development
of Alzheimer’s disease which are:
1. Increase in levels of Aβ, possibly through over production, reduced clearance,
or increased aggregation propensity of Aβ (mechanism unknown).
2. Oligomerisation, aggregation and deposition of Aβ (mechanism unknown).
3. Aggregate stress (mechanism unknown).
4. Formation of neurofibrillary tangles (mechanism unknown).
5. Neuronal dysfunction and death (mechanism unknown).
6. Alzheimer’s disease caused by loss of neuronal matter.
There are multiple hypotheses for all the ‘unknown mechanisms’ of the amyloid
hypothesis. More recently there has been a consensus towards the toxicity being
in some way related to Aβ oligomers. The Aβ related hypotheses seem to suggest
that it is not Aβ itself that is neurotoxic. Therefore, this thesis works towards
the end goal to gain an understanding of how the initial oligomerisation process
occurs, starting with how dimerisation can occur. The hypothesis of aggregation
investigated is the metal-amyloid hypothesis, which suggests that it is metal cations
that are responsible for the dimerisation and aggregation of Aβ.
1.2 Amyloid-β
Aβ mainly exists in two major forms Aβ40 & Aβ42, having 40 and 42 amino acid
residues, respectively. The production of Aβ occurs widely in the body by most
cell types [33]. In neurons Aβ is released into the extracellular space at a rate of 2
to 4 Aβ molecules per neuron per second [34]. In Alzheimer’s disease patients, the
concentrations of Aβ have been found to be in the low nanomolar regime, in the
cerebrospinal fluid (CSF) and tens of picomolar in the blood plasma (see table 1.1).
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Aβ42 is thought to be more related to neurotoxicity than Aβ40.
Control MCI AD
Sample size 18 29 39
CSF Aβ40 / nm 1.4(5) 1.6(7) 1.4(5)
CSF Aβ42 / nm 0.20(8) 0.2(1) 0.12(6)
Plasma Aβ40 / pm 60(20) 60(20) 60(10)
Plasma Aβ42 / pm 30(30) 20(10) 20(20)
Table 1.1: Levels of Aβ40 & Aβ42 in the cerebrospinal fluid (CSF) and blood plasma
for cognitively healthy patients (Control), mild cognitive impairment (MCI), and
Alzheimer’s disease (AD) patients. [35]
Other than in Alzheimer’s disease, Aβ has been seen to accumulate in inclusion-
body myositis, an inflammatory muscle disease leading to muscular degenera-
tion [36;37].
1.2.1 Production of Amyloid-β
Aβ is produced by the cleavage of the amyloid precursor protein (APP) by β-secretase
(BACE-1), γ-secretase and ϵ-secretase producing varying lengths of Aβ’s [38;39]. Al-
ternatively, APP can be cleaved by α-secretase to produce p3 (Aβ17–40/42). The
cleavage occurs within the Aβ region of APP which prevents Aβ from being pro-
duced [40;41]. Figure 1.4 shows an overview of the process.
APP is a transmembrane protein of mass 110 kDa to 135 kDa. The variations
in mass arise from alternative splicing and post-translational modifications. Al-
ternative splicing produces mainly three different APP’s (695, 751 & 770 amino
acids) [42].
The first cleavage is by β-secretase between met596 and asp597 [43]. The cleavage
is external to the cell’s plasma membrane to which β-secretase is bound [44]. It is this
cleavage from which Aβ gets its name.
The second cleavage is by ϵ-secretase which produces two lengths of Aβ, 48 &
49 residues in length [39;45].
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Figure 1.4: The production of Aβ and p3 from the cleavage of the amyloid precursor
protein (APP), by β-secretase (BACE-1), γ-secretase and α-secretase. Reproduced
with permission from Henry W. Querfurth, M.D., Ph.D., and Frank M. LaFerla,
Ph.D. N Engl J Med 2010; 362:329-344, Copyright Massachusetts Medical Society.
Finally, Aβ48/49 is cleaved successively by γ-secretase, releasing tripeptides, i.e.
Aβ49 -itl Aβ46 -viv Aβ43 -iat Aβ40 (1.1)
to produce Aβ40, and
Aβ48 -vit Aβ45 -tvi Aβ42 (1.2)
to produce Aβ42 [39]. γ-secretase is membrane bound and the cleavage occurs within
the membrane [46]. This suggests that longer variants of Aβ may exist on the mem-
brane, and only when sufficiently short can they detach into the CSF (Cerebrospinal
fluid). It is possible that these are involved in the initial aggregation.
Alternatively, α-secretase (ADAM10) can cut the APP within the Aβ region,
producing p3 [41]. The cleavage occurs between lys16 and leu17 in the Aβ region [47].
1.2.2 Transport of Amyloid-β
Aβ may be moved across the blood brain barrier by Aβ-pumps, such as ABCB1 (ATP
(Adenosine triphosphatebinding) binding cassette (ABC), subfamily B, number
1) [48]. Whether toxic oligomers form in the brain or elsewhere, such as the muscles
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(as in sporadic inclusion-body myositis) and then act as a template for their further
production in the brain is an open question.
Studies have shown that neurons may internalise Aβ using various lipid raft
associated receptors [49].
1.2.3 Structure of Amyloid-β
Aβ is peptide, typically of 40 or 42 amino acids in length and is thought to be the
culprit in Alzheimer’s disease. The primary structure of Aβ is shown in table 1.2.
The amino acids are joined by peptide bonds forming the backbone, with the
Table 1.2: The primary structure of Aβ40 & Aβ42. Colour scheme: AGILPV - Amino
acids with non-polar sidechains, FYW - Aromatic amino acids, CM - Sulfur contain-
ing amino acids, DENQRHSTK - Amino acids with polar sidechains (the charged
residues are denoted with + or −, respectively.
1 5 10 15
asp− ala glu− phe arg+ his asp− ser gly tyr glu− val his his gln
16 20 25 30
lys+ leu val phe phe ala glu− asp− val gly ser asn lys+ gly ala
31 35 40 (41 42)
ile ile gly leu met val gly gly val val (ile ala)
sidechains determining the amino acid’s properties. Aβ40 has a mass of 4330.9 Da,
and Aβ42 of 4515.1 Da. In solution, Aβ has a hydrodynamic radius of 0.9(1) nm [50].
In aqueous solution (pH 7), the majority of the Aβ is found to have a median
net electrostatic charge of −3 e, however there is further evidence for a −4 e charged
state and a very small population of Aβ in a −2 e charged state [51].
Aβ has three histidines (his6, his13 & his14) which are good ligands for binding
Cu2+. The acid dissociation constant (p𝐾a) of histidine is approximately 6. When
Cu2+ binds to amino acids, it has the effect of lowering the p𝐾a of a nearby amide
group into physiological range [52].
Aβ has one tyrosine (tyr) with an absorbance of 1280 cm−1m−1 at 280 nm. The
tyrosine absorbance may be used to quantify the amount of the peptide for experi-
ments.
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Of the two most common forms of Aβ, Aβ42 has been found to be more neur-
otoxic and aggregate more rapidly [53]. Aβ42 contains two extra C-terminal amino
acids isoleucine (ile) and alanine (ala) which make the peptide more hydrophobic [8].
Aβ43 has a further polar C-terminal threonine (thr) and has been found to have a
even higher propensity to aggregate and to be more neurotoxic than Aβ42 [54].
Aβ40 has been shown to precipitate in vitro, for concentrations greater than
14 µm [55], therefore the concentration for oligomerisation is less than this value.
Secondary & Tertiary Structure
In aqueous solution Aβ is thought to be mostly unstructured, in a flexible collapsed
coil [50].
A structure has also been found by NMR (nuclear magnetic resonance) when
in an aqueous solution of fluorinated alcohols [56]. Figure 1.5 shows there are two
[56]
Figure 1.5: Conformation of Aβ42 in an aqueous solution of fluorinated alcohols
from the Protein Data Bank (PDB). The thicker red part shows the α-helix structure.
The N-terminus is on the right of the diagram. (PDB ID: 1IYT)
α-helical regions, linked by a more flexible region between them (approximately
residues 27 to 29). This causes the side chains to point away from the core of the helix.
The main differences between the NMR structures found were small fluctuations in
the angle between the helical sections and the positions of the ends of the peptide
chain. They were both quite varied suggesting that they are unaffected by structural
interactions. The aqueous fluorinated alcohol solution was chosen such that Aβ
would adopt the helical structure and so may not reflect in vivo conditions [56]. Aβ
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in membranes is also thought to be in an α-helical conformation [57]. In amyloid
plaques it has a β-sheet conformation. Within a membrane, conformational change
may be difficult as the hydrogen bonds that hold the core α-helix shape would need
to be broken in the apolar environment of the membrane.
Quaternary Structure
Fibrils NMR has been used to find the to structure of Aβ fibrils (see Fig. 1.6, in
vitro). Aβ is layered in a β-sheet formation. There are two β-sheet regions, residues
(a) Coloured by β-sheet or loop (b) Coloured by Aβ monomer [58]
Figure 1.6: Cross-section of Aβ42 in fibrils (residues 17 to 42). Residues 1 to 16
could not be located. The direction of the β-sheet arrows are from the N-terminus
to the C-terminus. (PDB ID: 2BEG)
18-26 and 31-42. The N-terminus (residues 1-16) could not be located using NMR
which suggests that they do not hold a relatively fixed position in space. The stagger
between the layers of the two β-sheets may vary.
In fibres, these β-sheet structures pack together as shown in figure 1.7. Longer
fibrils have been observed using electron cryomicrography (see Fig. 1.8) by embed-
ding the fibrils in ice [61]. The fibrils were shown to be helical in shape [61].
Alternative conformations have also been shown. In Alzheimer’s disease patients,
fibrils consist of mostly Aβ40, such as in figure 1.9. However, the number of clinical
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(a) Two-fold symmetry (2LMO) (b) Three-fold symmetry (2LMP) [59;60]
Figure 1.7: Cross-section of Aβ40 in fibrils determined via NMR and electron micro-
scopy. (PDB ID: 2LMO & 2LMP)
[61]
Figure 1.8: Electron micrograph of an Aβ40 fibril embedded in ice (top). Projec-
tion of the 3D reconstructed fibril (middle). Side-view surface rendering of the
reconstructed fibril (bottom). Copyright 2015 National Academy of Sciences, USA.
(a) Coloured by β-sheet or loop (b) Coloured by Aβ monomer [62]
Figure 1.9: Aβ40 fibril from Alzheimer’s disease brain, all residues located. (PDB ID:
2M4J)
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studies of fibrils from patients is too low to determine whether the fibril properties
are fundamentally different from that in vitro. Understanding the role of fibrils,
their formation and evolution is further complicated by the purity and composition
of the fibrils. There may be modifications to peptides in vivo that alter the way
in which fibres are formed, such as oxidative damage, truncation [63] or binding to
metals.
The dissociation constant of Aβ from Aβ40 fibrils was measured to be 0.6 s−1 and
from Aβ42 fibrils to be 10−2 s−1 [64]. The rate of disaggregation into soluble species
was measured by a further group to be 9(3) s−1 [65].
Super resolution images of fibres have been observed on HeLa cells showing
different morphologies [66].
Oligomers Oligomers are thought to be the cause of neurotoxicity in Alzheimer’s
disease and have been shown to affect long term potentiation in the hippocampus [67].
Though their mechanism of action is unclear with multiple hypotheses proposed [68],
such as interactions with receptors, channel formation, and oxidative stress. It
is possible to detect femtomolar concentrations of Aβ oligomers in the CSF of
patients [69].
Molecular dynamics simulations suggest that the structure of the oligomers is
quite polymorphic [70]. It has been found that Aβ40 (10 µm) rapidly forms spherical
oligomers which then slowly convert into fibrils [71].
Identifying the structure and formation of toxic oligomers is fundamental to
understanding the molecular mechanisms behind Alzheimer’s disease. However,
just being able to reliably produce toxic species of oligomer would allow for drug
discovery and optimisation.
1.2.4 The Evolution of Amyloid-β and Murine Amyloid-β
The Aβ sequence in the APP arose approximately 5× 108 years ago in the common
ancestor of jawed vertebrates, and the β-cut site approximately 4× 108 years ago in
the common ancestor of tetrapods and lobe-finned fish [72]. Aβ is well conserved
across a variety of species (see Fig. 1.10).
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10. 20. 30. 40.
Homo DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGMVGGVVIAT 42
Mus DAEFGHDSGFEVRHQKLVFFAEDVGSNKGAIIGMVGGVVIAT 42
Gallus DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGMVGGVVIAT 42
Xenopus DSEYRHDTAYEVHHQKLVFFAEEVGSNKGAIIGMVGGVVIAT 42
Latimeria DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGMVGGIVIAT 42
Danio 1 EAEERHS...EVYHQKLVFFAEDVSSNKGAIIGMVGGVVIAT 39
Danio 2 DIEERHNAGYDVRDKRLMFLAEDMGSNKGAIIGMVGGVVIAT 42
Raja ETEFRQDSGYEVHHQKLVFFPEDVGSNKGAIIGMVGGVVIAT 42
consensus daEfrhdsgyeVhhqkLvFfaEdvgSNKGAIIGMVGGvVIAT
charge
hydrophob.
Figure 1.10: Aβ sequence for different genera. The consensus shows the conserved
residues. For the charge, positive is blue, and negative is red. ‘hydrophob.’ is the
hydrophobicity, above the line for hydrophobic, below for hydrophilic. Approximate
translation of genus: Homo – human, Mus – mouse, Gallus – junglefowl (bird),
Xenopus – clawed frog, Latimeria – coelacanth (fish), Danio – Danionin (fish), Raja –
skates. [72]
Interestingly in non-human primates, the APP sequence is homologus to that
in humans with developing Aβ plaques. However, they do not appear to have any
neurodegeneration related to Alzheimer’s disease [73]. It has been suggested that this
is due to structural variation in multimeric Aβ [74].
Of further interest is the murine (mouse/rat) sequence of Aβ. The sequence has
only three mutations, all in the N-terminal region: arg5 → gly, tyr10 → phe, and
his13 → arg. However, murines do not show the Aβ deposits [75;76]. The positively
charged arginine is moved from residue 5 to 13, removing a histidine. The loss of a
histidine is thought to change the binding of Aβ to metal cations, such as zinc and
copper [76]. Therefore, identifying differences between human and murine Aβ, may
give insight into the mechanism of Aβ aggregation.
There are a number of familial mutations in and around the Aβ sequence in
the human genome that further increase the probability of getting Alzheimer’s
disease [77–79].
34
1.3 Toxicity and Aggregation
The mechanism of the toxicity of oligomers in Alzheimer’s disease is currently
unknown. However, there are many proposed mechanisms [80], these include inter-
acting with receptors on and in the cell causing them to malfunction, leading to cell
death [80;81]. Alternatively, Aβ oligomers may form pores in the membrane of the
cells, upsetting ion homeostasis leading to cell death [82;83].
1.3.1 Interactions with Receptors
Extracellular Aβ oligomers are thought to bind to receptors on the cell surface
interfering with their downstream pathways, see figure 1.11 [80]. However, there
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Figure 1.11: Putative Aβ oligomer binding receptors and potential signalling path-
ways thought to be involved in the synaptotoxicity of Aβ oligomers. In this model
there are two general categories of signalling pathways: those that signal via tyrosine
kinase (tyr k, fyn, and c-Abl), and those that hyperactivate CDK5/glycogen synthase
kinase (GSK3β). [81] Copyright 2015 National Academy of Sciences, USA.
have not been any receptors identified that are highly specific to Aβ oligomers, nor
have the signalling mechanisms been fully elucidated for those that have been found
to interact [80].
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1.3.2 Channel Formation in Cell Membranes
It has been proposed that Aβ oligomers form pores in the cell membrane [84;85].
These pores may then upset the membrane’s permeability and the cell’s ion homeo-
stasis. It has been shown that Aβ may form Ca2+ pores [86;87]. These Ca2+ channels
have been shown to be blocked by Zn2+ [88]. Ca2+ is important in neurotransmission
as an influx of Ca2+ causes vesicles to release neurotransmitters into the synaptic
cleft. In physiology, Ca2+ flows into the cell via voltage-gated Ca2+ channels, which
activate when an action potential reaches them.
1.3.3 Oxidative Stress
One of the characteristics of brains in Alzheimer’s disease patients is oxidative
stress [89]. This is proposed to be caused by redox chemistry of metal ions with
Aβ [90;91]. Aβ has been shown to catalyse the reduction of Cu2+ & Fe3+ to Cu+ &
Fe2+, producing hydrogen peroxide, which may then lead to the Fenton reaction
Men+ + H2O2 −−−→Me(n+1)+ + HO· + OH− (1.3)
Me(n+1)+ + H2O2 −−−→Men+ + HOO· + H+ (1.4)
producing oxygen-radical species [92;93]. This redox cycling, which produces ROS
(reactive oxygen species) may then lead to oxidative damage of surrounding mater-
ial [94]. The damage to Aβ itself, has been used to determine the coordination modes
to the redox active Aβ ·Cu coordinations [95]. It has been proposed that the purpose
of Aβ may be as part of a copper regulatory system that reduces oxidative stress (see
Fig. 1.12) [96].
Also, it has been proposed that this redox chemistry may turn tyr10 into a tyrosyl
radical allowing it to cross-link with a tyrosine on another Aβ, forming a covalently
linked dimer [97].
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[96]
Figure 1.12: Proposed mechanisms for the effects of metal ions in the brain and
their effects on Aβ production and aggregation. SOD (superoxide dismutase) is an
anti-oxidant which reduces oxidative stress (ox-stress). This is thought to be down-
regulated as intracellular (IC) levels of copper are decreased. Copper is exported
from cells when APP is expressed, increasing the levels in the CSF (cerebrospinal
fluid) forming a negative feedback loop. In Alzheimer’s disease the feedback loop
is insufficient to prevent APP expression and thus Aβ production & accumulation.
Therefore it is thought that an intracellular copper deficiency may cause the over-
production of Aβ and then Alzheimer’s disease. Copyright (c) 2005 John Wiley
& Sons. Metals and Amyloid-β in Alzheimer’s disease, Christa J. Maynard, et al.,
International Journal of Experimental Pathology, 86:3. [96]
1.4 Therapeutic Strategies Against Alzheimer’s Disease
There are currently 4 drugs that help with the symptoms of Alzheimer’s disease (see
Section 1.1.2). However, there are no drugs that prevent or cure Alzheimer’s disease.
In the US, there are approximately 1500 completed and ongoing clinical trials of
which 64 are completed with results from phase 3 or 4 [98].
In clinical trials based on the Aβ cascade hypothesis, there are three main
approaches: preventing the production of Aβ, inhibiting the formation of oligomers,
and promoting the clearance or degradation of Aβ. However, there have not been
any successful phase 3 trials. Furthermore, some trials have been terminated as the
effects of the drugs were worse than the placebo. This may be because there is a lack
of understanding of the molecular mechanisms behind Alzheimer’s disease.
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1.4.1 Inhibiting Aβ Production
The therapeutic strategies applied to inhibiting the production of Aβ are to prevent
the cleavage of Aβ from being completed by preventing cleavage by β-secretase or
γ-secretase, or alternatively to promote the cleavage by α-secretase to produce p3
instead.
α-Secretase Modulators These increase the cleavage by α-secretase, cutting APP
in the Aβ region to form the shorter peptide p3.
Acitretin (Soriatane, Neotigason, RO 101670. Phase 2, Completed) Increases
expression of ADAM10 (α-secretase). In the trial, α-secretase-derived
APP was increased by 25 %, but β-secretase-derived APP was unchanged.
It was expected to decrease as the alternative cleavage pathway was
promoted. Aβ42 levels were unchanged, though Aβ40 levels were not
measured. The trial was completed in 2011. [99]
β-Secretase Inhibitors The development of β-secretase inhibitors has been diffi-
cult due to problems with brain access, cell penetration, and oral bioavail-
ability [100]. Furthermore, neuregulin-1 is also a substrate of β-secretase.
Neuregulin-1 is essential for the normal development of the nervous system
and the heart, also effecting the myelination of neurons [101;102].
LY2886721 (Phase 2, Failed) Terminated before completion due to abnor-
mal liver biochemical tests [103]. The study was terminated in mid 2013
however the results are as of yet still unpublished. LY2886721 was a
derivative of LY2811376, the first β-secretase inhibitor.
MK-8931 (Phase 2/3, Ongoing) The phase I trial showed a dose dependent
decrease of Aβ in the CSF by up to 92 % and was completed in Jun 2012,
but the results are still unpublished [104].
γ-Secretase Inhibitors Development of γ-secretase inhibitors has been most prob-
lematic as inhibiting γ-secretase also interferes with Notch signalling. Notch
has many physiological functions in regulating cell growth and catabolising
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membrane protein fragments. This in turn causes serious side effects such as
an increased risk of skin cancers and infections. [105]
Semagacestat (LY450139 Dihydrate, hydroxylvaleryl monobenzocapro-
lactam. Phase 3, Terminated) Terminated before completion due to
increased weight loss, increase in skin cancers and infections. Patients in
the semegacestat groups showed greater worsening of dementia than the
placebo group. [106;107]
Avagacestat (BMS-708163. Phase 2, Failed) Terminated before completion as
the required efficacy was not observed [108]. Avagacestat was designed
to selectively avoid Notch interference [109] though others disagree [110].
The study was terminated in Nov 2012 however the results are still
unpublished.
Tarenflurbil (Flurizan, R-flurbiprofen, MPC-7869, (R)-2-(3-Fluoro-4-phenyl-
phenyl) propanoic acid. Phase 3, Failed) No improvement in cognitive
ability or ability to carry out daily activities [111]. Thought to lower
Aβ42 and act as an anti-inflammatory through allosteric modulation of
γ-secretase [112;113].
NIC5-15 (Pinitol, D-Pinitol. Phase 2, Ongoing) Thought to modulate γ-
secretase to reduce Aβ production whilst sparing the cleavage of Notch.
1.4.2 Inhibiting Oligomerisation
The development of inhibitors of Aβ oligomerisation has been challenging due to
the unknown structure of Aβ oligomers and lack of a formation mechanism.
PBT2 (Phase 2, Failed) A derivative of clioquinol (CQ), and is thought to reduce Aβ
aggregation by interfering with its interactions with copper and zinc. There
was no evidence for the reduction of amyloid plaques or relative improvement
in cognition and function. However, there was a trend showing hippocampal
brain volume was preserved. This aspect of the study is still ongoing. [114] CQ
is used in the studies in section 3.6.
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ELND005 (AZD-103, Scylloinositol, cyclohexane-1,2,3,4,5,6-hexol. Phase 2, Com-
pleted) Thought to neutralise small toxic oligomers and prevent them ag-
gregating [115;116]. Aβ levels in a CSF were reduced in the mild Alzheimer’s
disease subgroup. ELND005 had serious adverse affects. [117] The study is
being continued for the mild Alzheimer’s disease subgroup.
1.4.3 Promoting Clearance or Degradation
This is the largest category of drugs, attempting to intervene in the amyloid hy-
pothesis, typically applying either a passive immunotherapy (giving the patient
antibodies∗) or an active immunotherapy (giving the patient a vaccine).
Solanezumab (LY2062430. Phase 3, Failed) No significant improvement in worsen-
ing of dementia, compared to the placebo group [118]. There was decreased
unbound Aβ40 in the CSF, but increased levels of Aβ42 [119]. Trials are still
ongoing testing its effect on familial mutations and mild Alzheimer’s disease
patients.
Gantenerumab (RO4909832, RG1450. Phase 3, Ongoing) Human IgG1 (Immuno-
globulin G subclass 1) antibody with specific binding to Aβ in plaques. [120]
Simvastatin (Phase 4, Complete) Has been shown to lower levels of Aβ in the brain
and CSF in animals models [121]. Simvastatin improved some measures of
cognitive function, but did not decrease CSF levels of Aβ42 [122].
Bapineuzumab (Phase 3, Failed) IgG1 antibody that binds soluble and fibrillar Aβ.
Six phase 3 trials, four of which were terminated before completion. The four
later trials were terminated after there was no improvement seen in the initial
two trials. No treatment differences in CSF levels of Aβ.
CAD-106 (Phase 2, Complete) Aβ vaccine recognising Aβ3–6, binding to monomers
and oligomers [123]. Results not yet published.
AN1792 (AIP 001. Phase 2, Failed) Vaccine recognising full length Aβ. The follow
up to the trial showed less decline in cognitive measures, but also decrease in
∗Drugs ending in -mab are monoclonal antibodies (mAb).
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brain volume. Dosing was halted in the trial after some patients developed
brain inflammation. [124]
Affitope AD02 (Phase 2, Failed) Aβ vaccine recognising Aβ6. In this trial their
‘placebo’ (AD04) showed more stabilisation than AD02. [125]
BAN2401 (Phase 2, Ongoing) Humanized IgG1 monoclonal antibodies that binds
selectively to large, soluble Aβ.
Crenezumab (MABT5102A, RG7412. Phase 2, Ongoing) Monoclonal antibody
against Aβ.
Octagam (Intravenous Immunoglobulin, NewGam. Phase 2, Failed) Uses naturally
occurring polyclonal autoantibodies against Aβ. The CSF levels of Aβ were
unchanged with no cognitive or functional benefit shown. [126]
Ponezumab (PF-04360365. Phase 2, Failed) Passive immunotherapy treatment
against Aβ40. No change in brain or CSF Aβ burden. [127]
Vanutide Cridificar (ACC-001, PF-05236806. Phase 2, Failed) Vaccine against
Aβ42. Designed to avoid the safety concerns of AN1792. No apparent clinical
benefit seen. [128]
1.5 The Role of the Membrane
The role of the membrane is implicit in the formation of Aβ from APP given that
Aβ is part of the transmembrane region of APP, and that the secretases that cleave
it are also membrane bound [129]. The N-terminus of Aβ consists of predominantly
hydrophobic residues which have been shown to interact with and disrupt mem-
branes [130]. However, it is oligomers that are thought to be neurotoxic rather than
monomers or fibrils.
Aβ oligomers have been shown to cause cognitive loss in rats [131]. Oligomers
have been shown to affect synaptic plasticity, whereas undissolved fibrils and
monomers do not [132]. These oligomers increase the conductance of the membrane,
possibly by forming Ca2+-permeable channels [133]. This increase in conductance is
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also seen for other amyloid forming proteins [134]. Even picomolar concentrations
of Aβ40 or Aβ42 oligomers increase intracellular Ca2+ in astrocytes. However, this
was not observed in neurons [135]. This may be due to differences in the membrane
composition, such as the decreased level of cholesterol in neurons as compared
to astrocytes [136]. Cholesterol levels in neurons have been previously linked to
Alzheimer’s disease [137]. The early stages of Alzheimer’s disease have been thought
to be linked with synaptic loss rather than neuronal death [138]. With regards to
metals, Cu2+ was found to destabilise lipid bilayers, but the membrane could be
stabilised by the addition of Aβ42 [139].
On the cell membrane there are regions known as lipid rafts, which are microdo-
mains containing sphingomyelin and cholesterol, and are enriched with gangliosides
(sialic acid-containing glycosphingolipids) [140–142]. The ganglioside GM1 has been
shown to bind to Aβ in vivo [143] and to catalyse Aβ40 aggregation [144], possibly
with the Aβ ·GM1 complex acting as a seed [145]. It has been proposed that GM1
sequesters Aβ after its cleavage [146]. The Aβ fibrils formed in the presence of GM1
were of a different morphology to those without GM1 [144].
GM1, when in aqueous solutions of 0.8 µm to 156 µm, spontaneously forms
micelles of 168(4) GM1 units [147]. The 𝐾d (equilibrium dissociation constant) of
Aβ40 (with a tyr10 → trp mutation, to increase intrinsic fluorescence) was found
to be 1.4 µm [148]. Using an N-terminal dye label, the 𝐾d was measured to be
0.11(2) µm [149]. Using NMR the 𝐾d was measured to be approximately 5 µm [150].
This suggests that the 𝐾d of Aβ to GM1 micelles is in the hundreds of nanomolar to
low micromolar regime. For monomeric GM1 the 𝐾d is approximately 1 mm [150].
On micelles and membrane-mimics, Aβ has been shown to adopt an α-helical
conformation, however the regions that form α-helices are strongly dependent
on experimental conditions [151]. NMR has been used to determine the relative
hydrophobicity of the environment of the residues of Aβ to determine their position
relative to the micellar-water interface [152]. Residues 1–11 are in solution, 12–25
are in the membrane, 26–30 are in solution, 31–36 are in the membrane, 37–38
are in solution, and 39–40 are in the membrane [152]. On GM1 micelles, Aβ forms
two α-helical segments from his14-val24 and ile31-val36 [152;153]. The positions of
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the residues in a GM1 micelle have been determined by applying FRET (Förster
resonance energy transfer) techniques, to determine the distance of the mutated
residues from the micellar centre (see Fig. 1.13). Furthermore, it has been shown
[154]
Figure 1.13: Illustration of the position of Aβ in GM1 micelles, by using FRET
to measure the distance of different amino acids (C12, C26) from the micellar
centre [154]. Reprinted from Biophysical Journal, 99:5, I. Mikhalyov, et al., Designed
Fluorescent Probes Reveal Interactions between Amyloid-β(1–40) Peptides and GM1
Gangliosides in Micelles and Lipid Vesicles, 1510–1519, Copyright 2010, with
permission from Elsevier.
that once Aβ is bound, it was able to undergo conformational change from α-helix to
β-sheet with cholesterol [149;155]. These may act a seed for aggregation and suggests
that cholesterol is a risk factor.
Sodium dodecyl sulfate (SDS) micelles have also been used as a membrane
mimic, although its composition is of less physiological relevance [156;157].
The kinetics of binding of Aβ40 to a supported lipid bilayer of the phos-
phatidylcholine phospholipid POPC and the phosphatidylglycerol phospholipid
POPG was determined,
{Membrane binding site} + Aβ40
𝑘on
𝑘off
{Membrane binding site} ·Aβ40 ,
(1.5)
where 𝑘on was 4.3(3)× 103 m−1 s−1∗, and 𝑘off was < 2× 109 s−1 [158].
∗Note the units of 𝑘on given are incorrect as it is reaction between components on a surface and in
solution, whereas the units are for both components being in solution.
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1.6 The Role of Metal Ions
Transition metals, in particular Zn2+, Cu2+ & Fe2+, have been shown to be con-
nected to multiple neurodegenerative diseases, including Alzheimer’s disease [159].
Aβ is an intrinsically disordered peptide fluctuating amongst different transient
structures [160]. Upon metal binding, the structure of Aβ is thought to become more
defined. However, unlike typical metalloproteins, Aβ has several binding modes to
the metal ions and a much lower binding affinity.
The equilibrium dissociation constant (𝐾d) of Aβ to Zn2+ has been measured
to be in the range of 1 µm to 100 µm, whereas values the 𝐾d for Cu2+ range from
10 pm to 100 nm [161;162]. For comparison, the 𝐾d of HSA (human serum albumin),
a common protein in the CSF to Zn2+ is approximately 30 nm and for Cu2+ is
approximately 1 pm [163].
HSA is the most common protein in blood plasma with many known roles [164].
In the CSF, HSA is at concentrations of approximately 3 µm [165;166], significantly
higher than the concentrations of Aβ. This, combined with its stronger 𝐾d’s for
Zn2+ (∼30nm) & Cu2+ (∼7pm) [167], suggest that for these ranges of the metal ion-Aβ
𝐾d, monomeric Aβ cannot compete with HSA for binding to these metal cations,
unless HSA is already saturated with metal ions. The concentrations of Zn2+ in
the CSF is 160(40) nm (𝑛 = 52) [168], whereas Cu2+ is 220(90) nm (𝑛 = 113) [169], well
below the concentration of HSA. Therefore, if, as in the Aβ metal hypothesis that
Aβ oligomerisation is caused by metals, where and when can this happen?
During the process of synaptic transmission Zn2+ and Cu2+ are transiently re-
leased into the synaptic cleft (see Fig. 1.14) [170]. Zn2+ concentrations may reach
200 µm to 300 µm in the synaptic cleft [172] when it is released from synaptic ves-
icles into the cleft [173], whereas Cu2+ may reach concentrations of approximately
15 µm [174;175]. These values are above the range of the 𝐾d’s determined. Is it here
where the oligomers first form resulting in Alzheimer’s disease, after binding to
metal ions? The 𝐾d suggests they could bind to metals at these equilibrium concen-
trations. However, due to the transient nature of synaptic release only the kinetics
can determine whether they do bind.
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Figure 1.14: Zn2+, Cu2+ and glutamate in synaptic transmission. In the amyloid-
metal hypothesis. One treatment strategy is to use the MPACs (Metal-protein
attenuating compounds) to remove metals from Aβ, its oligomers and plaques. It is
not known whether Aβ is co-released with Zn2+. ZnT4 & ATP7a, are Zn2+ & Cu2+
transporters, respectively. NMDAr is an NMDA receptor which may be activated by
glutamate. [171]
It has also been shown that increased synaptic transmission activity correlates
to an increase in release of Aβ via endocytosis-associated mechanisms [176].
1.6.1 Metal Ions and Alzheimer’s Disease
Studies of Aβ plaques have shown elevated levels of Zn2+, Cu2+ and Fe3+, with dry
weight concentrations of approximately 70 µm, 340 µm and 350 µm, respectively, in
healthy brains [177]. Whereas in brains with Alzheimer’s disease the concentrations
were elevated to approximately 400 µm, 1 mm and 1 mm for Zn2+, Cu2+ and Fe3+, re-
spectively [177]. In the CSF, the concentrations of zinc and copper are nanomolar (see
table 1.3), but are elevated in Alzheimer’s disease patients. It has been hypothesised
that Alzheimer’s disease is caused by the dishomeostasis of Zn2+ in the brain [179].
There has been shown to be an overlap between the areas of the brain rich
in glutamatergic receptors, free vesicular zinc and Aβ plaques, in certain APP
transgenic mice [180].
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Control Alzheimer’s disease
Zinc / µm 0.08(5) 0.1(1)
Copper / µm 0.16(3) 0.3(2)
Iron / µm 4(1) 4.3(7)
Table 1.3: Concentration of metal ions in the CSF in control patients (𝑛 = 15) and
patients with Alzheimer’s disease (𝑛 = 21). [178]
Metal ions have been shown to enhance the fibrillisation rate of Aβ, and metal
chelators can reverse the effect [76;181]. However, metal-induced aggregates are
mainly non-fibrillar [182;183], but small metal-induced aggregates may act as seeds
for the Aβ fibrillisation process [184;185]. It has also been proposed that the different
coordinations of Aβ with Cu2+, or Zn2+ are related to the different morphologies
and toxicities of aggregates [186].
It was also shown that Cu2+ or Zn2+ binding to fibrils does not induce structural
changes in the β-sheet structure of the hydrophobic core residues [187;188]. However,
for Zn2+ there was some evidence of breaking the salt bridge between asp23 and
lys28.
Coordination of Cu2+ to fibrils is similar to that of monomeric Aβ, with a 𝐾d of
approximately 10 pm [189].
1.6.2 Zinc
Zn2+ coordination typically involves four or six ligands. It is believed that all three
histidines and glutamate11 are involved in the coordination of Zn2+ to Aβ [190–195].
It has been shown that Aβ may coordinate with up to three Zn2+’s [186]. It has been
found possible for intermolecular His-Zn2+-His bridges to be formed between two
Aβ’s [196]. This allows for Zn2+ assisted dimers to form, but also for the transfer
of Zn2+ (see Fig. 1.15) [197]. Zn2+ has been shown to stabilise oligomers on short
timescales [198].
The 𝐾d of Zn2+ binding to Aβ has been measured by many groups (see table 1.4),
with values ranging from 1 µm to 300 µm. The methods used are described below:
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Figure 1.15: Schematic of the exchange of Zn2+ between two Aβ’s, and transient
dimer formation. Copyright (c) 2009. Copper and Zinc Binding to Amyloid-β:
Coordination, Dynamics, Aggregation, Reactivity and Metal-Ion Transfer, P. Faller,
ChemBioChem.
65Zn2+ displacement Aβ is immobilised onto a surface and immersed in a solution
of Zn2+ and 65Zn2+. The solution is then washed off and the radioactivity of the
bound Aβ · 65Zn2+ is measured, so that the proportion of Aβ bound to Zn2+ can be
calculated [199;200] This method will underestimate the 𝐾d if the dissociation rate of
Aβ · 65Zn2+ is close to or faster than the washing time.
tyr fluorescence tyr10 has an intrinsic fluorescence which is enhanced when Aβ
binds to Zn2+ [201]. Zn2+ is then titrated into the solution of Aβ and the increase in
fluorescence is fitted to a binding curve, obtaining the 𝐾d. However, the intrinsic
fluorescence of tyr is very weak with an absorbance 𝜀 of 1280m−1 cm−1 and quantum
yield 𝜑 of 0.14 [202]. Thus, in order to obtain sufficient signal to noise for the
measurement, micromolar concentrations of Aβ are required, possibly leading to
aggregation.
ITC Isothermal titration calorimetry is performed by measuring the power re-
quired to heat a reaction when the solution is kept at a constant temperature. The
heat loss of the solution (known) and the energy given off by the reaction (unknown)
is balanced against the input power (known). For a known heat loss, this allows for
the determination of the Gibbs energy (∆𝐺) of the reaction and thus the 𝐾d via
∆𝐺 = 𝐾B𝑇 ln(𝐾d) , (1.6)
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where 𝑇 is the temperature and 𝐾B is Boltzmann’s constant. Due to the small
energy change of the reaction per molecule, high numbers of reactions and thus
concentrations are required. The high concentrations (>10µm) of Aβ & Zn2+ are
likely to induce rapid aggregation.
Zincon competition Zincon binding to Zn2+ (𝐾d = 12.6µm) introduces a distinct
absorbtion band at 620 nm (𝜀max = 23200m−1 cm−1) which can be used to determine
the concentration of Zincon ·Zn2+ by absorbance. Then by titration of Zincon into a
solution of Aβ ·Zn2+, the 𝐾d of Aβ with Zn2+ can be found relative to that of Zincon
with Zn2+ by the equilibrium of
Zincon ·Zn2+ + Aβ −−−⇀↽−− Zincon + Aβ ·Zn2+ (1.7)
reached. This requires the 𝐾d of Zincon ·Zn2+ to be known accurately, be similar
to the 𝐾d of Aβ ·Zn2+ and for negligible free Zn2+, i.e. the concentration of Aβ
must be much greater than the 𝐾d of Aβ ·Zn2+ and the total concentration of Zn2+.
10µm ≫̸ (7 µm to 14 µm). [203–205]
Tyr fluorescence by Cu2+ Competition Tyr10 is quenched by paramagnetic Cu2+.
Therefore, by fluorescence of tyr10 the concentration of Aβ ·Cu can determined.
Given that the binding sites are the same [206], the 𝐾d of Aβ ·Zn relative to that of
Aβ ·Cu can be determined from the competition
Aβ ·Cu + Zn2+ −−−⇀↽−− Aβ + Cu2+ + Zn2+ −−−⇀↽−− Cu2+ + Aβ ·Zn . (1.8)
This requires an accurate determination of the 𝐾d of Aβ ·Cu which varies in the
literature from 10 pm to 100 nm (see §1.6.3).
NMR In nuclear magnetic resonance, molecules are placed in a magnetic field, so
that the magnetic quantum (𝑚l) energy levels of nuclei with an intrinsic magnetic
moment (non-zero spin) are split, and they then try to align to the magnetic field.
The unpaired nucleons are excited with a 90° radio-frequency pulse at the resonant
frequency of the difference in the energy levels caused by the magnetic field. This
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causes the magnetic moment of the spins to become perpendicular to the applied
magnetic field and align the phases of the moments as they precess around the
applied magnetic field vector. The signal obtained by NMR is from the spins
realigning to the applied magnetic field emitting photons. However, the signal is
reduced by the spins dephasing. The environment around the spins, i.e. caused
by the surrounding electrons and other atoms in the molecule, perturbs the local
magnetic field, and thus the frequency of photon given off and dephasing. These
variations in the signal allow probing of molecular structure. Changes in the signal
can be correlated to Zn2+ binding to Aβ. However, to obtain sufficient signal for
NMR high concentrations are required.
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𝐾d/µm Aβ [Aβ]/µm Conditions Method
5.2 Aβ40 20 mm Tris, pH 7.4 65Zn2+ displacement [199]
3.2 Aβ40 ∼ 0.5 10 mm Tris, pH 7.4 65Zn2+ displacement [200]
3.2 Aβ40 ∼ 0.5 10 mm Hepes, pH 7.4 65Zn2+ displacement [200]
300 Aβ40 3 10 mm Tris, 100 mm NaCl, pH 7.4 Tyr fluorescence [201]
57 Aβ42 3 10 mm Tris, 100 mm NaCl, pH 7.4 Tyr fluorescence [201]
22(15) Aβ16 ∼15 20 mm Tris, 100 mm NaCl, pH 7.4 ITC [203]
71(5) Aβ16 140 20 mm Tris, 100 mm NaCl, pH 7.4 ITC [203]
10(8) Aβ28 ∼15 20 mm Tris, 100 mm NaCl, pH 7.4 ITC [203]
30(4) Aβ28 140 20 mm Tris, 100 mm NaCl, pH 7.4 ITC [203]
7(3) Aβ40 10 20 mm Tris, 100 mm NaCl, pH 7.4 ITC [203]
3(2) Aβ40 70 20 mm Tris, 100 mm NaCl, pH 7.4 ITC [203]
14(5) Aβ16 10 20 mm HEPES, 100 mm NaCl, pH 7.4 Zincon competition [203]
12(5) Aβ28 10 20 mm HEPES, 100 mm NaCl, pH 7.4 Zincon competition [203]
7(3) Aβ40 10 20 mm HEPES, 100 mm NaCl, pH 7.4 Zincon competition [203]
7(3) Aβ42 10 20 mm HEPES, 100 mm NaCl, pH 7.4 Zincon competition [203]
6.6(2) Aβ28 10 10 mm HEPES, pH 7.2 Tyr fluo, Cu2+ comp [192]
1.10(8) Aβ28 10 10 mm Na Phosphate, pH 7.2 Tyr fluo, Cu2+ comp [192]
1.20(3) Aβ40 50 10 mm Na Phosphate, pH 7.2 NMR [192]
60(14) Aβ40 4 10 mm Tris, 100 mm NaCl, pH 7.4 Tyr fluorescence [206]
184(30) Aβ40 4 100 mm Tris, 100 mm NaCl, pH 7.4 Tyr fluorescence [206]
65(3) Aβ40 4 20 mm HEPES, 100 mm NaCl, pH 7.4 Tyr fluorescence [206]
91(16) Aβ42 4 20 mm HEPES, 100 mm NaCl, pH 7.4 Tyr fluorescence [206]
11 Aβ16 >50 50 mm HEPES, pH 7.1 Competition [207]
210(20) Aβ40 75 10 mm HEPES, pH 7.4, 281 K NMR [208]
Table 1.4: Measurements of the 𝐾d of Aβ with Zn2+, at near physiological pH. Sorted
by publication date. Abbreviations: fluo - fluorescence, comp - competition. [161;206]
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1.6.3 Copper
The coordination of Cu2+ to Aβ is dependent on the pH, which varies the level of
protonation of Aβ (see Fig. 1.16). This is also true for murine Aβ ·Cu, with mutations
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Figure 1.16: Relative concentration of Aβ16 ·Cu complexes at different pH’s, where
L is Aβ. Reprinted from Coordination Chemistry Reviews, 256:19-20, T. Kowalik-
Jankowska, et al., Coordination abilities of the 1–16 and 1–28 fragments of β-amyloid
peptide towards copper(II) ions: a combined potentiometric and spectroscopic study,
270-282, Copyright 2003, with permission from Elsevier. [209]
causing different protonation states to form (see Fig. 1.16). At physiological pH,
there are two dominant forms of Aβ ·Cu for human Aβ, termed ‘Component I’
((Aβ ·Cu)i) and ‘Component II’ ((Aβ ·Cu)ii) [210–212], with a p𝐾a of pH 7.7 [213], caused
by the deprotonation of the asp1-ala2 peptide bond [214]. For murine Aβ, the p𝐾a is
pH 6.2 for the two components, but their coordination spheres are different [213].
Coordination spheres have been proposed (see Fig. 1.17) [159;215–217]. For both
human and murine Aβ, the binding of Cu2+ is to the N-terminal region. The
coordination of Cu2+ to Aβ16 has been shown to be the same as to full length
Aβ [218–220]. Thus shorter lengths of Aβ are an acceptable model for the interactions
of Aβ with Cu2+.
Cu+ has been shown to bind to Aβ (see Fig. 1.17) with a 𝐾d of approximately
50 nm [221]. Copper whilst bound to Aβ is capable of undergoing redox chemistry
and the intermediate redox active states have been determined [95].
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Figure 1.17: Proposed major coordination spheres of human Aβ ·Cu, and the rela-
tionship between them. The minor coordination spheres are the other combinations
of histidines binding. [159]
Aβ has been shown to bind multiple Cu2+ with to up to four Cu2+’s bound [222;223].
Furthermore it was shown that oligomers of Aβ16 ·Cu up to a 17-mer may be
formed [222]. However, the measurements used 0.2 mm Aβ16 and 0 mm to 4 mm
Cu(Gly)2, at pH 6.5 in NEM buffer.
For the measurement of the 𝐾d of Aβ with a single Cu2+ ion there have been
a large number of inconsistent measurements spread over approximately four
orders of magnitude. Three methods have been applied to determining the 𝐾d:
Quenching of intrinsic tyr10 fluorescence, ITC, and potentiometry. These methods
are reasonably (approximately one order of magnitude) consistent with themselves,
but differ between them (see Fig. 1.18). One possible reason for the discrepancy
between measurement methods is due to their sensitivity and thus the different
concentrations required for a measurement. At higher concentrations Aβ will
aggregate and it is not clear from the measurements if the binding affinity measured
is purely that of monomeric Aβ, but also that of oligomers, which likely have a lower
𝐾d.
The 𝐾d of Cu2+ binding to Aβ has been measured by many groups (see tables 1.5
& 1.6) with values ranging from approximately 10 pm to 100 nm. The measurements
are further complicated by the weak binding of Cu2+ to components in the buffer,
reducing the apparent concentration of Cu2+ and increasing the apparent 𝐾d. Phos-
phate buffers such as PBS (phosphate buffered saline) should not be used at all as the
phosphates in the buffer form insoluble Cu3(PO4)2 with Cu
2+, which precipitates
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and may act as seeds for aggregation.
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Figure 1.18: Relationship between Aβ peptide concentrations and reported c𝐾ML
(c𝐾ML = [M ·L]/([M][L]), conditional binding constant for a metal-ligand (M ·L) inter-
action) values for Cu2+ binding, according to various experimental methodologies.
Reprinted from Coordination Chemistry Reviews, 256:19-20, I. Zawisza, et al.,
Affinity of copper and zinc ions to proteins and peptides related to neurodegen-
erative conditions (Aβ, APP, α-synuclein, PrP), 2297–2307, Copyright 2012, with
permission from Elsevier. [161]
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𝐾d/nm Aβ [Aβ]/µm Conditions C 𝐾
App
d /µm
73 Aβ40 3 10 mm Tris, 100 mm NaCl, pH 7.4 1.34 1.6(9) [201]
91 Aβ42 3 10 mm Tris, 100 mm NaCl, pH 7.4 1.34 2.0(8) [201]
53 Aβ16 10 100 mm Tris, 150 mm NaCl, pH 7.4 2.94 47(5) [219]
32 Aβ28 10 100 mm Tris, 150 mm NaCl, pH 7.4 2.94 28(5) [219]
21 Aβ40 10 100 mm Tris, 150 mm NaCl, pH 7.4 2.94 11(1) [219]
120 Aβ40 10 50 mm PBS, 100 mm NaCl, pH 7.4 1.82 8 [224]
370 Aβ28 10 50 mm HEPES, pH 7.2 0.87 2.5(2) [192]
77 Aβ28 10 10 mm HEPES, pH 7.2 1.51 2.5(2) [192]
370 Aβ40 4 20 mm Tris, 100 mm NaCl, pH 7.3 1.10 0.047(23) [206]
35 Aβ40 4 20 mm Tris, 100 mm NaCl, pH 7.3 1.53 1.21(41) [206]
24 Aβ40 4 50 mm Tris, 100 mm NaCl, pH 7.3 2.20 3.82(89) [206]
54 Aβ40 4 100 mm Tris, 100 mm NaCl, pH 7.3 2.74 30.1(57) [206]
36 Aβ40 4 20 mm HEPES, 100 mm NaCl, pH 7.4 1.19 0.57(23) [206]
24 Aβ40 4 50 mm HEPES, 100 mm NaCl, pH 7.4 1.57 0.90(21) [206]
34 Aβ40 4 100 mm HEPES, 100 mm NaCl, pH 7.4 1.86 2.5(06) [206]
48 Aβ42 4 20 mm HEPES, 100 mm NaCl, pH 7.4 1.19 0.76(100) [206]
57 Aβ40 8.2 20 mm to 100 mm HEPES, pH 7.4 [225]
0.09 Aβ16 10 100 mm HEPES, pH 7.4 3.5 [226]
0.04 Aβ40 10 100 mm HEPES, pH 7.4 [226]
0.1 Aβ16 0.2 10 mm MOPS, pH 7.4 0 0.1 [227]
Table 1.5: Measurements of the 𝐾d of Aβ with Cu2+ from using the intrinsic fluores-
cence of tyr10. 𝐾d = 𝐾
App
d /10
𝐶 [228]. Sorted by publication date. [161;206]
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𝐾d/nm Aβ [Aβ]/µm Conditions
Isothermal Titration Calorimetry:
91 Aβ16 70 50 mm HEPES, pH 7.4 [229]
67 Aβ28 70 50 mm HEPES, pH 7.4 [229]
0.67 Aβ16 20 mm HEPES, pH 7.2 [230]
0.34 Aβ16 20 mm HEPES, pH 7.4 [230]
0.33 Aβ16 20 mm PIPES, pH 7.2 [230]
0.91 Aβ40 20 mm HEPES, pH 7.2 [230]
0.42 Aβ40 20 mm HEPES, pH 7.4 [230]
1.1 Aβ40 20 mm PIPES, pH 7.2 [230]
0.67 Aβ40 20 mm HEPES, pH 7.2 [231]
0.95(10) Aβ16 150 20 mm ACES, 100 mm NaCl, pH 7.4 [232]
0.96(10) Aβ16 150 50 mm ACES, 100 mm NaCl, pH 7.4 [232]
0.95(10) Aβ16 150 100 mm ACES, 100 mm NaCl, pH 7.4 [232]
1.7(3) Aβ28 150 20 mm ACES, 100 mm NaCl, pH 7.4 [232]
Potentiometry:
0.21 Aβ16 1100 100 mm KNO3
[209]
0.024 Aβ28 1100 100 mm KNO3
[209]
0.12 Aβ16PEG 2000 200 mm KCl [223]
Table 1.6: Measurements of the 𝐾d of Aβ with Cu2+ by ITC and potentiometry.
Sorted by method, then publication date. [161;206]
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1.6.4 Mixed Zn2+ & Cu2+ Complexes with Aβ
Zn2+ has been shown to influence the sub-conformations of (Aβ ·Cu)i, but not that of
(Aβ ·Cu)ii [194]. However, this does not affect reactive oxygen species production [233].
Mixed Zn2+& Cu2+ complexes have been shown to form on Aβ16-PEG which are
stable at physiological pH [234]. At high concentrations of Zn2+, the Zn2+ binding
pushes the Cu2+ to the N-terminus freeing up his13 and his14 to bind to the excess
Zn2+.
1.6.5 Metal Binding Kinetics
Very little is known about the kinetics of Aβ with Zn2+ or Cu2+. It has been proposed
that their association is likely to be diffusion limited [198;235].
It has been suggested that the movement of the metal ion between different
binding sites is on the time scales of milliseconds or faster, as it is faster than the
time resolution of NMR. [159;197] This has been suggested to still be as fast as when
Aβ is bound in fibrils [187].
1.7 Summary
Aβ is a small peptide of 40/42 residues, that is thought to be involved in Alzheimer’s
disease and is found aggregated in fibrils and plaques. However, it is thought that
small oligomers of Aβ are toxic, rather than in monomeric or fibrillar form. The
mechanism of the toxicity and the mechanism of oligomer formation is unclear.
One hypothesis is that the oligomerisation is caused by Aβ binding to metal ions
including Zn2+ and Cu2+. The equilibrium dissociation constants (𝐾d) for Aβ with
a Zn2+ & Cu2+ are across many orders of magnitude, 1 µm to 100 µm for Aβ ·Zn and
10 pm to 100 nm Cu2+. However, the binding of Aβ to Zn2+ or Cu2+ is too weak to
compete against common metal binding proteins, such as HSA, in the cerebrospinal
fluid. This suggests that Aβ ·Zn and Aβ ·Cu do not form in equilibrium in the CSF.
Zn2+ and Cu2+ are released during neurotransmission, reaching concentrations
of 300 µm and 15 µm respectively. The concentrations are transiently above the 𝐾d
of Aβ with Zn2+ or Cu2+ suggesting that complexes may be able to form. However,
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the kinetic parameters required to estimate the magnitude of complex formation
are unknown.
Amyloid-β, Metal Ions, Membranes, and this Thesis
The aim of this work is to investigate the amyloid-metal hypothesis, with Zn2+ or
Cu2+ as the initial steps in the formation of Aβ dimers. This thesis concentrates
on the determination of the kinetics of Aβ binding to Cu2+ and Zn2+ in vitro. As
the kinetics are fundamental biophysical properties their values measured in vitro,
should be equally applicable in vivo.
The principles and methods applied, lists of the materials used in this thesis are
described in chapter 2. In particular, stopped flow is the main technique used to
determine kinetics. Stopped flow is used to measure the change in fluorescence of a
reaction as it progresses in time.
In chapter 3, the kinetics of Aβ binding to a single Cu2+ are determined. The
removal of Cu2+ from Aβ ·Cu by various ligands is determined, which may provide
a methodology for drug optimisation. The kinetics of Aβ binding to more than one
Cu2+ is also investigated.
In chapter 4, initially the binding of Aβ to HSA and the aggregation of Aβ with
Zn2+ in thermodynamic equilibrium is investigated. The kinetics of Aβ binding to
Zn2+ and the rates of formation of mixed metal Aβ ·Cu ·Zn complexes is determined.
In chapter 5, Aβ is shown to bind to various model membranes and an order
of magnitude estimate of the number of Aβ on synaptic membranes is made. The
kinetics of Aβ bound to a GM1 micelle with to a single Cu2+ are determined.
In chapter 6, a toy model of a synapse is developed to gain some perspective on
the parameters obtained in the previous chapters, by making a rough estimate of
the binding of Aβ to metal ions under approximate synaptic conditions.
Chapter 7 outlines some of the implications of Aβ and metals from a kinetics
point of view in physiology and the pathology of Alzheimer’s disease.
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Chapter 2
Methods and Materials
2.1 Fluorescence
Fluorescence occurs when an electron in a molecule absorbs a photon, causing it
to move into an excited state, and then later emits some of the energy as a lower
energy (longer wavelength) photon (see Fig. 2.1). This difference in excitation and
emission photon energy allows filters to be used to separate the emitted light from
the excitation source. This phenomena is the basis on which the interactions of
Amyloid-β are probed in this thesis, by labelling one of the components of the system
with a small molecule fluorescent dye. Other types of fluorophore are available, such
as quantum dots and fluorescent proteins. Although their fluorescent properties
may be better, they are both considerably larger than Aβ, and may have a larger
adverse influence on the system.
The electrons of a molecule are primarily separated into different energy levels
by the apparent electrostatic field from the nuclei. These electronic energy levels
are sub-divided by the vibration and rotation modes accessible to the molecule. In
fluorescence, an electron in its ground state can absorb a photon exciting it into a
higher energy state, when the energy of the photon matches the difference in energy
between the two states. The absorbance spectrum of a molecule shows the relative
ease at which different photon energies (wavelengths) can be absorbed. Once the
electron is in an excited state, there are multiple pathways by which it can return
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Figure 2.1: A Jablonski diagram illustrating some of the possible transitions for a
fluorophore. The solid lines are photon adsorbtion or emission processes, the wavy
lines are internal processes in the flurophore, where ‘IC’ is internal conversion, and
‘ISC’ is intersystem crossing. Sn are the singlet states the nth energy level, and Tn
are the triplet states of the nth energy level. The vertical axis represents the energy.
Adapted from [236].
to the ground state. Typically, for fluorescence, the electron undergoes vibrational
relaxation (in approximately a picosecond) into the lowest energy excited state of
the vibrational band. It then emits a photon (after approximately a nanosecond),
to move into one of the vibrational modes of the ground state, before undergoing
vibrational relaxation again into the ground state. The variation in available modes
gives the characteristic emission spectrum for fluorescent molecules.
One alternative to the molecule undergoing fluorescence is internal conversion.
Here the electron moves directly into one of the vibrational modes of the ground
state, however this is relatively rare. The internal conversion between excited states
(in approximately a picosecond) is much more probable, and faster than fluorescent
emission, so typically the electron relaxes into the lowest energy excited state before
emitting.
Another significant relaxation pathway is intersystem crossing. It is caused
by the electron undergoing a ‘forbidden transition’ from a singlet state into a
triplet state. Forbidden, as it requires the spin state of the electron to change.
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In the triplet state, the electron may emit a photon to return to the ground state
(phosphorescence, at least microseconds), as in fluorescence. Alternatively it may
again undergo intersystem crossing into one of the vibrational modes of the ground
state. The long lived nature of this state gives rise to blinking, as the fluorophore is
dark whilst in this state. Whilst in this state the fluorophore is ‘deactivated’, and
the molecule is dark. This phenomena is used for some super-resolution imaging
techniques, to aid with the localisation of molecules.
One major problem for fluorescence studies is photobleaching, in which the
fluorophore is permanently damaged preventing further fluorescence. This is usu-
ally caused when the fluorophore is in the triplet state. This state can then interact
with the triplet ground state of molecular oxygen (O2), which results in the oxida-
tion of the fluorophore. This process limits the useful lifetime of the fluorophore, in
particular with higher excitation intensities, such as when imaging.
2.1.1 Förster Resonance Energy Transfer
Föster resonance energy transfer or fluorescence resonance energy transfer (FRET)
is a distance dependent non radiative energy transfer between two different fluoro-
phores [237]. It is used to show the co-localisation of the two flurophores (∼10 nm)
and allows for the distance between the two fluorophores to be determined.
FRET can occur between two fluorophores when the emission spectrum of one
(donor fluorophore) overlaps with the absorption of the other (acceptor fluorophore).
The donor absorbs a photon, and the energy is non-radiatively transfered to the
acceptor, by a dipole-dipole interaction between the transition dipoles. The acceptor
can then emit the photon by fluorescence. The energy transfer efficiency (𝐸)
𝐸 =
1
1 + ( 𝑟𝑅0 )
6 (2.1)
is very dependent on the distance between the flurophores (𝑟). This allows FRET to
be used as a ‘molecular ruler’, for distances of a few nanometers. The Förster radius
61
(𝑅0) is given by
𝑅0 =
√︃
9000𝑄0 ln(10)𝜅2𝐽
128𝜋5𝑛4𝑁a
, (2.2)
where 𝑄0 is the quantum efficiency of the donor, 𝜅2 is the dipole orientation factor
(typically 2/3 for freely rotating dyes), 𝑛 is the refractive index of the medium, 𝑁a is
Avogadro’s number, and 𝐽 is the spectral overlap integral
𝐽 =
∫︁ ∞
0
𝐹D(𝜆)𝜀A(𝜆)𝜆
4d𝜆 , (2.3)
where 𝐹D is the normalised donor emission spectrum, and 𝜀A is the acceptor molar
extinction coefficient. For the FRET pair BODIPY-FL [238] (donor) and Hilyte Texas
red (acceptor) used in these studies, 𝑅0 ≈ 5.6nm in water (𝑛 = 1.33), see figure 2.2.
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Figure 2.2: Normalised donor emission spectrum, acceptor molar extinction coef-
ficient and spectral overlap for BODIPY-FL [238] (donor) and Hilyte Texas red (ac-
ceptor).
2.2 Experimental Methods
2.2.1 Cleaning and Decontamination
In order for experimental data to be reproducible it is vital that equipment is
thoroughly cleaned, such that the experiments are not affected by the history of
the equipment. To clean the equipment, initially it is rinsed with MQ. Then left in
1 mm EDTA solution for a few minutes. The latter removes metal ions adsorbed to
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surfaces. After that, it is left in 1 v/v% decon 90 overnight. This removes surface
adsorbed proteins and peptides. Finally, it is flushed with copious amounts of MQ.
This method of cleaning is applied to both quartz cuvettes and the stopped flow
machine.
2.2.2 Stopped Flow
A stopped flow machine (KinetAsyst SF-61DX2, Hi-Tech Scientific) is used to meas-
ure the progress of chemical reactions in time. It is able to measure fluorescence,
FRET, adsorbance and anisotropy. There are two modes available, ‘single mixing’
mode, in which there is one mixing step of two solutions immediately before meas-
uring, and ‘double mixing’ mode. In double mixing mode, two samples are mixed
into an ‘age loop’, and left to react for a set amount of time. This solution is then
mixed with a third solution and the fluorescence is measured. The concentration is
halved in each mixing step. A diagram of the flow circuit is shown in figure 2.3.
Samples are were excited at 488 nm by a xenon lamp via a monochromator or a
fiber coupled laser diode (MCLS1-473-20, Thorlabs) at 473 nm. The advantage of
the laser is that higher intensities are available. However, due to the laser power’s
digital feedback system it is unstable at >100 ms timescales, as it causes steps in the
intensity. The light sources are fiber coupled to the optical cell. For the detectors,
photon multiplier tubes are used. For fluorescence measurements the emission
is filtered with a 510 nm long pass filter (510ALP, Omega Filters), to remove the
excitation light. Alternatively a 515 nm long pass filter is used (515 GY, Comar). For
anisotropy measurements, in addition to the long pass filter, there are two polarising
filters (half-wave plate). The data-points were taken using the log time-scale scheme.
This gives batches of linearly spaced points, logarithmically distributed. For analysis,
the data points are weighted by the difference in time between them, as this is likely
to be proportional to the error. This is used as the PMT (photon multiplier tube)
does not give the number of photons, nor does the stopped flow machine give the
integration time used. The dead time of the system is ∼1 ms, so only the data points
after 2 ms are used.
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Figure 2.3: Schematic of the stopped flow machine.
Single Mixing Samples are placed into syringes C & D, from the sample reservoir.
The valves for A & B are left open, disconnecting the syringes from the flow circuit.
The syringes are driven by pneumatic piston. This pushes the solutions through the
flow circuit, mixing just before the optical cell, filling the stop syringe. The solution
in the optical cell, while flowing, has only had about 1 ms since mixing to reach the
optical cell. Once the stop syringe is filled with ∼90 µl, it hits the stop stop, ceasing
the flow, and the data recording starts. This allows the progress of the reaction to be
followed in time, from freshly mixed solution.
Double Mixing Samples for the first mixing are placed in syringes A & B. Buffer is
placed into syringe D, and the sample for the second mixing is placed into syringe C.
When double mixing, all the valves are closed, to connect all four sample syringes to
the flow circuit. Firstly, the front stop is moved in front of drive 1, such that ∼150 µl
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of solution can be pushed through the circuit. The back stop is placed behind drive
2, to prevent any solution being pushed into C & D. When the stops are in place,
drive 1 is powered, mixing solutions A & B together, to fill and flush the age loop.
Once it hits the front stop, a timer is started, allowing the sample to age. Once the
set time has elapsed, drive two is powered. This pushes sample C into the second
mixer, and uses the buffer in D to push the aged solution through into the second
mixer. Once the stop syringe is filled with ∼240 µl, it hits the stop stop, and the
data recording starts with the actual age time calculated.
2.2.3 Fluorometry
A spectrofluorometer (Fluoromax-3, Horiba or Fluoromax-4, Horiba) is used to
measure the output fluorescence of samples, with different incident wavelengths.
The light source used in the fluorometer is a xenon arc lamp to produce visible
and UV light by bremsstrahlung. A diffraction grating separates the light into
different wavelengths, and the chosen excitation wavelength is centred on a slit.
The slit width selects the bandwidth of wavelengths to excite the sample. The
windows of the cuvette which holds the sample, require at least 110 µl. The cuvette
has a maximum capacity of ∼2 ml. The fluorescence is collected perpendicular to
the excitation beam. This is then diffracted off another grating, and put through
the emission slit to select the emission bandwidth of the light of interest. A PMT
(photon multiplier tube) is used to count the number of photons over a time interval.
The PMT is less sensitive at longer wavelengths, so does not give an absolute count
of photons, but this can be corrected for.
2.2.4 Ultraviolet-Visible Spectrophotometry
UV/Vis Spectroscopy (ultraviolet-visible spectrophotometry) is used to measure
the absorption spectrum of a sample. This can then be used to determine the
concentration of substances that absorb light.
The UV/Vis spectrometer (Lambda 25, PerkinElmer) uses two lamps to produce
the different range of wavelengths needed. Deuterium for UV, and tungsten mainly
for visible light [239]. UV/Vis spectrometers are similar in operation to fluorometers
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using gratings to separate out the spectrum. The quartz cuvette holds approximately
600 µl of sample, with a path length of 10 mm. The absorbance (𝐴) is calculated
from the amount of light that is transmitted through the sample, by
𝐴 = − log(𝑇 ) , (2.4)
where 𝑇 is the fraction of transmitted light. As the sample may fluoresce, the
beam wavelength is selected to measure the transmitted proportion of light. The
bandwidth of the system is fixed at 1 nm. [239]
As transmittance is measured, it is important to ‘zero’ the spectrometer with
respect to the buffer solution. This removes background absorbance from the cuvette
and components of the buffer. ‘Scatterers’ in solution may also appear to absorb
light. One source of ‘scatterers’ are bubbles in the cuvette. These may be from
when solution is initially put into the cuvette, or when a cold solution increases in
temperature it becomes less soluble to gasses forming bubbles. Another source is the
aggregation of proteins. Changes of concentrations of proteins in the buffer solution,
or proteins adsorbed to the surface of the cuvette from a previous measurement will
also affect the absorbance spectrum.
Determining Sample Concentration
The concentration of a sample (𝐶) can be determined from the absorbance (𝐴) and
known extinction coefficient (𝜀) at a specific wavelength, using Beer’s Law
𝐶 =
𝐴
𝜀𝐿
, (2.5)
where 𝐿 is the path length of the light through the cuvette. For dye labelled samples,
the peak absorbance (𝐴peak) of the dye is used to determine the concentration of
the dye. For unlabelled proteins, the concentration can be determined if it contains
UV absorbing amino acids, such as tyrosine or tryptophan, typically measured at
280 nm. Human Aβ contains one tyrosine at position 10. When a peptide is dye
labelled, the label usually contributes some absorbance at 280 nm, by a factor 𝜙
proportional to 𝐴peak. The concentration of the peptide can thus be determined
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from
𝐶 =
𝐴280nm −𝜙𝐴peak
𝜀280nm𝐿
. (2.6)
However, this does not give the proportion of labelled peptide. Here it will be
assumed that the concentration of the dye is the concentration of the dye labelled
peptide.
2.2.5 Microscopy Methods
Confocal Microscopy
Confocal microscopes are used to observe femtolitre volumes, and unlike conven-
tional microscopes, use an aperture to block some of the out of focus light not
from the focal plane (see Fig. 2.4) [240]. The aperture reduces the apparent emission
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Figure 2.4: Illustration of how the detector aperture blocks out of focus light from
out of focus planes in a confocal microscope. Adapted from [240].
volume in the direction of the beam. This allows for higher spatial frequencies
to be observed with less background, out of focus light. In this thesis, confocal
microscopy is used for fluorescence correlation spectroscopy (FCS) and measuring
FRET.
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Microscopy Setup The custom-built microscope setup used is shown in fig-
ure 2.5 [241], and was built by Dr. Liming Ying. The argon ion laser (35LAP321-230,
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Figure 2.5: Confocal microscopy setup.
Melles Griot, USA) was used to excite fluorophores in the confocal volume. The
laser is tunable to different wavelengths. 488 nm and 514 nm light is used to excite
the Hilyte 488 and Hilyte 555 dyes, respectively. In the figure 2.5, the first mirror
actually is a pair of mirrors, to redirect and lift the beam to the height of the
microscope. The neutral density filter reduces the laser intensity by a factor of
10−𝐷 , where 𝐷 is the optical density [242]. The Dove prism totally internally reflects
the beam, and is used to remove the laser’s plasma lines [243]. The beam expander
focuses the beam to a point and the collimating lense recollimates the beam after
it has expanded. The spatial filter, an aperture at the focus, ‘cleans up’ the beam
by removing aberrations, i.e. the ring-shaped pattern around the main beam in the
Fourier plane (one focal length from the lense). In the next pair of mirrors, the
first changes the position that the beam will hit the second mirror, changing the
entry position into the inverted microscope. The second mirror corrects the entry
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angle. The aperture on entry to the microscope reduces the size of the beam such
that it under fills the back-aperture of the objective. This elongates and enlarges
the confocal volume, and reduces diffraction fringes, to produce a nearly Gaussian
illumination profile [244]. Under filling the back aperture of the objective has been
shown experimentally by Hess et al. to improve FCS measurements [244]. The laser
power is measured after the aperture and before entry into the microscope. The
inverted microscope (Nikon Eclipse TE2000-U) uses a high numerical aperture
oil-immersion objective (Apo TIRF 60×, NA 1.49, Nikon, UK). This produces less
reflected light than a water-immersion objective due to the similarities in the
refractive indexes of the oil and glass [245]. Oil immersion objectives are also better
at light collection [246]. Type FF immersion oil (Cargille, USA) is used, as it has
virtually no fluorescence. The microscope is used to focus the beam 6 µm into the
solution from the surface of the slide for the experiments. 6 µm is used so that the
confocal intensity profile is consistent across measurements. The excitation filter is
a bandpass filter to let through the beam. The dichroic separates the excitation and
emission beam, reflecting the excitation beam towards the objective, and allowing
the emission fluorescence to pass through. The lense within the microscope focuses
the light to a point where the confocal pinhole is placed. The dichroic is used
in FRET experiments, to separate the donor and acceptor fluorescence signal for
detection. In FCS experiments, the beam splitter is used to increase temporal
resolution. The emission filters reduce misdirected photons, and photons that
are not in the fluorophore’s main emission range. The final lenses focus the emis-
sion to an approximately 80 µm spot on the APD (avalanche photodiode) (single
photon counting module spcm-aqr-14). The sensor is approximately 180 µm across,
however the edges are less sensitive [247]. They have a dead time of 50 ns between
detecting pulses [247]. The APD’s are connected to a digital hardware correlator
(flex02-01d/c) with a sample rate of 640 MHz [248]. They are also connected to a
multichannel scaler (MCS-pci) in a computer, which records counts, with rates of
up to 150 MHz [249].
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Figure 2.6: The difference in beam configuration for wide field and TIRF microscopy.
Adapted from [250].
TIRF / Wide Field Microscopy
TIRF (Total Internal Reflection Fluorescence) and wide field microscopes are similar
in setup to confocal microscopes, but do not have the pinhole to block out of focus
light.
In wide field microscopy the beam goes through the centre of the objective
exciting the fluorophores directly (see Fig. 2.6a). This illuminates a large amount of
the solution, increasing the background noise due to out of focus flurophores.
In TIRF microscopy an evanescent wave is produced, from total internal reflec-
tion (TIR) of the beam in the objective. This is used to excite the fluorophores. The
intensity of the evanescent wave exponentially decreases into the sample, typically
propagating 100 nm into the sample from the glass slide/sample interface [251]. The
intensity (𝐼) is given by
𝐼(𝑧) = 𝐼(0)e
𝑧
𝑑 , where 𝑑 =
𝜆
4𝜋
(︁
𝑛21 sin
2(𝜃)−𝑛22
)︁− 12 , (2.7)
𝑧 is the distance from the slide, 𝜆 is the wavelength, 𝜃 is the angle of incidence
and 𝑛1 & 𝑛2 are the refractive indices of the slide & sample, respectively [252]. The
propagation distance can be decreased by increasing the incidence angle [250].
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The lateral resolution of confocal, TIRF and wide field is diffraction limited
to approximately 𝜆2𝑛
[253]. TIRF has the highest axial resolution (∼100 nm), then
confocal (∼1 µm), and wide field with the least [254].
Microscopy Setup The custom-built microscope setup used is shown in fig-
ure 2.7 [241], built by Dr. Liming Ying. The equipment and setup is similar to the
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Figure 2.7: TIRF/Wide field microscopy setup.
confocal setup in figure 2.5, so only the differences will be described. The shutter
is used to control the blocking of the beam, and is unblocked just after a series of
images starts to be taken. This reduces the amount of photobleaching that occurs
before acquisition. To switch between TIRF and wide field mode there are a pair
of flip mirrors, which are raised or lowered. These are also used during alignment,
allowing the TIRF and wide field to show the same lateral position on the slide. Type
DF oil (Cargille, USA) is used for the objective. It has slightly more fluorescence
than FF oil, but has a higher viscosity which more closely matches the refractive
index of cover slips. The EMCCD Camera (CoolView EM 1000, Photonic Science)
records the image.
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2.3 Analytical Methods
2.3.1 Fluorescence Correlation Spectroscopy
The confocal microscope setup is used to monitor the intensity fluctuations as fluoro-
phores diffuse across the confocal volume. In fluorescence correlation spectroscopy
(FCS), the signal from the APD is auto-correlated, which looks for repeating patterns
in the signal. FCS can give the average diffusion time for a fluorophore to cross the
confocal volume and the average concentration of molecules in the confocal volume.
The normalised autocorrelation (𝐺(𝜏)) function correlates the time series with
itself, shifted by time 𝜏 :
𝐺(𝜏) =
⟨𝐼(𝑡)𝐼(𝑡 + 𝜏)⟩
⟨𝐼(𝑡)⟩2 − 1 , (2.8)
where 𝐼(𝑡) is the photon count at time 𝑡 [255], and
⟨𝑓 (𝑡)⟩ = 1
𝑇
∫︁ 𝑇
0
𝑓 (𝑡)d𝑡 , (2.9)
where 𝑇 is the measurement time. This produces traces such as in figure 2.8. The
different time scales in an FCS curve correspond to different types of behaviour
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Figure 2.8: The different timescales over which the FCS curve is affected by different
processes. [256]
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in the system. The system described in section 2.2.5 is only capable of detecting
the longer scale behaviour due to the dead time of the detectors. The diffusion
component (>10−2 ms) can be measured with one APD, and the photophysical
behaviour of the fluorophores (10−4 ms to 10−2 ms), such as triplet state blinking,
with two APD’s and a beam splitter. Under this setup the signals are pseudo-
autocorrelated (cross-correlation with signals that are similar). If two APD’s are not
used then the autocorrelation curve rises very steeply at the ‘triplet’ timescales, as
the APD’s dead time correlates. Using two APD’s reduces the effective dead time of
the detector.
When comparing the signal with itself at long time scales, the signal from
different molecules diffusing through the confocal volume may or may not ‘line up’
as diffusion is a random process. The rise in correlation when moving to shorter
time scales is due to signal from the same molecule starting to align. The length
of time spent in the confocal volume varies for different molecules as they random
walk through the focus. Therefore initially (from decreasing 𝜏) the signal from the
molecules that spent longest in the focus overlap, increasing 𝐺(𝜏), then the ones
which spent less and less time, until 𝜏 is much shorter than the diffusion time, then
there is effectively no difference in 𝐺(𝜏). The position of the S-shape depends on the
diffusion time of the molecules. The slower the molecules, the longer the diffusion
time, and the further the curve is shifted to longer 𝜏 . The amplitude of the S-shape
is inversely proportional to the concentration of fluorescent particles.
Autocorrelation is related to, and can be calculated by way of a Fourier trans-
form, as 𝐺(𝜏) = 𝐼(𝜏) ⋆ 𝐼(𝜏) = ℱ −1[ℱ (𝐼(𝜏))2]. It therefore suffers from some of the
same problems as Fourier transforms, in particular time information about when
something happened is lost.
The diffusion part of FCS curves can be fitted with
𝐺2D(𝜏) =
𝛾
𝑁
(︁
1 + 𝜏𝜏D
)︁ +𝐶 , (2.10)
where 𝛾 is the shape factor, 𝑁 is the average number of molecules in the focus
and 𝜏D is the average time for a molecule to traverse the radial dimension of the
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volume [255]. This assumes that the diffusion is two dimensional. When using the
form for a three dimensional confocal volume, one of the parameters cannot be
fitted. This is due to the length of the confocal volume (approximately 1 µm), over
which there is little signal fluctuation for movement in the direction of the beam
axis. 𝐺(0) = 𝛾/𝑁 is the amplitude of the correlation function at 𝜏 = 0 [255]. This can
be used to estimate the concentration (𝐶)
𝐶 =
𝑁
𝑁A ×𝑉 ≈
1
𝐺(0)×𝑁A ×𝑉 , (2.11)
where 𝑁A is Avogadro’s number and V is the focal volume (approximately 1 fl). The
diffusion time
𝜏D =
𝜔20
4𝐷
, where 𝜔0 =
FWHM√︀
2ln(2)
, (2.12)
𝐷 is the diffusion coefficient, 𝜔0 is the beam waist and FWHM is the full width half
maximum (the diameter of the confocal volume at half of the maximal intensity) [255].
Multiple component curves, due to multiple fluorescent species with different
𝜏D’s (𝜏1 & 𝜏2), can be fitted with
𝐺(𝜏) =
𝐺1(0)(︁
1 + 𝜏𝜏1
)︁ + 𝐺2(0)(︁
1 + 𝜏𝜏2
)︁ +𝐶 , (2.13)
where
𝐹1 =
𝐺1(0)
𝐺1(0) +𝐺2(0)
and 𝐹2 =
𝐺2(0)
𝐺1(0) +𝐺2(0)
(2.14)
are the relative population fractions of type 1 and type 2, respectively. This can then
be used to calculate the mean diffusion time
𝜏D = 𝐹1𝜏1 +𝐹2𝜏2 (2.15)
for both species diffusing through the confocal volume.
One problem with FCS is its inability to separate components with similar
diffusion times. It has been shown for a two component system that the 𝜏D’s need to
differ by a factor of 1.6 to distinguish the two components [257].
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When there is triplet state behaviour, 𝐺(𝜏) can be modified to
𝐺(𝜏) =
⎛⎜⎜⎜⎜⎜⎜⎝ 𝐺1(0)(︁1 + 𝜏𝜏1 )︁ +
𝐺2(0)(︁
1 + 𝜏𝜏2
)︁⎞⎟⎟⎟⎟⎟⎟⎠(︁1−𝐹 +𝐹e −𝜏𝑡m )︁+𝐶 , (2.16)
where 𝐹 is the fraction of molecules in the dark state and 𝑡m is mean triplet state
lifetime [256]. Triplet state behaviour in typically in the 10−4 ms to 10−2 ms region,
and is dependent on the excitation intensity. This is because increasing the intensity
increases the cycling rate of the fluorophore, increasing the probability that the
transition is into the dark triplet state, making it more prominent in the FCS curve.
If the behaviour is not intensity dependant it may be due to other processes, such as
the movement of the fluorophore if it causes it to be quenched by the molecule it is
attached to. Increasing the excitation intensity can also photobleach the fluorophores
more quickly, decreasing their apparent diffusion time.
2.3.2 Binding Reactions and Equilibria
The law of mass action can be used to predict the progress and behaviour of a
chemical reaction in time. The law of mass action states that the rate of production
of products is proportional to the product of the concentrations of the constituents,
and vice versa for the reverse reaction. That is
A + B
𝑘on−−−⇀↽−−
𝑘off
C (2.17)
gives us
d[C]
d𝑡
= 𝑘on[A][B]− 𝑘off[C] , and d[A]d𝑡 =
d[B]
d𝑡
= 𝑘off[C]− 𝑘on[A][B] , (2.18)
where 𝑡 is time, and [x] denotes the concentration of x. When reactions are performed
the total amounts of A and B are known in all its forms. Conservation of matter can
then be used to give
[A]T = [A] + [C] , and [B]T = [B] + [C] , (2.19)
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where [𝑥]T is the total concentration of 𝑥. These equations can be used to determine
the reaction’s transient and steady state behaviour.
The reaction will eventually reach steady state, that is
d[A]
d𝑡
=
d[B]
d𝑡
=
d[C]
d𝑡
= 0 , (2.20)
as 𝑡→∞. Therefore the equilibrium dissociation constant 𝐾d
𝐾d =
𝑘off
𝑘on
=
[A][B]
[C]
(2.21)
can be determined from the 𝑘on and 𝑘off. The thermodynamic parameter 𝐾d can thus
be used to determine the concentration of reactants and products in equilibrium. In
general, equilibrium constants are denoted with uppercase letters, whereas rates
are denoted with lowercase letters.
To determine the transient state behaviour of the reaction, the differential equa-
tions are solved. The experiments in this thesis are performed under pseudo first
order conditions, that is when one of the reactants is in greater excess, i.e. [A]≪ [B].
Here we will assume that to be true when less than 5 % of one of the reactants is
consumed, i.e. 20× [A] < [B]. This produces simpler analytical solutions, but is also
beneficial under practical conditions.
In the above model, the pseudo-first order condition reduces the equations to
d[A]
d𝑡
= 𝑘off[C]− 𝑘on[A][B] , d[C]d𝑡 = 𝑘on[A][B]− 𝑘off[C] , (2.22)
[A]T = [A] + [C] ,
d[B]
d𝑡
= 0 . (2.23)
To which the solutions are
[A] =
[A]T𝑘off
𝑘off + 𝑘on[B]
+
(︃
[𝐴]|𝑡=0 −
[A]T𝑘off
𝑘off + 𝑘on[B]
)︃
e−(𝑘off+𝑘on[B])𝑡 , (2.24)
[C] =
[A]T[B]𝑘on
𝑘off + 𝑘on[B]
+
(︃
[𝐴]|𝑡=0 −
[A]T𝑘off
𝑘off + 𝑘on[B]
)︃
e−(𝑘off+𝑘on[B])𝑡 , (2.25)
which are exponentials with linear dependence on [B] for the rates.
For comparison without the pseudo-first order condition the differential equa-
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tion are non-linear, with the solutions
[A] =
−𝑘off − 𝑘on𝑐1 +𝛼 tan
(︁
1
2𝛼(𝑐3 − 𝑡)
)︁
2𝑘on
, (2.26)
[B] =
−𝑘off + 𝑘on𝑐1 +𝛼 tan
(︁
1
2𝛼(𝑐3 − 𝑡)
)︁
2𝑘on
, (2.27)
[C] =
𝑘off𝑘on(𝑐1 + 2𝑐2)−𝛼 tan
(︁
1
2𝛼(𝑐3 − 𝑡)
)︁
2𝑘on
, (2.28)
where
𝛼 =
√︁
−(𝑘off + 𝑘on𝑐1)2 − 4𝑘off𝑘on𝑐2 , (2.29)
and 𝑐1, 𝑐2 & 𝑐3 are the constants of integration. However, when determining the
constants of integration using the initial conditions, the equations are transcendental
making solutions difficult to find algebraically.
The Hill Equation
The Hill equation is a phenomenological equation commonly used to describe
cooperative binding of a ligand L to a receptor. At equilibrium it gives the ratio of
ligand bound receptors to total receptors (𝜃)
𝜃 =
1
1 +𝐾d/[L]𝛽
=
1
1 + (𝐾A/[L])
𝛽
, (2.30)
where 𝐾A is the microscopic dissociation constant and 𝛽 is the Hill coefficient. If
𝛽 > 1, then there is positive cooperativity, that is when one ligand has bound, it
increases affinity for the next ligand to bind to it. If 𝛽 = 1 then there is no effect on
the next ligand binding, and if 𝛽 < 1 then it is harder for the next ligand to bind.
This model assumes that [L] is the free ligand concentration, which is true when
the concentration of ligand is much greater than the concentration of receptors. It
can be derived from the model
R + L
Kd−−−⇀↽−− R ·L (2.31)
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when 𝛽 = 1, for a receptor R and ligand L. The ratio of bound receptors is
𝜃 =
[R ·L]
[R] + [R ·L] = 1−
[R]
[R]T
, (2.32)
where [R]T is the total concentration of receptor. Given the assumption that the
ligand concentration is constant then
𝐾d =
[R][L]
[R ·L] =
[R][L]
[R]T − [R]
=⇒ [R]
[R]T
=
𝐾d
[L] +𝐾d
, (2.33)
and thus
𝜃 = 1− 𝐾d
[L] +𝐾d
=
[L]
[L] +𝐾d
=
1
1 +𝐾d/[L]
. (2.34)
If the receptor is fluorescent and quenches when a ligand binds, then the fluor-
escence (𝐹) is
𝐹 = 𝐹b +𝜆(1−𝜃)[R]T , (2.35)
where 𝐹b is the background fluorescence, 𝜆 is a constant proportional to the amount
of fluorescence per receptor, and [R]T is the total concentration of the receptor. Then
the maximal fluorescence (𝐹max), when no ligand is bound (𝜃→ 0) is
𝐹max = lim
𝜃→0 (𝐹b +𝜆(1−𝜃)[R]T) = 𝐹b +𝜆[R]T =⇒ 𝜆[R]T = 𝐹max −𝐹b . (2.36)
Therefore the fluorescence traces may be fitted with the form
𝐹 = 𝐹b +
𝐹b −𝐹max
1 + ([L]/𝐾a)𝛽
. (2.37)
This function is sigmoidal, with amplitude 𝐹b −𝐹max and offset 𝐹b.
1 : 1 Stoichiometry Binding Model
1 : 1 stoichiometry binding is
A + C
Kd−−−⇀↽−− A ·C , (2.38)
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for reactants A & C and product A ·C, with an associated 𝐾d. When the total
concentrations of A is approximately that of C, the Hill equation cannot be applied.
However, there is an analytical solution to the model.
The model gives the equations
𝐾d =
[A][C]
[A ·C] , and
[A]T = [A] + [A ·C]
[C]T = [A] + [A ·C]
(2.39)
which may be solved to give
[A] =
[A]T − [C]T −𝐾d ±
√︀
(𝐾d + [C]T − [A]T)2 + 4𝐾d[A]T
2
. (2.40)
Taking the limit [C]T →∞, shows that the + form is the relevant form.
If unbound A is fluorescent, the total fluorescence (𝐹) is
𝐹 = 𝐹b +𝜆[A] , and 𝜆 =
𝐹max −𝐹b
[A]T
, (2.41)
where 𝐹b is the background fluorescence, 𝜆 is a constant proportional to the amount
of fluorescence per free A, and 𝐹max is the maximal fluorescence when no C is bound
to A. Therefore the fluorescence as a function of [A]T is
𝐹 = 𝐹b +
𝐹max −𝐹b
2[A]T
(︂
[A]T − [C]T −𝐾d +
√︁
(𝐾d + [C]T − [A]T)2 + 4𝐾d[A]T
)︂
, (2.42)
which may be used to fit fluorescence binding curves.
2.4 Materials and Sample Preparation
2.4.1 Amyloid-β Samples
Aβ stock solutions should be dissolved at high pH (∼ pH 9), to prevent aggregation,
aliquoted, and stored at −20 ∘C. All Aβ samples were purchased from AnaSpec,
via Cambridge Bioscience. They have a purity of ≥ 95%, obtained from the peak
area by HPLC (high-performance liquid chromatography), except when custom
synthesised.
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Unlabelled Amyloid-β’s:
Aβ16 Beta-Amyloid (1–16), Human
Sequence: DAEFRHDSGYEVHHQK
Aβ40 Beta-Amyloid (1–40), Human
Sequence: DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV
Aβ42 Beta-Amyloid (1–42), Human
Sequence: DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
C-Terminally or Mid-Labelled Amyloid-β’s:
Aβ16LysHL488 Beta-Amyloid (1–15)-Lys16(HiLyte Fluor 488), Human
Sequence: DAEFRHDSGYEVHHQ-K(HiLyte Fluor 488)
RatAβ16LysHL488 CBDM-5/Beta-Amyloid (1–15)-Lys16(HiLyte Fluor 488). This
peptide was custom synthesised and has a purity of > 90%, peak area by
HPLC.
Sequence: DAEFGHDSGFEVRHQ-K(HiLyte Fluor 488)
Aβ28LysHL488 Beta-Amyloid (1–28)-Lys(HiLyte Fluor 488), Human
Sequence: DAEFRHDSGYEVHHQKLVFFAEDVGSNK-K(HiLyte Fluor 488)
Aβ40Cys20HL488 CBDM-6/(Hilyte488)Cys20-BetaAmyloid (1–40). This peptide
was custom synthesised and has a purity of > 90%, peak area by HPLC.
Sequence: DAEFRHDSGYEVHHQKLVF-C(HiLyte Fluor 488)-AEDVGSNKGA-
IIGLMVGGVV
N-Terminally Labelled Amyloid-β’s:
Aβ16HL555 Beta-Amyloid (1–16), HiLyte Fluor 555-labeled, Human
Sequence: HiLyte Fluor 555-DAEFRHDSGYEVHHQK
Aβ40HL488 Beta-Amyloid (1–40), HiLyte Fluor 488-labeled, Human
Sequence: HiLyte Fluor 488-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGA-
IIGLMVGGVV
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Aβ40CysHL555 [Cys(HiLyte Fluor 555 C2 maleimide)]-Beta-Amyloid (1–40), Hu-
man
Sequence: C(HiLyte Fluor 555 C2 maleimide)-DAEFRHDSGYEVHHQKLVFF-
AEDVGSNKGAIIGLMVGGVV
Aβ40HLTR Beta-Amyloid (1–40), HiLyte Fluor TR-labeled
Sequence: HiLyte Fluor TR-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGA-
IIGLMVGGVV
Aβ40HL647 Beta-Amyloid (1–40), HiLyte Fluor 647-labeled, Human
Sequence: HiLyte Fluor 647-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGA-
IIGLMVGGVV
Aβ42HL488 Beta-Amyloid (1–42), HiLyte Fluor 488-labeled, Human
Sequence: HiLyte Fluor 488-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGA-
IIGLMVGGVVIA
2.4.2 Serum Albumins
HSA (human serum albumin) is found in the CSF in the range of 1 µm to 6 µm, and
is an important carrier protein and metal binder. BSA (bovine serum albumin) is
the equivalent in cows. It is also used to block surfaces, such as glass or quartz, to
prevent the surface adsorption of other proteins.
BSA Albumin from Bovine serum. Purity ≥ 99% for agarose gel electrophoresis.
Purchased from Sigma-Aldrich.
BSA-AL488 Albumin from Bovine Serum (BSA), Alexa Fluor 488 conjugate. The
specification for the maximum degree of labelling is 5-8 moles of dye per mole
protein. Purchased from Life Technologies.
HSA Albumin from human serum Purity ≥ 99% for agarose gel electrophoresis.
Purchased from Sigma-Aldrich.
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2.4.3 Metal Chlorides
The metal chlorides were dissolved in MQ at 20 mm. The exception was NaCl, which
was dissolved at 2m in MQ, as it was used to make buffer solutions. The divalent
metal chlorides can cause buffers to precipitate, in particular with PBS, and thus
Good’s buffers are recommended. For this reason Hepes was chosen as the buffer
for the metal experiments. However, millimolar concentrations of Cu2+ and Zn2+
still cause precipitation, and should still be stored in MQ.
NaCl Sodium chloride. Purity ≥ 99.5%. Purchased from Sigma-Aldrich.
MgCl2 Magnesium chloride hexahydrate. Purity > 99%. Purchased from Sigma-
Aldrich.
CaCl2 Calcium chloride dihydrate. Purity > 99%. Purchased from Sigma-Aldrich.
MnCl2 Manganese(II) chloride tetrahydrate. Purity > 99.99%. Purchased from
Sigma-Aldrich.
FeCl2 Iron(II) chloride tetrahydrate. Purity > 99%. Purchased from Sigma-Aldrich.
CoCl2 Colbolt(II) chloride, anhydrous. Purity 99.7%. Purchased from Alfa Aesar.
NiCl2 Nickel(II) chloride hexahydrate. Purchased from Sigma-Aldric.
CuCl2 Copper(II) chloride dihydrate. Purity > 99%. Purchased from Alfa Aesar.
ZnCl2 Zinc chloride. Purchased from Fluka Analytical.
CdCl2 Cadmium chloride. Purity > 99.99%. Purchased from Sigma-Aldrich.
2.4.4 Model Membrane Components
GM1 Monosialoganglioside GM1 from bovine brain. Also known as Ganglioside
GM1, and monosialo. Purity ≥ 95%, by TLC (thin layer chromatography).
Purchased from Sigma-Aldrich.
GM1 Bodipy BODIPY FL C5-Ganglioside GM1. Purity ≥ 90%, by HPLC. Purchased
from Invitrogen.
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Cholesterol Cholesterol. Also known as 3β-Hydroxy-5-cholestene, and 5-Cholesten-
3β-ol . Purity ≥ 90%, by gas chromatography. Purchased from Sigma-Aldrich
Sphingomyelin Sphingomyelin from bovine brain. Also known as N-Acyl-4-
sphingenyl-1-O-phosphorylcholine, and N-Acyl-D-sphingosine-1-phosphocholine.
Purity ≥ 97%, by TLC. Purchased from Sigma-Aldrich.
POPC 2-Oleoyl-1-palmitoyl-sn-glycero-3-phosphocholine. Also known as (7R,17Z)-
4-Hydroxy-N,N,N-trimethyl-9-oxo-7-[[(1-oxohexadecyl)oxy]methyl]-3,5,8-
trioxa-4-phosphahexacos-17-en-1-aminium 4-oxide, inner salt, 1-Palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine, 1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-
glycero-3-phosphocholine, 1-Hexadecanoyl-2-(cis-9-octadecenoyl)-sn-glycero-
3-phosphocholine, 3-sn-Phosphatidylcholine, 2-oleoyl-1-palmitoyl, L-β-
Oleoyl-γ-palmitoyl-α-lecithin, PC(16:0/18:1(9Z)), PC(16:0/18:1), PC(16:0/18:1w9),
and POPC. Purity ≥ 95%, by gas chromatography, and ≥ 98%, by TLC. Pur-
chased from Sigma-Aldrich.
POPG 2-Oleoyl-1-palmitoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt.
Also known as (9Z)-9-Octadecenoic acid (1R)-1-[[[(2,3-dihydroxypropoxy). . .
hydroxyphosphinyl]oxy]methyl]-2-[(1-oxohexadecyl)oxy]ethyl ester mono-
sodium salt, 1-Palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) so-
dium salt, 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol sodium salt, 1-
hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1′-rac-glycerol) so-
dium salt, L-α-Phosphatidyl-DL-glycerol, β-oleoyl-γ-palmitoyl sodium salt,
PG(16:0/18:1(9Z)), POPG-Na, and POPG. Purity ≥ 98%, by TLC. Purchased
from Sigma-Aldrich.
2.4.5 Buffers and Solvents
Buffers are used to keep the pH of the solutions at a known concentration, as the pH
can be affected by reactions, and can effect the protonation states of molecules. The
buffers also contain NaCl, to keep the ionic strength at near physiological conditions.
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Buffers:
Hepes HEPES. Also Known as 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid.
Purchased from Alfa Aesar or Sigma-Aldrich, as buffer solutions at pH 6.5, 7.5
& 8.0.
Hepes NaCl 50 mm Hepes with 100 mm NaCl, at pH 7.5 unless otherwise stated.
Hepes BSA Hepes NaCl with 0.3 gl−1 BSA (4.32 µm).
PBS Phosphate buffered Saline. The 10× solution was diluted in MQ to containe
11.9 mm phosphates, 137 mm sodium chloride, and 2.7 mm potassium chloride
at pH 7.4(1). Purchased from Fisher Scientific. PBS should not be used with
divalent metal cations as it will precipitate.
PBS BSA PBS with 0.3 gl−1 BSA (4.32 µm).
Tween TWEEN 20, for molecular biology. Also known as Polyethylene glycol
sorbitan monolaurate, and Polyoxyethylenesorbitan monolaurate. Purchased
from Sigma-Aldrich. This was used in some buffers at 0.05 % volume.
Solvents:
MQ Purified and deionised water, with a resistivity of 18.2 MΩcm.
Methanol Methanol. Purity 99.8%, by gas chromatography. Purchased from VWR.
Choloroform Chloroform, anhydrous. Purity > 99%. Purchased from Sigma-
Aldrich.
DMSO Dimethyl Sulfoxide. Purity ≥ 99.9%. Purchased from Sigma-Aldrich.
Ethanol Ethanol, 190 proof, for molecular biology. Purchased from Sigma-Aldrich.
Ammonium Hydroxide Ammonium hydroxide. Purchased from Sigam-Aldrich.
2.4.6 Other Small Molecules
EDTA Ethylenediaminetetraacetic acid. Purchased from Fisher Scientific.
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Fluozin FluoZin-1, Tripotassium Salt, cell impermeant. It is based on the N-(2-
methoxyphenyl)iminodiacetate chelator. Purity ≥ 90%, by HPLC. Purchased
from Invitrogen.
Glycine Glycine. Purity ≥ 99%. Purchased from Sigma-Aldrich.
CQ Clioquinol. Also known as 5-Chloro-7-iodo-8-quinolinol, 5-Chloro-8-hydroxy-
7-iodoquinoline, and Iodochlorhydroxyquin. Purity 98.9%, by HPLC. Pur-
chased from Sigma-Aldrich. CQ was disolved at 20 mm in DMSO, or 2 mm in
Ethanol.
L2-b L-2b. Also known as N1,N1-dimethyl-(pyridin-2-ylmethyl)benzene-1,4-
diamine. Acquired from Prof. Mi Hee Lim, University of Michigan. L2-b
solution was prepared by dissolving in methanol, and leaving it to evaporate,
then dissolving in Hepes NaCl at 4 mm. It is important that the L2-b is
prepared fresh, as otherwise it will oxidise and change colour.
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Chapter 3
Interactions of Amyloid-β with
Cu2+
Cu2+ is thought to be implicated in Alzheimer’s disease as it is found bound to Aβ
plaques in vivo, and also found to bind in vitro. However, whether Cu2+ binding
plays a critical role in the events leading to Alzheimer’s disease is still undetermined.
It is thought that Cu2+ bound to Aβ may play a role in promoting Aβ oligomerisation
and aggregation, or producing reactive oxidative species. Thus studying the binding
of Cu2+ to Aβ may give insight into physiological events leading to Alzheimer’s
disease.
Over the past 20 years the studies of Cu2+ binding to Aβ have given an estimate
of the equilibrium dissociation constant (𝐾d) to be between 10 pm to 100 nm [161],
showing that there are two forms of Aβ bound Cu2+, and binding coordinations
have been suggested. This, combined with the concentration of Cu2+ along with
the known concentrations and 𝐾d’s of competitors in the CSF, eliminates the pos-
sibility of monomeric Aβ binding Cu2+ in the CSF. This leaves areas with higher
concentrations of Cu2+ or a lack of competitors. One such example is the synaptic
cleft. However, the possibility of binding there, given the transient nature of its
Cu2+ release and diffusion, cannot be determined from thermodynamics alone. The
knowledge of the kinetics of the interactions, from which the thermodynamics may
be derived, is required. Further to this, the parameters determining the binding of
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multiple Cu2+ ions to Aβ, although shown, are yet to be addressed.
Here the quenching of a covalently attached external fluorophore to Aβ by Cu2+
is exploited to study the binding and kinetics of Aβ to a single, and then multiple,
Cu2+ ions. The competitiveness of Aβ compared to HSA or glycine is determined,
and the copper assisted dimerisation rate is measured. This is mainly carried out by
using stopped-flow methodologies to look at the temporal change in fluorescence as
reactions progress.
3.1 Quenching of Labelled Aβ by Cu2+
One of the methods used in the literature to measure the 𝐾d of Aβ binding to Cu2+
involves measuring quenching of the intrinsic fluorescence of the tyrosine in Aβ,
once Cu2+ is bound. The main drawback with this methodology is the low sens-
itivity in measuring the fluorescence. This is due to tyrosine’s small absorbance
(𝜀 = 1400cm−1m−1 at 274 nm), combined with its low quantum efficiency (𝜑 = 0.14).
This therefore requires high concentrations of Aβ to obtain sufficient signal, complic-
ating experiments by unquantifiable amounts of oligomerisation and aggregation.
Furthermore, this method cannot be applied to murine Aβ, given its lack of an
intrinsic tyrosine.
It is known that engineered fluorescent dyes are also quenched by Cu2+, due to
its paramagnetic∗ properties. This poses the question as to whether engineered dyes
can also be used to investigate Aβ binding to Cu2+, given their increased brightness.
For comparison, HL488 has 𝜀 = 68000cm−1m−1 (at 503 nm) and 𝜑 = 0.91. This
is over two orders of magnitude brighter for a similar excitation intensity at its
absorption maxima. It is also sufficiently bright to be suitable for single molecule
studies.
To determine the quenching selectivity of Cu2+ by labelled Aβ, compared to
other common divalent cations (M2+), the fluorescence of 100 nm of labelled Aβ was
measured with (𝐹), and without (𝐹0) 100 µm of divalent cations, in Hepes NaCl. 50 s
was allowed for the Aβ ·M2+ reaction to complete. The fluorescence was measured
∗Atoms or ions with unpaired electrons in the d-orbital are paramagnetic.
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using the fluorometer. The samples were left to equilibrate with the quartz cuvettes
for 2 h at 25 ∘C before measurement. The excitation and emission wavelengths
for data collection were 480 nm/527 nm, 520 nm/564 nm, and 605 nm/670 nm, for
Hilyte 488, Hilyte 555 and Hilyte 647, N-terminally labelled Aβ respectively.
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Figure 3.1: Quenching selectivity of 100 nm N-terminally labelled Aβ, by 100 µm of
chosen common divalent cations. 𝐹0 is the initial fluorescence intensity without the
cations, whereas 𝐹 is the the fluorescence in the presence of the cations. Fe2+ was
not used as it oxidises very quickly in Hepes NaCl.
The results shown in figure 3.1 show that Cu2+ does bind and quench labelled
Aβ. Excluding the labelled Aβ42, the dye is almost completely quenched to 98.7(5) %,
whereas the other metal cations were quenched to 14(8) %. The Cu2+ quenches a
range of dyes, allowing any of these to be used for Cu2+ binding studies. This data
also shows that Cu2+ could interfere in studies which do not specifically account
for this effect, also employing labelled Aβ, and would likely prevent FRET studies.
Free Alexa Fluor 488 C5 maleimide (similar to HL488) did not quench with 100 µm
Cu2+, and free Hilyte Fluor 488 maleimide was not quenched by 10 µm CuCl2.
At higher concentrations, other mechanisms of quenching, such as Stern-Volmer
quenching [258] may occur.
Aβ42 is known to aggregate with Cu2+ and Zn2+. This suggests that the increased
quenching for Zn2+, Co2+, Ni2+ and Cd2+ may be due to aggregates bringing the
dyes close together, allowing quenching via Homo-FRET. The decreased quenching
of Aβ42 by Cu2+ could be due to larger structures forming in solution, preventing
some of the Aβ’s from binding to Cu2+.
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Apart from Cu2+, the other metal cations also appear to reduce the fluorescence
of labelled Aβ16/40, by about 15 %. As surface adsorption of Aβ is a problem, the Aβ
samples were left in the cuvettes for 1 h to equilibrate. To test the effect of mixing,
the experiment was performed with and without mixing, without adding sample to
the cuvette. For Aβ40HL647, the intensity was found to drop by approximately 13 %,
where as without mixing there was little difference. This suggests that the small
decreases in figure 3.1 are an artifact of the method used. For future experiments
it suggests that when 100 nm concentrations of Aβ or less are used, the actual
concentration may be lower than expected, and that surface adsorption of Aβ onto
pipette tips may also be a problem.
The quenching of fluorescently labelled Aβ by Cu2+ is the basis for the rest
of the work in this chapter. This phenomenon will be used to investigate the
thermodynamics and kinetics of Aβ binding to Cu2+ ions, and is why Cu2+ is
preferentially studied, rather than Zn2+. It has been previously shown that dyes
may be quenched by Cu2+ [259], and other paramagnetic metal ions [260], however it
seems that this phenomenon has not been exploited to understand the binding of
metals to proteins and peptides.
3.2 Multiple Binding Phases of Aβ to Cu2+
To investigate the binding of Cu2+ to labelled Aβ, titrations were performed. This
would allow for the equilibrium dissociation constant (𝐾d) to be measured. Know-
ing the 𝐾𝑑 allows the concentration of the Aβ ·Cu complexes to be predicted, given
the concentration of Aβ and Cu2+. The 𝐾d can then be used to calculate the con-
centration of Aβ ·Cu formed in equilibrium in the CSF. It also gives the minimal
concentration required for transient concentrations of Cu2+ to reach for binding to
occur. However, whether binding does or does not occur, would still depend on the
kinetics of the reaction.
To determine the quenching profile of labelled Aβ by Cu2+, CuCl2 was titrated
into 133 nm of Aβ16LysHL488 in Hepes NaCl, measuring the fluorescence. The Aβ
sample was left to equilibrate in the quartz cuvettes for 2 h at 25 ∘C, before titration.
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The sample was excited at 480 nm, and the emission intensity was integrated across
500 nm to 600 nm.
The results shown in figure 3.2 show that there are three apparent phases of Cu2+
binding to Aβ, and that the quenching level is similar to that of the N-terminally
labelled Aβ’s with 100 µm Cu2+. Fitting the binding curves with Hill functions (see
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Figure 3.2: Fluorescence titration of 133 nm HL488 C-terminally labelled Aβ16,
varying Cu2+, in Hepes NaCl. The normalisation of (b) and (c) is approximate,
relative to (a) and (b) respectively. The errors in (b) are large in comparison to (a)
and (c) due to an increased intensity for two of the repeats. 𝑛 is the number of
repeats.
Eqn. 2.30), gives the 𝐾A’s and 𝛼’s shown in table 3.1. The first phase appears to be
standard binding, as 𝛼 ≈ 1. However, as the 𝐾d ≫ [Aβ], approximations of the Hill
function are no longer valid, and it overestimates the value of the 𝐾d. Refitting with
the 1:1 binding equation, a Hill function gives 𝐾d’s of 165(9) nm & 9.0(4) µm, with
an 𝛼 for the second phase of 2.0(1). In section 3.5, the 𝐾d of the first copper binding
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Phase 1 Phase 2 Phase 3
𝐾A/nm 𝛼 𝐾A/µm 𝛼 𝐾A/µm 𝛼
10 nm to 200 µm 250(20) 1.0(1) 9.8(4) 2.3(1)
1 µm to 100 µm 9.0(3) 4.3(3) 49(3) 7.3(7)
10 µm to 100 µm 52(1) 5.2(4)
Table 3.1: Parameters of the multiple Hill fits of the data shown in figure 3.2. For the
fitting of (b) & (c), the parameters of the first & second phase were fixed, respectively.
The values are not corrected for the Hepes ·Cu2+ interaction, this underestimates
the concentration of Cu2+ by a factor of approximately 3 (see §3.3 & §3.5).
is derived from the kinetics to be approximately 1 nm, over an order of magnitude
lower than measured here. This suggests that the measurement here is an artifact,
possibly due to surface adsorption of Aβ or Cu2+. The later phases are likely more
reliable as the concentration of Cu2+ is much higher, and is much greater than the
concentration of Aβ, negating some of the problems of surface adsorption.
The second and third phases have 𝐾A’s of approximately 9 µm, and 50 µm. How-
ever, the phases are much steeper than expected for standard stoichiometric binding.
In the Hill model, 𝛼 > 1 suggests that cooperative ligand binding may be occurring,
but here the number of Cu2+ binding at each phase is unknown. Given that Cu2+ has
a strong positive charge, and that Aβ is a short peptide, it is unlikely that multiple
Cu2+ ions would bind with a similar 𝐾d. An alternative possibility is that the Cu2+
is causing the Aβ to oligomerise.
To investigate the possibility of oligomerisation the same titration was performed
using the FCS setup. However, 14 nm of labelled Aβ was used, as 133 nm is too con-
centrated to perform FCS. This allows for the concentration of fluorescent particles
to be measured, via 𝐺0, and also the mean diffusion time of the complex. If all
the Aβ’s form dimers, the 𝐺0 should double, as it is inversely proportional to the
concentration of fluorescent particles.
Figure 3.3 shows that intensity of the FCS experiments still shows two phases,
in approximately the same position as the fluorometer measurement, even with the
order of magnitude reduction in Aβ concentration. The graph of 𝐺0 is flat across the
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Figure 3.3: The quenching of 14 nm Aβ16LysHL488 by Cu2+, the fluorescence in-
tensity, 𝐺0 and mean diffusion time of the complex, measured using FCS. a) The
fitted intensity curve is a two Hill function with 𝐾A’s of 0.5(1) µm & 14 µm, with
𝛼’s of 5(6) & 2.4(9). The fluorometer fit was scaled to the data range from the FCS
measurement, for comparison. b) For 𝐺0 the fit gives 𝐾A = 41(1)µm and 𝛼 = 2.5(1).
c) For the mean diffusion time, the fit gives 𝐾A’s of 0.14(2) µm & 5.5(8) µm, with 𝛼’s
of 2.1(4) & 1.8(3).
first two phases, showing that the first two phases are not oligomerisation. However,
there is drop in the concentration of fluorescent particles in line with the third
phase. In section 3.3.1 it is shown that the third phase is also not oligomerisation.
Therefore, the third phase is either deposition of Aβ onto the surface, or the labelled
Aβ is quenched to a point such that FCS no longer works. The diffusion time
also seems to follow a trend towards the labelled molecules getting smaller as
the Cu2+ concentration increases. Assuming the molecules are spherical, there is
approximately a 15 % total decrease in the hydrodynamic radius. Interestingly,
the phases for decrease in mean diffusion time are not aligned with the phases for
decrease in intensity, but are shifted to lower concentrations. This suggests that
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transient binding of Cu2+ to Aβ is causing the Aβ to spend more time in a more
compact state, even when most of the time is not spent bound to Cu2+.
The 𝐾𝑑 ’s measured here show that Aβ ·Cu complexes cannot form in the steady
state conditions of the CSF, due to it being unable to compete with other metal
binding proteins, such as HSA, which is more prevalent and has a picomolar 𝐾d.
3.2.1 Comparison with N-Terminally Labelled Aβ
N-terminal modifications on Aβ are known to reduce the binding affinity of Cu2+ to
Aβ [210;261], turning the amine into an amide∗. Here Cu2+ was titrated into 100 nm N-
terminally labelled Aβ in Hepes NaCl. Again the binding curves were steeper than
expected for standard 1 : 1 binding stoichiometry, and thus the Hill equation was
used. The results shown in figure 3.4, show that the baseline is not flat, in particular
for Aβ40/42, whereas Aβ16 appears flat. This is likely due to the hydrophobic tail on
Solution 𝐾A/µm 𝛼
Aβ16HL555 4.3(6) 1.5(1) (𝑛 = 5)
Aβ40HL488 3.5(8) 1.3(2) (𝑛 = 6)
Aβ42HL647 5.6(6) 1.5(1) (𝑛 = 7)
Table 3.2: Fitted parameters for the Hill function in figure 3.4.
Aβ40/42 increasing surface adsorption. To account for this behaviour an exponential
term is put into the Hill Equation (𝐹([Cu]))
𝐹′([Cu]) = 𝐹b + (1 + (𝐴e−𝑏[Cu] − 1))× (𝐹([Cu])−𝐹b) , (3.1)
where 𝐴 and 𝑏 are parameters for the exponential term, and 𝐹b is the baseline of the
quenched fluorescence.
The results in figure 3.4 and table 3.2 show that N-terminally labelled Aβ
binding to Cu2+ is considerably weaker. This suggests that the N-terminal amine is
involved in the coordination with Cu2+, or that there is some steric hindrance from
∗Loss of the lone pair of electrons on the N-terminal Nitrogen.
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the attached dye. It also suggests that the hydrophobic C-terminal region does not
affect Cu2+ binding, given that the measured 𝐾A’s are within error of each other.
These results show that N-terminally labelled Aβ should not be used to investig-
ate unmodified Aβ.
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Figure 3.4: Fluorescence Titration curves for 100 nm labelled Aβ with Cu2+, with
the microscopic dissociation constant (𝐾A) closest to the mean of multiple runs.
Fitted parameters for the Hill function are shown in table 3.2. The corresponding
fluorescence spectra are shown as inset, for selected copper concentrations. They
are normalised by 𝐹 ↦→ 𝐹/(𝐹max(1− 𝑏))
3.3 Association Kinetics of Aβ Binding to Cu2+
To determine whether Aβ is able to bind Cu2+ in the transiently high concentrations
of Cu2+ during synaptic transmission, the association rate 𝑘on is required. After
release, the ‘free’ Cu2+ concentration is depleted by binding to other Cu2+ binding
proteins, and diffusion across and out of the synapse.
To measure the Aβ + Cu2+ −−−→ Aβ ·Cu association rate, 25 nm of HL488 labelled
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human or murine Aβ, was mixed with 500 nm CuCl2, in Hepes NaCl (except for
Aβ16LysHL488, which was performed with 20 nm and 400 nM CuCl2). The fluores-
cent traces were fitted with exponentials, and the rate of the largest and fastest was
taken to be the apparent association rate (𝑘on(App)). This is true when the binding is
assumed to be irreversible. If the reaction is reversible, the reaction is
Aβ + Cu2+
𝑘on
𝑘off
Aβ ·Cu . (3.2)
Under pseudo-first-order conditions, this gives the differential equations
d[Aβ]
d𝑡
= −𝑘on[Aβ][Cu2+] + 𝑘off[Aβ ·Cu] , (3.3)
d[Aβ ·Cu]
d𝑡
= +𝑘on[Aβ][Cu
2+]− 𝑘off[Aβ ·Cu] , (3.4)
and
[Aβ]T = [Aβ] + [Aβ ·Cu] . (3.5)
The solutions are therefore
[Aβ] = [Aβ]T − [Aβ ·Cu] ∝ 𝑐+ e−(𝑘off+𝑘on[Cu2+])𝑡 , (3.6)
for a constant 𝑐. Thus the irreversibility assumption is valid when
𝑘off≪ 𝑘on[Cu2+] . (3.7)
In section 3.5, 𝑘off is shown to be approximately 0.5 s−1, and therefore the irreversib-
ility of the reaction is a valid assumption. Due to the weak binding of Hepes to Cu2+,
the Hepes concentration was varied in the Hepes NaCl from 10 mm to 100 mm, to
determine the effect of Hepes on the binding. The resulting rates of 𝑘−1on(App) against
Hepes concentration were phenomenologically fitted with a zero centered parabola
𝑘−1on(App) = 𝐴[Hepes]
2 +𝐶 , (3.8)
where 𝐴 describes the shape of the parabola, and 𝐶 the intercept. 𝐶 is thus the
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inverse of the Hepes independent association rate constant (𝑘on).
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Figure 3.5: Determination of the Hepes independent association rate. 25 nm labelled
Aβ was reacted with 500 nm Cu2+ with various Hepes concentrations, all with
100 mm NaCl. The Aβ16 was 20 nm Aβ with 400 nm Cu2+. The fitting parameters
are summarised in table 3.3.
𝐴/mm−2 s 𝑘on/108m−1 s−1 𝐾Hepes@50mm
Aβ16LysHL488 3.5(5) 5.1(6) 3.0(6)
Aβ28LysHL488 6.3(5) 4.9(1) 4.1(7)
Aβ40Cys20HL488 4.1(3) 4.9(5) 3.5(4)
Murine Aβ16LysHL488 3.4(1) 6.1(3) 3.6(2)
Table 3.3: Summary of Hepes independent Aβ + Cu2+ −−−→ Aβ ·Cu association rate
constants 𝑘on = 𝐶−1 and fitting parameters from figure 3.5. 𝐾Hepes@50mm repres-
ents the factor of the apparent reduction in Cu2+ concentration at 50 mm Hepes.
The results in figure 3.5 and table 3.3 show that the mean Hepes independent
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association rate is 5.0(3)× 108 m−1 s−1. This is close to the diffusion limit of approx-
imately 109 m−1 s−1 and much faster than initially expected. This may possibly
be due to electrostatic interactions between the positively charged Cu2+ and the
negatively charged Aβ. The near diffusion limited nature suggests that Aβ is able to
bind to Cu2+, whilst the concentration is dropping due to diffusion. Therefore the
limiting factor as to whether Aβ is able to bind in the transient Cu2+ concentration,
is the depletion by other Cu2+ binding molecules, such as HSA or the Cu2+ binding
amino acids.
3.3.1 The Binding of the Second Cu2+ to Aβ
Are the Second and Third Phases Dimerisation or Aggregation?
It was shown in figure 3.3, using FCS, that the second phase was not dimerisation
of Aβ, but another copper binding to Aβ. This is assumed to be the binding of a
second copper ion. To confirm these results, the concentration of Aβ was varied to
look for changes in the rate of fluorescent quenching. If dimerisation is occurring,
the rate should be highly dependent on Aβ concentration. This methodology can
simultaneously be applied to determining whether the third phase is aggregation.
To investigate the dependence of the second and third phase on Aβ concentration,
25 nm, 50 nm and 100 nm Aβ16LysHL488 was mixed with 10 µm CuCl2, in Hepes
NaCl.
The results in figure 3.6 show that with 10 µm Cu2+, the second and third
phases are visible. Normalising out the difference in brightness due to the different
concentrations of labelled Aβ, shows that the rates are indistinguishable across a
factor of 4 change in the Aβ concentration. Therefore neither the second, nor third
phase is dimerisation of the Aβ.
Kinetics of the Second Cu2+ Binding to Aβ
To investigate the binding rate of the second Cu2+ to Aβ, 50 nm of Aβ16LysHL488
was mixed with varying concentrations of CuCl2 from 5 µm to 20 µm, and the ap-
parent association rate 𝑘Appon was measured by fitting the phase with an exponential.
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Figure 3.6: To investigate the dependence of the second quenching phase on Aβ
concentration, 25 nm, 50 nm or 100 nm Aβ16LysHL488 was mixed with 10 µm CuCl2.
Given that there is not a factor of 16 difference between the 25 nm and 100 nm curves,
there is no apparent dimerisation.
Equation 3.6 shows, that assuming the same model for binding, the solution is
exponential with the rate
𝑘
App
on = 𝑘off + 𝑘on[Cu
2+] . (3.9)
That is ignoring the reaction Aβ + Cu2+ −−−→ Aβ ·Cu, as the rate is >800s−1, and
only considering Aβ ·Cu + Cu2+ −−−⇀↽−− Aβ ·Cu2. Therefore, when varying the Cu2+
concentration near the 𝐾d,
𝑘off ≈ 𝑘on[Cu2+] , (3.10)
and thus plotting 𝑘Appon against [Cu2+] should be linear, where the intercept is the
dissociation rate constant of Aβ ·Cu2 −−−→ Aβ ·Cu + Cu2+ (𝑘off), and the gradient is
the association rate constant of Aβ ·Cu + Cu2+ −−−→ Aβ ·Cu2 (𝑘on).
The results in figure 3.7 show that the apparent rate appears to be linear with
𝑘off = 7.3(7)s−1, and 𝑘on = 4.2(6)× 105m−1 s−1 (the rate is not corrected for the effect
of the buffer on apparent Cu2+ concentration). The second copper binding 𝐾d is
therefore 17(3) µm. This is approximately half (2 𝜎 to 3 𝜎 ) the previous measurement
in table 3.1, but confirms that the 𝐾d is in the low 10’s of micromolar regime.
However, the association rate is four orders of magnitude below the diffusion
limited rate. This suggests that a second or third copper is unlikely to bind in the
transient Cu2+ release of neurotransmission, given the diffusion of copper out of
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the synapse.
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Figure 3.7: The apparent rate of the second phase of 50 nm Aβ16LysHL488 with
copper. This gives the association rate to be 4.2(6)× 105 m−1 s−1 and the dissociation
rate to be 7.3(7) s−1.
3.3.2 Activation Energy
To confirm the near diffusion limited rate of the first Cu2+ binding to Aβ, the
activation energy was measured. 100 nm of Aβ16LysHL488 or 20 nm Aβ28LysHL488
was mixed with 1 µm or 400 nm CuCl2 respectively and the temperature was varied.
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Figure 3.8: Arrhenius plots of Aβ binding to Cu2+. The rate constant 𝐾App is the
reaction rate divided by the concentration of Cu2+. a) 100 nm Aβ16LysHL488 mixed
with 1 µm Cu2+. This gives an 𝐸A = 27(2)kJmol−1 for the association rate constant.
b) 20 nm Aβ28LysHL488 mixed with 400 nm Cu2+. This gives an 𝐸A = 32(1)kJmol−1
for the association rate constant. The rates are not corrected for the effect of Cu2+
binding to Hepes.
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The results in figure 3.8 show that the activation energy for Aβ16 is 27(2)kJmol−1,
and for Aβ28 is 32(1)kJmol−1, within 2 𝜎 . Here, the activation energy is the activ-
ation energy of Aβ binding to Cu2+ as the dissociation rate is negligible. The
activation energy of the association is small, given that the contribution from the
viscosity of water is approximately 17 kJmol−1. Correcting for this, gives activation
energies of 10(2) kJmol−1 (∼4 kB T) & 15(1) kJmol−1 (∼6 kB T), for Aβ16 & Aβ28, re-
spectively. These are very low, further suggesting that the binding of Aβ to Cu2+ is
near diffusion limited.
For comparison, the activation of the second Cu2+ binding to Aβ was meas-
ured. 200 nm Aβ16LysHL488 was mixed with 10 µm CuCl2, in Hepes NaCl, and the
temperature was varied.
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Figure 3.9: Arrhenius plot of the binding of a second Cu2+ to Aβ ·Cu. 𝑘App is the
apparent rate of this reaction. 200 nm of Aβ16LysHL488 was mixed with 10 µm Cu2+,
giving an 𝐸A = 43(2)kJmol−1. The rates are not corrected for the binding of Cu2+ to
Hepes.
The results in figure 3.9, give the activation energy to be 43(2) kJmol−1. However,
as the 10 µm Cu2+ used is close to the 𝐾d, the 𝑘App is made up of a mixture of
the dissociation rate, and the apparent association rate. The activation energy
is therefore likely to be an overestimate of the activation energy of the second
Cu2+ binding, as typically intermolecular processes, such as dissociation, are more
strongly dependent on temperature.
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3.3.3 Association of N-Terminally Labelled Aβ
To determine whether the difference in 𝐾d’s for the N-terminally labelled and C-
terminally labelled Aβ peptides was due to the association, dissociation or both, the
Cu2+ binding to Aβ16HL488 was measured.
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Figure 3.10: Determination of the association rate constant of Aβ16HL488 with Cu2+
by varying the Hepes concentration in the buffer. 50 nm Aβ40HL488 was mixed
with 1 µm Cu2+ and fitted with an exponential to obtain 𝑘on(App). This gives a rate
constant 𝑘on = 4.6(2)× 108m−1 s−1.
The results in figure 3.10 show that the association rate constant to be
4.6(2)× 108 m−1 s−1, similar to the C-terminally labelled Aβ. The difference in
𝐾d’s is therefore due to a difference in dissociation rate constants. This also shows
that the N-terminal amine is not involved in the initial binding to Cu2+, but is
involved in the stability of the Aβ ·Cu complex. Using the 𝐾d for the second binding
phase from table 3.2, 3.5(8) µm, gives the 𝑘off to be 1.4(4) ms−1.
These results suggest that N-terminal modifications to Aβ such as acetylated Aβ
or pyroglutamate-modified Aβ affect the length of time that Cu2+ is bound to Aβ,
rather than whether or how fast it binds.
3.4 Competition for Cu2+ from HSA and Glycine
Although the binding of Cu2+ to Aβ is near diffusion limited, there are other com-
ponents in the CSF that also bind copper and are found at orders of magnitude
higher concentrations than Aβ. Some examples are proteins such as HSA, and amino
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acids, such as glycine. The binding of glycine is known to be near diffusion limited
for the anionic form [262].
3.4.1 HSA
To determine whether Aβ could compete against HSA in binding Cu2+, 50 nm Aβ16
was premixed with 5 µm HSA (approximately physiological concentration in the
CSF), this solution was then mixed with varying concentrations of Cu2+.
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Figure 3.11: Competition of Aβ & HSA for Cu2+. 5 µm HSA was premixed with
50 nm Aβ16LysHL488, and then mixed with various concentrations of Cu2+ using
stopped flow. a) Normalised raw traces. b) Maximal proportion of Aβ bound to
Cu2+, assuming that the fluorescence of Aβ ·Cu is 2/3 of free Aβ. 2/3 was chosen as
it was similar to the apparent quenching level of the first phase in the fluorometer
titration experiments (Fig. 3.2). Determination of the exact value is not necessary
given the qualitative nature of this experiment. The solid line is a phenomenological
fit of a offset logarithm.
Figure 3.11 shows that at short time scales the Aβ is bound to Cu2+, and HSA
is not able to compete. However, at longer timescales, the Cu2+ dissociates from
the Aβ ·Cu. Therefore, the 𝐾d of HSA with Cu2+ is lower than that of Aβ with Cu2+.
The plot of maximal Aβ ·Cu formation shows that at 5 µm Cu2+, only half the Aβ
forms Aβ ·Cu. For stoichiometric binding of Cu2+ to HSA, this value should tend
to 1 rather than 0.5, as when the concentration of Cu2+ is above that of HSA all Aβ
should form Aβ ·Cu. Therefore, HSA must have multiple binding sites for copper,
allowing it to soak up more than its equivalence in Cu2+. The figure shows that the
binding rate of HSA to Cu2+ is similar to that of Aβ.
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Given that the binding and removal of Cu2+ are temporally well separated
in figure 3.11, the maximal binding of Aβ to Cu2+ may be determined by only
considering the binding reactions, i.e.
Aβ + HSA + Cu2+
𝑘
HS
A
on
Aβ ·Cu + HSA
𝑘 Aβon
HSA.Cu + Aβ
. (3.11)
This ignores the dissociation of Cu2+ from the ligands and any interactions between
them. The reaction was simulated in python using scipy’s Dormand-Prince method
for solving the differential equations (see Appx. A.1) varying the ratio 𝑘HSAon /𝑘
Aβ
on .
The results in figure 3.12, based on the shape of the curves when compared to
figure 3.11, suggests that the 𝑘HSAon < 𝑘
Aβ
on , at approximately 107 m−1 s−1 to 108 m−1 s−1.
There are currently no literature values for comparison. It may be possible to
0
0.2
0.4
0.6
0.8
1
0 1 2 3 4 5 6 7
[A
β
·C
u
]/
[A
β
] T
ot
al
[CuCl2]/µm
kHSAon /k
Aβ
on
10−1
10−2/3
10−1/3
100
101/3
102/3
101
Figure 3.12: Simulation of the competition of Aβ & HSA for Cu2+. 5 µm HSA
was mixed with 50 nm Aβ, and various concentrations of Cu2+ from equation 3.11.
Proportion of Aβ bound to Cu2+ after 1 s, varying the ratio of the association of Cu2+
with HSA (𝑘HSAon ) to that of Aβ (𝑘
Aβ
on = 3× 108m−1 s−1).
further this methodology to obtain a more accurate value and determine the binding
stoichiometry of Cu2+ to HSA.
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3.4.2 Glycine
When the competition experiment between HSA and Aβ for Cu2+ (see § 3.4.1) was
repeated with glycine, fluorescence quenching by the Cu2+ was observed, but there
was no fluorescence recovery. This suggests that the 𝐾d of Cu2+ with glycine is much
greater than a few micromolar, that ternary Aβ ·Cu ·Gly complexes can form, or that
the solution reaches equilibrium within the dead time. The CSF concentration of
glycine in one study was 11(2) µm (𝑛 = 21) [263].
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Figure 3.13: Competition for Cu2+ between Aβ and glycine. a) 500 nm CuCl2 pre-
mixed with various concentrations of glycine to form complexes, which was then
mixed using stopped flow with 60 nm Aβ16LysHL488. b) 100 nm Aβ16LysHL488 was
premixed with 100 nm Cu2+, which was then mixed using stopped flow with various
concentrations of glycine. ‘Before’ and ‘After’ represent the baselines of fluores-
cence of Aβ without Cu2+ or glycine, before and after the other measurements,
respectively.
To determine the effect on Aβ binding to Cu2+, 500 nm CuCl2 premixed with
various concentrations of glycine was then mixed using stopped flow with 60 nm
Aβ16LysHL488. Figure 3.13a shows that low concentrations of Cu2+ can still bind to
Aβ, even with high concentrations of glycine.
To determine the effect of glycine on Aβ ·Cu, 100 nm Aβ16LysHL488 was pre-
mixed with 100 nm Cu2+, and then mixed using stopped flow with various concen-
trations of glycine. Figure 3.13b shows that tens of micromolar of glycine is unable
to completely remove the Cu2+ from the Aβ ·Cu complex.
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3.5 Dissociation Kinetics of the Aβ ·Cu Complex
To independently determine the 𝐾d from the underlying kinetics, both the associ-
ation and dissociation rate constants are required. The dissociation rate constant
will also determine the likely lifetime of the Aβ ·Cu complex, and thus whether the
complex has time to interact with other ligands in the synapse.
To determine the dissociation rate, the Aβ ·Cu complex was preformed by stoi-
chiometric mixing of labelled 100 nm Aβ and 100 nm CuCl2. This equilibrium
mixture of Aβ, Cu2+ & Aβ ·Cu was then mixed with various concentrations of a Cu2+
binding ligand (HSA, EDTA, Aβ16, Aβ40) in much greater excess to quickly remove
the unbound Cu2+.
The model was expected to be
Aβ ·Cu + L 𝐾off Aβ + Cu2+ + L Aβ + Cu.L , (3.12)
in which the dissociation of Cu2+ from Aβ ·Cu is irreversible, due to the excess of
ligand. This model gives the differential equation
d[Aβ ·Cu]
d𝑡
= −𝑘off[Aβ ·Cu] , (3.13)
and thus the solution
[Aβ] = [Aβ]T − [Aβ ·Cu]
⃒⃒⃒
𝑡=0
e−𝑘off𝑡 , (3.14)
and is independent of ligand concentration. However, the results (such as in fig-
ure 3.14) show a linear dependence on ligand concentration, rather than no de-
pendence. Therefore this simplistic model is incorrect and the ligand is interacting
directly with the Aβ ·Cu complex.
To incorporate the dissociation of the Aβ ·Cu both directly and assisted by a Cu2+
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binding ligand, the model
Aβ ·Cu
Aβ + Cu2+
+
L
Aβ + Cu ·L
+ L
𝑘Loff
𝑘off
(3.15)
was used, with a direct interaction between Aβ ·Cu and the ligand. This gives the
differential equation
d[Aβ ·Cu]
d𝑡
= −𝑘off[Aβ ·Cu]− 𝑘Loff[Aβ ·Cu][L] (3.16)
and
[Aβ]T = [Aβ] + [Aβ ·Cu] , (3.17)
gives the solution to be
[Aβ] = [Aβ]T − e−(𝑘off+𝑘Loff[L])𝑡[Aβ ·Cu]
⃒⃒⃒
𝑡=0
, (3.18)
to which the rate is linear with ligand concentration ((𝑘off + 𝑘Loff[L]).
The reverse reactions were not considered as the free copper concentration
should be kept low by the competing Cu2+ ligand. The solution is a single expo-
nential and plotting the apparent rate as a function of [L] may be used to obtain
the off-rate (𝑘off, intercept) and removal rate constant via the ligand (𝑘Loff, gradi-
ent). However this model is unphysical as the copper ion ‘jumps’ from the Aβ ·Cu
complex to the Cu ·L complex. A more physical equivalent is
Aβ ·Cu
(Aβ ·Cu ·L)*
Aβ + Cu2+
Aβ + Cu ·L
𝑘Loff
+L
𝑘off
+L
, (3.19)
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with an explicit ternary complex forming. However, the significance of 𝑘Loff is
unclear, other than as a rate constant related to the removal of Cu2+ from Aβ ·Cu.
Inserting the explicit ternary complex formation into the model, it becomes
Aβ ·Cu + L
(Aβ ·Cu ·L)*
Aβ + Cu2+ + L
Aβ+ Cu ·L
𝑘Toff
𝑘off
𝑘Ton
, (3.20)
with the differential equations
d[Aβ ·Cu]
d𝑡
= −𝑘off[Aβ ·Cu]− 𝑘Ton[L][Aβ ·Cu] , (3.21)
d[(Aβ ·Cu ·L)*]
d𝑡
= +𝑘Ton[L][Aβ ·Cu]− 𝑘Toff[(Aβ ·Cu ·L)*] , (3.22)
which have the solutions
[Aβ ·Cu] = e−(𝑘off+𝑘Ton[L])𝑡[Aβ ·Cu]⃒⃒⃒
𝑡=0
, (3.23)
[(Aβ ·Cu ·L)*] = e−𝑘Toff𝑡[(Aβ ·Cu ·L)*]⃒⃒⃒
𝑡=0
− (e
−(𝑘off+𝑘Ton[L])𝑡 − e−𝑘Toff𝑡)𝑘Ton[L][Aβ ·Cu]
⃒⃒⃒
𝑡=0
𝑘off + 𝑘Ton[L]− 𝑘Toff . (3.24)
This gives the concentration of free Aβ to be
[Aβ] = [Aβ]T − [Aβ ·Cu]− [(Aβ ·Cu ·L)*] . (3.25)
The solution is therefore a double exponential, with rates (𝑘off + 𝑘Ton[𝐿]) and
𝑘Toff. Therefore the 𝑘Loff in the previous model corresponds to the ternary complex
formation rate. The amplitude of the 𝑘Toff should increase, relative to the amplitude
of the (𝑘off + 𝑘Ton[L]) exponential. In the raw data, none of the other exponentials
fitted this description. It is therefore likely that the 𝑘Toff phase is too fast to observe
and that the ternary complex is not highly populated, and thus very transient under
these conditions. If it was the rate limiting step, there would be no dependence in
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the apparent rate on ligand concentration.
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Figure 3.14: Apparent removal rate of copper by various ligands from
Aβ16LysHL488 ·Cu. The labelled Aβ16 and Cu2+ were premixed at 100 nm, before
being mixed with twice the various concentrations of ligand on the graphs.
EDTA HSA Aβ16 Aβ40
𝑘Ton 𝑘off 𝑘Ton 𝑘off 𝑘Ton 𝑘off 𝑘Ton 𝑘off
mAβ16 ·Cu 7.7(6) 0.157(3) 10.7(4) 0.185(2)
Aβ16 ·Cu 55(3) 0.42(2) 41(3) 0.52(1) 102(8) 0.58(3)
Aβ28 ·Cu 95(6) 0.29(3) 27(1) 0.75(6) 123(7) 0.68(3)
Aβ40 ·Cu 96(4) 0.46(2) 25(1) 0.611(8) 122(8) 0.77(3) 79(4) 0.66(1)
Table 3.4: Summary of fitted rates for the removal of Cu2+ from various Aβ ·Cu’s by
a ligand for figures 3.14, 3.15, 3.16 & 3.17. 𝑘Ton is the ternary complex formation
rate constant of (Aβ ·Cu ·L)* with units of 103 m−1 s−1. 𝑘off is the dissociation rate
constant of Aβ ·Cu, with units of s−1.
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Figure 3.15: Apparent removal rate of copper by various ligands from murine
Aβ28LysHL488 ·Cu. The labelled Aβ28 and Cu2+ were premixed at 100 nm, before
being mixed twice with various concentrations of ligand on the graphs.
The dissociation rate and ternary complex formation was measured for labelled
Aβ16 ·Cu (Fig. 3.14), labelled Aβ28 ·Cu (Fig. 3.15), labelled Aβ40 ·Cu (Fig. 3.16) and
labelled murine mAβ16 ·Cu (Fig. 3.17). The ligands used were EDTA, HSA, unla-
belled Aβ16, and unlabelled Aβ40. A summary of the results are shown in table 3.4.
It was also found that the dissociation rates do not appear to be dependent on the
concentration of Hepes, with 2 µm EDTA.
The human Aβ sequences have a mean dissociation rate constant of 0.6(2) s−1
(0.51(8) s−1 for Aβ16, 0.6(2) s−1 for Aβ28, and 0.6(2) s−1 for Aβ40). Using these disso-
ciation rate constants with the association rate constants from table 3.3, gives the
mean 𝐾d to be 1.2(4) nm (1.0(2) nm for Aβ16, 1.2(4) nm for Aβ16, and 1.2(2) nm for
Aβ40). This fits within the literature range of 10 pm to 100 nm.
The dissociation rate shows that the Aβ ·Cu complex is relatively long lived, with
a lifetime of 1.7(6) s (half-life of 1.2(4) s). This would give the Aβ ·Cu complex time
110
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
0 1 2 3 4 5 6 7 8
A
p
p
ar
en
t
R
at
e/
s
[EDTA]/µm
(a) EDTA
0.6
0.65
0.7
0.75
0.8
0.85
0 1 2 3 4 5 6 7 8
A
p
p
ar
en
t
R
at
e/
s
[HSA]/µm
(b) HSA
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
1.6
1.7
1.8
0 1 2 3 4 5 6 7 8
A
p
p
ar
en
t
R
at
e/
s
[Aβ16]/µm
(c) Aβ16
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
0 1 2 3 4 5 6 7 8
A
p
p
ar
en
t
R
at
e/
s
[Aβ40]/µm
(d) Aβ40
Figure 3.16: Apparent removal rate of copper by various ligands from
Aβ40Cys20HL488 ·Cu. The labelled Aβ40 and Cu2+ were premixed at 100 nm, before
being mixed with twice the various concentrations of ligand.
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Figure 3.17: Apparent removal rate of copper by various ligands from murine
Aβ16LysHL488 ·Cu. The labelled Aβ16 and Cu2+ were premixed at 100 nm, before
being mixed with twice the various concentrations of ligand.
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to interact with other molecules and likely last between synaptic transmissions. It
may therefore be possible to enhance the concentration of Aβ ·Cu in the synapse,
through repeated synaptic transmissions, as a form of short-term synaptic plasticity.
For comparison, murine Aβ has the mean dissociation rate of 0.17(2) s−1, giving a
𝐾d of 280(40) pm. The 𝐾d for murine Aβ with Cu2+ is therefore a factor of 4 stronger
than human Aβ, with a lifetime of 5.9(7) s (half-life of 4.1(5) s). This suggests that
the act of binding Cu2+ alone is not the initial step in the cause of Alzheimer’s
disease, as muridae do not develop Alzheimer’s disease.
The ternary complex formation rate (𝑘Ton) varies somewhat between ligands and
although similar for Aβ28 and Aβ40, is more different for Aβ16. This suggests that
Aβ28 is a better model for studying Aβ ·Cu interactions than Aβ16. Surprisingly, the
strong copper chelator EDTA is less effective at removing the Cu2+ from Aβ ·Cu
than Aβ. Can this kind of experiment be used to measure and improve the efficacy
and efficiency of finding drug candidates to interrupt Aβ ·Cu interactions?
When the ligand used is Aβ itself, the ternary complex formation rate becomes
the copper assisted dimerisation rate. The mean copper assisted dimerisation rate is
1.2(1)× 105 m−1 s−1. This is three orders of magnitude faster than the literature value
of approximately 102 m−1 s−1 [264] for unassisted dimerisation, drastically reducing
the concentration of Aβ required for dimerisation to occur. For comparison, the
copper assisted dimerisation rate for murine-human Aβ16 is an order of magnitude
slower than human-human Aβ16 dimerisation. This difference may be the reason as
to why muridae are immune to Alzheimer’s disease.
3.6 Targeting Aβ ·Cu with Clioquinol and L2-b
Clioquinol (CQ) and L2-b are two drug candidates (see Fig. 3.18), whose efficacy
is thought to be derived from interfering with and removal of Aβ ·Cu. CQ is a
derivative of PBT2, which is currently in clinical trials. L2-b is a bi-functional
ligand which also targets Aβ itself. Clioquinol promotes the degradation of metal-
dependent Aβ oligomers to restore endocytosis and ameliorate Aβ toxicity [265].
To test the efficacy of L-2b and CQ at removing Cu2+ from Aβ ·Cu, the same
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Figure 3.18: Chemical structures of clioquinol and L2-b.
procedure as in section 3.5 was used. 100 nm labelled Aβ, was premixed with 100 nm
CuCl2 to form Aβ ·Cu. This was then mixed with various concentrations of the drug
candidates using stopped flow. However, unlike in section 3.5, there were two
apparent phases to the fluorescence recovery. In the CQ experiments there was also
a slow quenching phase (see §3.6.1), due to the solvent (either DMSO or ethanol)
initially used to dissolve the CQ. This phase was ignored in all analysis.
The results in figure 3.19 show the two apparent removal rates of Cu2+ from
Aβ ·Cu. Both phases appear quicker with CQ and L2-b, than for HSA, EDTA or
Aβ16. This suggests that CQ and L2-b are more effective at removing Cu2+ from
Aβ ·Cu. The rate at which the rate of the kinetic phases increase in rate is different
for the two phases. The rate of the faster phase is steeper than that of the slower
phases. This suggests that the L2-b and CQ each act on Aβ ·Cu under two different
mechanisms.
To quantify the relative effectiveness of ligands, the mean apparent removal rate
of all the phases at 10 µm ligand was chosen as a metric. This was calculated by
taking the mean removal rate, weighted by the amplitudes of the individual phases,
for different ligand concentrations. The mean removal rates were then fitted with
a line (see Fig. 3.20), and finally interpolating to 10 µm Ligand concentration for
comparison of the effectiveness of the ligands.
The data in table 3.5 shows that CQ appears to be the best at Cu2+ removal.
The worst appears to be HSA, and is likely due to its bulky size (67 kDa) making
it more difficult to bind to the Aβ ·Cu complex. EDTA is also unexpectedly slow,
given that it is a strong metal chelator and has a very low 𝐾d. This is prbably due
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to the electrostatic interactions between Aβ ·Cu and EDTA. EDTA has a charge of
−4 e, whereas the charge of Aβ alone is approximately −3 e suggesting that when
designing ligands to remove Aβ from Aβ ·Cu, it may be best for them to be less
negatively charged. It also shows that the binding affinity of ligands to Cu2+ does
not correlate with their ability to remove Cu2+ from Aβ ·Cu.
Mean Cu2+ Removal Rate at 10 µm Ligand / s−1
Aβ16 EDTA HSA CQ L2-b
Aβ16 ·Cu 1.28(6) 0.92(1) 0.84(1) 5.4(3) 2.3(1)
Aβ28 ·Cu 1.60(7) 1.06(5) 0.92(4) 7.3(9) 3(1)
Aβ40 ·Cu 2.6(2) 2.1(2) 5.1(3) 2.3(2)
Approx 𝐾d 1 nm 0.1 fm 1 pm 0.1 nm 0.2 nm
Table 3.5: The effectiveness of ligands at extracting Cu2+ from Aβ ·Cu, and the
approximate 𝐾d of the ligands binding to Cu2+. The mean removal rate at 10 µm
Ligand is calculated by fitting the mean rates of all the phases with a line (shown in
figure 3.20) and interpolating to 10 µm ligand concentration.
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Figure 3.19: The two apparent removal rates of Cu2+ from labelled Aβ ·Cu, by CQ
and L2-b. 100 nm CuCl2 premixed with 100 nm Aβ, to form Aβ ·Cu, then mixed
with various concentrations of CQ or L2-b.
115
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
0 5 10 15 20
M
ea
n
R
em
ov
al
R
at
e
/s
[Aβ16]/µm
Aβ16 ·Cu
Aβ28 ·Cu
Aβ40 ·Cu
(a) Removal by Aβ16
0
0.5
1
1.5
2
2.5
3
3.5
4
0 5 10 15 20
M
ea
n
R
em
ov
al
R
at
e
/s
[EDTA]/µm
Aβ16 ·Cu
Aβ28 ·Cu
Aβ40 ·Cu
(b) Removal by EDTA
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
0 5 10 15 20
M
ea
n
R
em
ov
al
R
at
e
/s
[HSA]/µm
Aβ16 ·Cu
Aβ28 ·Cu
(c) Removal by HSA
0
2
4
6
8
10
12
14
0 5 10 15 20
M
ea
n
R
em
ov
al
R
at
e
/s
[CQ]/µm
Aβ16 ·Cu
Aβ28 ·Cu
Aβ40 ·Cu
(d) Removal by CQ
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
5.5
6
0 5 10 15 20
M
ea
n
R
em
ov
al
R
at
e
/s
[L2-b]/µm
Aβ16 ·Cu
Aβ28 ·Cu
Aβ40 ·Cu
(e) Removal by L2-b
Figure 3.20: Mean removal rate of Cu2+ from 50 nm Aβ16 ·Cu, Aβ28 ·Cu or Aβ40.Cu
by various ligands. Solid lines are a linear fit of the data.
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3.6.1 The Effects of Ethanol and DMSO on Aβ
When measuring the removal rate of Cu2+ from Aβ by CQ, it was found that there
was a slow phase, in which the labelled Aβ was re-quenching after its recovery from
the removal of the Cu2+ (see Fig. 3.21). This slow phase is due to the DMSO or
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Figure 3.21: Removal of Cu2+ from Aβ ·Cu (50 nm) by 10.5 µm CQ in Ethanol or
DMSO.
ethanol that the CQ had been initially dissolved in. In figure 3.21 the effect of ethanol
and DMSO is visible, despite being only 0.52 v/v% and 0.052 v/v%, respectively.
The quenching could be due to structural re-arrangement and quenching of the
dye by the Aβ, possibly by the tyrosine. If the quenching is due to the tyrosine,
it could be tested by using murine Aβ. Ethanol and DMSO are common solvents
used in experiments with Aβ. However, even small v/v% appear to affect Aβ
experiments, especially in equilibrium measurements where the effects are not
temporally separated. Therefore some caution needs to be taken when reviewing
experiments in the literature, where the effects of residual solvents in the Aβ samples
have not been considered.
It was found that with higher ethanol concentrations (≳15 v/v%) there was an
increase in fluorescence, shown in figure 3.22. It therefore may be possible to use
labelled Aβ to study the folding of Aβ in different environments, for example, in
fluorinated alcohols Aβ has been shown to take an α-helix structure [56].
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Figure 3.22: Aβ40Cys20HL488 in Hepes NaCl, mixed with various percentage
volumes of Ethanol in Hepes NaCl, to investigate the folding effects. The final
v/v% is half the value in the key.
3.7 Mechanism for the Dissociation and Interconversion of
the Aβ ·Cu Complexes
The experiments used to determine the removal rates of Cu2+ from Aβ ·Cu for L2-b
and CQ revealed that there appeared to be two phases, in which the ligands interact
differently with the Aβ ·Cu complex. Is the reason for this that L2-b and CQ interact
differently from the other ligands, or that the increased reaction rates reveal a more
complex underlying mechanism of Aβ ·Cu? To test this, the removal of Cu2+ from
Aβ ·Cu by EDTA was repeated, increasing the concentration of EDTA across a wider
range, from 2 µm to 2 mm.
The results in figures 3.23 & 3.24, for Aβ16 & Aβ40 both show that the rates and
amplitudes for two phases can be obtained. This shows that the two phases are not
exclusive to L2-b and CQ. Given the vastly different structures of the ligands, this
suggests that two forms of the Aβ ·Cu complex exist, component I ((Aβ ·Cu)i) and
component II ((Aβ ·Cu)ii) each reacting with ligands very differently. The plot of
the relative amplitudes shows that the relative amplitudes of the phases change
with EDTA concentration. This shows the two components are able to directly
interconvert
(Aβ ·Cu)i (Aβ ·Cu)ii , (3.26)
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rather than the Cu2+ dissociating and re-associating
(Aβ ·Cu)i Aβ + Cu2+ (Aβ ·Cu)ii , (3.27)
as the less than millisecond binding of EDTA to Cu2+ would prevent re-association,
and thus the relative amplitudes would be independent of concentration. The min-
imal symmetric reaction scheme that takes into account of the interconversion, the
reactions of the complex with EDTA (the ligand L), and the spontaneous dissociation
of the two components is
Aβ + Cu2+
(Aβ ·Cu)i
𝑘
1→
2𝑘 2
→
1
(Aβ ·Cu)ii
Aβ + Cu ·L
𝑘1Loff+ L
+ L
𝑘2Loff
𝑘2off
𝑘1off
. (3.28)
The association of free Cu2+ with the ligand is not included as this reaction does not
contribute to any change of fluorescence. The formation of the ternary complex is
omitted, as it is transient and does not appear well populated.
This model gives the differential equations
d[(Aβ ·Cu)i ]
d𝑡
= −[(Aβ ·Cu)i ](𝑘1off + 𝑘1Loff[L] + 𝑘1→2) + [(Aβ ·Cu)ii]𝑘2→1 (3.29)
d[(Aβ ·Cu)ii]
d𝑡
= −[(Aβ ·Cu)ii](𝑘2off + 𝑘2Loff[L] + 𝑘2→1) + [(Aβ ·Cu)i ]𝑘1→2 (3.30)
and
[Aβ] = [Aβ]T − [(Aβ ·Cu)i ]− [(Aβ ·Cu)ii] , (3.31)
from the conservation of Aβ. If the experiments are performed under pseudo-first-
order conditions, i.e. the ligand is in greater excess by at least a factor of 20, then
d[L]
d𝑡
= 0 . (3.32)
With this simplification, there are analytical solutions for the differential equations,
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giving the concentrations of the two Aβ ·Cu species as a function of time as
[(Aβ ·Cu)i ] = 12𝛿
⎛⎜⎜⎜⎜⎜⎜⎜⎜⎝ e
− 12 𝑡(𝛼+𝛽)
(︁
(𝛽 +𝛾)[(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
− 2𝑘2→1[(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
)︁
+
+e− 12 𝑡(𝛼−𝛽)
(︁
(𝛽 −𝛾)[(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
+ 2𝑘2→1[(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
)︁
⎞⎟⎟⎟⎟⎟⎟⎟⎟⎠ ,
(3.33)
[(Aβ ·Cu)ii] = 12𝛿
⎛⎜⎜⎜⎜⎜⎜⎜⎜⎝ e
− 12 𝑡(𝛼+𝛽)
(︁
(𝛽 −𝛾)[(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
− 2𝑘1→2[(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
)︁
+
+e− 12 𝑡(𝛼−𝛽)
(︁
(𝛽 +𝛾)[(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
+ 2𝑘1→2[(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
)︁
⎞⎟⎟⎟⎟⎟⎟⎟⎟⎠ ,
(3.34)
where
𝛼 = 𝑘1→2 + 𝑘2→1 + 𝑘1off + 𝑘2off + (𝑘1Loff + 𝑘2Loff)[L] , (3.35)
𝛽 =
⎛⎜⎜⎜⎜⎜⎜⎜⎜⎝𝑘
2
1→2+2𝑘1→2(𝑘2→1 + 𝑘1off − 𝑘2off + (𝑘1Loff − 𝑘2Loff)[L])+
+(𝑘2→1 − 𝑘1off + 𝑘2off − (𝑘1Loff − 𝑘2Loff)[L])2
⎞⎟⎟⎟⎟⎟⎟⎟⎟⎠
1
2
, (3.36)
𝛾 = 𝑘1→2 − 𝑘2→1 + 𝑘1off − 𝑘2off + (𝑘1Loff − 𝑘2Loff)[L] , (3.37)
𝛿 =
√︁
−4{𝑘2→1(𝑘1off + 𝑘1Loff[L]) + (𝑘1→2 + 𝑘1off + 𝑘1Loff[L])(𝑘2off + 𝑘2Loff[L])}+𝛼2 .
(3.38)
The free Aβ concentration can be deduced from
[Aβ] = [Aβ]T − [(Aβ ·Cu)i ]− [(Aβ ·Cu)ii] , (3.39)
showing that the solutions are double exponential, with rates of 12 (𝛼 ± 𝛽).
The initial conditions used are
[(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
= [Aβ]T
𝑘2→1
𝑘1→2 + 𝑘2→1
(3.40)
and
[(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
= [Aβ]T
𝑘1→2
𝑘1→2 + 𝑘2→1
, (3.41)
assuming that all Aβ and Cu2+ form complexes that do not dissociate, and thus that
interconversion is the only mechanism of changing from one component to the other.
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The two double exponentials to the solution for [Aβ] therefore have amplitudes (𝐴𝑖)
and rates (𝑘𝑖) of
𝐴1 =
1
2𝛿
⎛⎜⎜⎜⎜⎜⎜⎜⎜⎝ (𝛽 +𝛾)[(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
− 2𝑘2→1[(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
+
+(𝛽 −𝛾)[(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
− 2𝑘1→2[(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
⎞⎟⎟⎟⎟⎟⎟⎟⎟⎠ , (3.42)
𝑘1 =
𝛼 + 𝛽
2
, (3.43)
𝐴2 =
1
2𝛿
⎛⎜⎜⎜⎜⎜⎜⎜⎜⎝ (𝛽 −𝛾)[(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
+ 2𝑘2→1[(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
+
+(𝛽 +𝛾)[(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
+ 2𝑘1→2[(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
⎞⎟⎟⎟⎟⎟⎟⎟⎟⎠ , (3.44)
𝑘2 =
𝛼 − 𝛽
2
, (3.45)
where 𝐴1 & 𝑘1 are the related to the fast phase and 𝐴2 & 𝑘2 are related to the slow
phase.
Given that it is unlikely that both states quench the fluorophore by the same
amount, a factor Γ is introduced into the amplitude contribution from the [(Aβ ·Cu)ii]
species. This gives the amplitudes to be
𝐴1 =
1
2𝛿
⎛⎜⎜⎜⎜⎜⎜⎜⎜⎝ (𝛽 +𝛾)[(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
− 2𝑘2→1[(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
+
+Γ ((𝛽 −𝛾)[(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
− 2𝑘1→2[(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
)
⎞⎟⎟⎟⎟⎟⎟⎟⎟⎠ , (3.46)
𝐴2 =
1
2𝛿
⎛⎜⎜⎜⎜⎜⎜⎜⎜⎝ (𝛽 −𝛾)[(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
+ 2𝑘2→1[(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
+
+Γ ((𝛽 +𝛾)[(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
+ 2𝑘1→2[(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
)
⎞⎟⎟⎟⎟⎟⎟⎟⎟⎠ , (3.47)
i.e. when Γ > 1 the contribution from (Aβ ·Cu)ii is greater. These amplitudes, along
with the two rates give the three parameters
𝐴1
𝐴1 +𝐴2
𝑘1 𝑘2 (3.48)
with which the data sets can be fitted. The use of the relative amplitude removes
the experimental error in the differing concentrations of Aβ in the preparation of
the complexes. The amplitude and rate parameters are obtained from the data by
individually fitting each fluorescence trace with a double exponential to obtain 𝐴1,
𝑘1, 𝐴2, & 𝑘2, from which the three parameters can be derived. These were fitted
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using Origin 7. The free parameters obtained through fitting this interconverting
model are
𝑘1off 𝑘1Loff 𝑘1→2 𝑘2off 𝑘2Loff 𝑘2→1 Γ . (3.49)
The model was fitted using Matlab 2013a, see appendix A.2.
The errors used to weight the three parameters are the errors derived from the
parameters for fitting the fluorescence recovery curves. Propagating the uncertainty
through the formulae for 𝐴1𝐴1+𝐴2 , 𝑘1, 𝑘2, and
𝐴1
𝐴1+𝐴2
, allows the error in the fitting
parameters to be obtained to compare the fitted model with the data. Although
theoretically it is possible to obtain analytical solutions to these, the solutions are
long, in particular for 𝐴1𝐴1+𝐴2 , or
𝐴1
𝐴1+𝐴2
. To simplify their acquisition and as they are
only calculated once, instead they are obtained numerically. Using central finite dif-
ference methods to obtain the partial derivatives 𝜕𝑓𝜕𝑥 , where 𝑓 ∈ { 𝐴1𝐴1+𝐴2 , 𝑘1, 𝑘2,
𝐴1
𝐴1+𝐴2
}
and 𝑥 ∈ {𝑘1off, 𝑘1Loff, 𝑘1→2, 𝑘2off, 𝑘2Loff, 𝑘2→1,Γ }, to get the error in each 𝑓 from
𝜎𝑓𝑖 =
⎯⎸⎷∑︁
𝑗
(︃
𝜕𝑓𝑖
𝜕𝑥𝑗
𝜎𝑥𝑗
)︃2
, (3.50)
given that the 𝑥’s are assumed uncorrelated. The 1 𝜎 uncertainty is shaded in the
figures.
High Ligand concentrations
At very high ligand concentrations, where the sum of the bimolecular reaction rates
is much faster than the interconversion rates, the variables 𝛼, 𝛽, 𝛾 , and 𝛿 reduce to
𝛼 = (𝑘1Loff + 𝑘2Loff)[L] , (3.51)
𝛽 = (𝑘1Loff − 𝑘2Loff)[L] , (3.52)
𝛾 = (𝑘1Loff − 𝑘2Loff)[L] , (3.53)
𝛿 =
√︁
−4𝑘1Loff𝑘2Loff[L]2 +𝛼2 = (𝑘1Loff − 𝑘2Loff)[L] , (3.54)
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and thus the rates become
𝑘1 =
𝛼 + 𝛽
2
= 𝑘1Loff[L] , (3.55)
𝑘2 =
𝛼 − 𝛽
2
= 𝑘2Loff[L] . (3.56)
The rates are linear with ligand concentrations, where the gradients are 𝑘1Loff, and
𝑘2Loff. For the amplitudes
𝛽 +𝛾 = 2(𝑘1Loff − 𝑘2Loff)[L] = 𝛿 , (3.57)
𝛽 −𝛾 = 0 , (3.58)
thus
𝐴1 =
1
2𝛿
(︁
2(𝑘1Loff − 𝑘2Loff)[L][(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
)︁
= [(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
, (3.59)
𝐴2 =
1
2𝛿
(︁
2Γ (𝑘1Loff − 𝑘2Loff)[L][(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
)︁
= Γ [(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
, (3.60)
and therefore
𝐴1
𝐴1 +𝐴2
=
[(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
[(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
+ Γ [(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
C 𝑅1 , (3.61)
𝐴2
𝐴1 +𝐴2
=
Γ [(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
[(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
+ Γ [(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
C 𝑅2 . (3.62)
So the relative amplitudes at high ligand concentrations are relative to the pro-
portions of the fluorescence recovery from the two species in equilibrium (𝑅1 and
𝑅2). Given that the fitted parameter Γ is known, the relative proportions of the
concentration can be obtained from
Γ𝑅1
Γ𝑅1 +𝑅2
=
[(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
[(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
+ [(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
, (3.63)
𝑅2
Γ𝑅1 +𝑅2
=
[(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
[(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
+ [(Aβ ·Cu)ii]
⃒⃒⃒
𝑡=0
. (3.64)
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This shows that the solutions reduce to the model without interconversion, i.e.
𝑘1→2 = 𝑘2→1 = 0, thus at high ligand concentrations (Aβ ·Cu)i, and (Aβ ·Cu)ii act
like independent species.
Low Ligand concentrations
Studying the reaction at very low ligand concentrations will allow for the derivation
of the apparent dissociation rate. At low ligand concentrations, where the contribu-
tions from the bimolecular reaction rates are negligible, thus the variables 𝛼, 𝛽, 𝛾 ,
and 𝛿 reduce to
𝛼 = 𝑘1→2 + 𝑘2→1 + 𝑘1off + 𝑘2off , (3.65)
𝛽 =
√︁
4𝑘1→2𝑘2→1 + (𝑘1→2 − 𝑘2→1 + 𝑘1off − 𝑘2off)2 , (3.66)
𝛾 = 𝑘1→2 − 𝑘2→1 + 𝑘1off − 𝑘2off , (3.67)
𝛿 =
√︁
−4(𝑘2→1𝑘1off + 𝑘2off(𝑘1→2 + 𝑘1off)) +𝛼2 . (3.68)
The experimental data shows that the amplitude of the fast phase becomes very
small, compared to that of the slow phase, so the rate of the slow phase approaches
the apparent dissociation rate
𝑘
App
off =
𝛼 − 𝛽
2
=
1
2
[︂
𝑘1→2 + 𝑘2→1 + 𝑘1off + 𝑘2off −
√︁
4𝑘1→2𝑘2→1 + (𝑘1→2 − 𝑘2→1 + 𝑘1off − 𝑘2off)2
]︂
,
(3.69)
which can be calculated from the fitted kinetic parameters.
The asymptotic apparent rate constant, at low ligand concentrations, can be
calculated by evaluating
𝑘
App
Loff = lim[L]→0
(︃
d𝑘2
d[L]
)︃
(3.70)
=
1
2
⎛⎜⎜⎜⎜⎝𝑘1Loff + 𝑘2Loff + (𝑘1Loff − 𝑘2Loff)(𝑘1→2 − 𝑘2→1 + 𝑘1off − 𝑘2off)√︀
(𝑘1→2 − 𝑘2→1 + 𝑘1off − 𝑘2off)2 − 4𝑘1→2𝑘2→1
⎞⎟⎟⎟⎟⎠ . (3.71)
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Given that 𝑘2Loff≪ 𝑘1Loff this reduces to
𝑘
App
Loff =
𝑘1Loff
2
⎛⎜⎜⎜⎜⎝1 + 𝑘1→2 − 𝑘2→1 + 𝑘1off − 𝑘2off√︀
(𝑘1→2 − 𝑘2→1 + 𝑘1off − 𝑘2off)2 + 4𝑘1→2𝑘2→1
⎞⎟⎟⎟⎟⎠ . (3.72)
Results
The results for Aβ16 (Fig. 3.23) and Aβ40 (Fig. 3.24) show that the model appears
to fit quite well. However, the fitting was unable to determine a value for 𝑘2off.
This is likely due to the spontaneous dissociation of the (Aβ ·Cu)ii complex being
too slow. The (Aβ ·Cu)ii complex most probably dissociates by interconverting to
(Aβ ·Cu)i, after which the Cu2+ dissociates. This simplifies the model slightly, with
the mechanism becoming
Aβ + Cu2+ (Aβ ·Cu)i
𝑘
1→
2𝑘 2
→
1
(Aβ ·Cu)ii
Aβ + Cu ·L
𝑘1Loff+ L
+ L
𝑘2Loff
𝑘1off . (3.73)
The amplitude data appears to deviate from the model at high ligand concentrations.
This is likely to be an artifact due to the data fitting. When the rate of the first
phases is approximately 100 s−1, the phase is partially within the dead time of the
stopped flow machine. Therefore the raw data no longer contains the whole of the
phase, and at short timescales there is decreased signal to noise. The apparent rates
appear to follow the model well, including the double sigmoidal shape in the second
phase. The data for the first phase is relatively noisy at low ligand concentrations
due to the small amplitude of the phase, making it harder to fit.
The model parameters, obtained through fitting, for the results are summarised
in table 3.6. The phases in the figures do not correspond to (Aβ ·Cu)i or (Aβ ·Cu)ii,
except at high EDTA concentrations.
The fitted parameters show that the interconversion is on the second timescale.
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Figure 3.23: Apparent rates and relative amplitudes of the two major phases seen in
the dissociation and removal by EDTA of Cu2+ from Aβ16LysHL488 ·Cu, in Hepes
NaCl (pH 7.5), fitted with the model in 3.28 (solid line). Model parameters are
shown in table 3.6.
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Figure 3.24: Apparent rates and relative amplitudes of the two major phases seen
in the dissociation and removal by EDTA of Cu2+ from Aβ40Cys20HL488 ·Cu, in
Hepes NaCl (pH 7.5), fitted with the model in 3.28 (solid line). Model parameters
are shown in table 3.6.
The time scales of the interconversion process span the timescales of neurotransmis-
sion, therefore the process may be of physiological relevance in the synapse. It was
thought that the two components were in fast equilibrium, according to NMR exper-
iments. However, these experiments show this is not the case. The fast relaxation
observed in the NMR experiments could be due to the interconversion of subspecies
of (Aβ ·Cu)i (such as the interchanging of the bound histidine), broadening the
observed NMR peaks.
The apparent dissociation constant 𝑘Appoff derived is within error of the means
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Sample Aβ16 Aβ40 mAβ16 Aβ16 Aβ40 mAβ16
pH 7.5 7.5 7.5 6.5 6.5 6.5
𝑘1off/s−1 0.8(1) 1.04(6) 1.2(1) 4.3(2) 5.1(4) 9.1(6)
𝑘1Loff/105m−1 s−1 1.3(1) 1.90(5) 1.1(1) 2.7(1) 3.4(2) 3.3(4)
𝑘1→2/s−1 0.9(2) 1.5(1) 1.8(2) 0.06(8) 0.2(1) 0.8(1)
𝑘2off/s−1 Not Determinable
𝑘2Loff/103m−1 s−1 1.48(6) 1.6(1) 0.106(4) 3.1(4) 3.2(5) 0.099(4)
𝑘2→1/s−1 2.22(3) 2.53(7) 0.430(4) 1.29(6) 1.57(9) 0.534(3)
Γ 1.1(2) 0.89(7) 1.3(1) 4(5) 1.3(8) 1.9(2)
𝑘
App
off /s
−1 0.54(7) 0.59(4) 0.15(2) 1.27(7) 1.47(9) 0.489(7)
Figure 3.23 3.24 3.25 3.27 3.28 3.26
Table 3.6: Summary of fitting parameters for the model (Eqn. 3.28) for the dissoci-
ation and removal by EDTA of Cu2+ from Aβ ·Cu.
obtained from the low ligand concentration experiments.
There is a two order of magnitude difference in the rate constants for the removal
of Cu2+ from the Aβ ·Cu complexes. The (Aβ ·Cu)ii complex is relatively inert, with
removal via the (Aβ ·Cu)ii complex starting to dominate at hundreds of micromolar
to millimolar concentrations of EDTA, when the rate starts to straighten. Since
EDTA reacts similarly as Aβ with the Aβ ·Cu complex, and as the reaction rates were
similar in the low ligand concentration experiments, this result suggests that copper
assisted dimerisation would occur via (Aβ ·Cu)i.
The values of the relative brightness of the two states Γ are approximately 1.
This suggests that the distances or interactions between the dye and the Cu2+ are
similar.
The experiment was similarly performed with murine Aβ16 (see Fig. 3.25). The
model fits the second phase’s rates well, but not the other rates or amplitudes. This
is because the second phase is large and slow, therefore its rate and amplitude are
obtained with a very small uncertainty. The proportion of the two components
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Figure 3.25: Apparent rates and relative amplitudes of the two major phases seen in
the dissociation and removal by EDTA of Cu2+ from murine Aβ16LysHL488 ·Cu, in
Hepes NaCl (pH 7.5), fitted with the model in 3.28 (solid line). Model parameters
are shown in table 3.6.
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Figure 3.26: Apparent rates and relative amplitudes of the two major phases seen in
the dissociation and removal by EDTA of Cu2+ from murine Aβ16LysHL488 ·Cu, in
Hepes NaCl (pH 6.5), fitted with the model in 3.28 (solid line). Model parameters
are shown in table 3.6.
for murine Aβ ·Cu are significantly different to human Aβ ·Cu. The second phase
is always much more dominant. The graph shows that the rates of the first phase
have been underestimated, refitting the rates with a line gives the Cu2+ removal rate
constant for (Aβ ·Cu)i to be 2.9(2)× 105 m−1 s−1, faster than for human Aβ. Compar-
atively, the equivalent rate constant for (Aβ ·Cu)ii is slightly slower. Therefore the
order of magnitude difference in Cu2+ assisted dimerisation rate constants, seen
in section 3.5, does not come from different removal rate constants, but from the
interconversion. This can be seen by calculating 𝑘AppLoff /𝑘1Loff. These are 0.59(5),
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0.50(2) & 0.096(7), for Aβ16 ·Cu, Aβ40 ·Cu & mAβ16 ·Cu, respectively.
To check whether the model is valid and whether the inconsistencies are reduced
when the relative proportions of the species are more equal, the experiment was
repeated at pH 6.5. This is closer to the literature p𝐾aof 6.3 for the murine Aβ ·Cu
complexes. Figure 3.26 shows that at a lower pH, the relative proportion of (Aβ ·Cu)i
has increased, agreeing with the literature in that the p𝐾ais less than 6.5. The model
appears to fit the data. The model may not fit so well at pH 7.5 due to other species
of Aβ ·Cu forming, that are not accounted for in the model.
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Figure 3.27: Apparent rates and relative amplitudes of the two major phases seen in
the dissociation and removal by EDTA of Cu2+ from Aβ16LysHL488, in Hepes NaCl
(pH 6.5), fitted with the model in 3.28 (solid line). Model parameters are shown in
table 3.6.
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Figure 3.28: Apparent rates and relative amplitudes of the two major phases seen
in the dissociation and removal by EDTA of Cu2+ from Aβ40Cys20HL488, in Hepes
NaCl (pH 6.5), fitted with the model in 3.28 (solid line). Model parameters are
shown in table 3.6.
The experiments were repeated for Aβ16 & Aβ40 at pH 6.5, with the results
shown in figures 3.27 & 3.28, respectively. These data sets do not fit will with the
model. The amplitudes at high EDTA concentrations suggest that the p𝐾afor Aβ16 &
Aβ40 are greater than pH 7.5, as the relative amplitude has become more dominant.
The relative amplitudes are expected to be equal in equilibrium when p𝐾a=pH. This
may not be true if multiple p𝐾a’s exist around this range.
3.8 Direct Observation of Aβ ·Cu Interconversion and the
Binding Mechanism
With the interconversion of the two Aβ ·Cu species and the dissociation mechanism
obtained, along with the rate at which Aβ and Cu2+ bind to form Aβ ·Cu, this leaves
the question of how does the binding mechanism relate to the interconversion and
dissociation? Does it bind directly to form (Aβ ·Cu)i, or (Aβ ·Cu)ii, or via a more
complex mechanism that leads to these?
To directly probe the binding and interconversion of the Aβ ·Cu complex,
stopped flow with double mixing was used. Initially Aβ was reacted with Cu2+
and then after a set delay with EDTA. Both the reactions of Aβ with Cu2+ and then
Aβ ·Cu with EDTA were under pseudo-first-order conditions. The Cu2+ concentra-
tion was chosen such that the binding reaction would complete within 2 ms, much
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faster than the interconversion. The EDTA concentration was chosen such that its
addition would ‘freeze’ the reaction and the fluorescence recovery amplitudes would
be proportional to the concentration of the two components. The reaction rate
with EDTA is used to determine which component is formed or if a new unknown
intermediary species existed.
The binding of copper to the two components with interconversion can be
described by
Aβ + Cu2+
𝑘on (Aβ ·Cu)i 𝑘1→2
𝑘2→1
(Aβ ·Cu)ii . (3.74)
This assumes that the Cu2+ binds directly to form (Aβ ·Cu)i, without visible interme-
diates. The underlying model would be the same for direct binding to (Aβ ·Cu)ii, as
without data, which complex forms first cannot be determined∗. Since the binding
of Aβ to Cu2+ is much faster than the interconversion, the model can be simplified
to
(Aβ ·Cu)i 𝑘1→2
𝑘2→1
(Aβ ·Cu)ii , (3.75)
with the initial conditions
(Aβ ·Cu)i
(Aβ ·Cu)i + (Aβ ·Cu)ii
⃒⃒⃒⃒⃒
𝑡=0
= 1 (3.76)
and thus
(Aβ ·Cu)ii
⃒⃒⃒
𝑡=0
= 0 . (3.77)
The model gives the differential equations
d[(Aβ ·Cu)i ]
d𝑡
= −𝑘1→2[(Aβ ·Cu)i ] + 𝑘2→1[(Aβ ·Cu)ii] , (3.78)
d[(Aβ ·Cu)ii]
d𝑡
= +𝑘1→2[(Aβ ·Cu)i ]− 𝑘2→1[(Aβ ·Cu)ii] , (3.79)
which predict the change in concentration of the two components. The solutions to
∗It will be shown that (Aβ ·Cu)i is formed initially and so this notation is used.
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these after applying the initial conditions are
[(Aβ ·Cu)i ] =
(𝑘2→1 + 𝑘1→2e−(𝑘1→2+𝑘2→1)𝑡) [(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
𝑘1→2 + 𝑘2→1
, (3.80)
[(Aβ ·Cu)ii] =
𝑘1→2(1− e−(𝑘1→2+𝑘2→1)𝑡) [(Aβ ·Cu)i ]
⃒⃒⃒
𝑡=0
𝑘1→2 + 𝑘2→1
, (3.81)
so the relative amplitudes of the two components are
[(Aβ ·Cu)i ]
[(Aβ ·Cu)i ] + [(Aβ ·Cu)ii] =
𝑘2→1 + 𝑘1→2e−(𝑘1→2+𝑘2→1)𝑡
𝑘1→2 + 𝑘2→1
, (3.82)
[(Aβ ·Cu)ii]
[(Aβ ·Cu)i ] + [(Aβ ·Cu)ii] =
𝑘1→2(1− e−(𝑘1→2+𝑘2→1)𝑡)
𝑘1→2 + 𝑘2→1
. (3.83)
The solutions show that the progress of the reactions in time are single exponentials,
with the rate as the relaxation rate constant (𝑘r = 𝑘1→2 +𝑘2→1). Therefore the relaxa-
tion rate constant can be obtained by periodically measuring the relative amplitudes
at different points in time. This allows the direct probing of the interconversion, for
comparison and confirmation of the previous results.
When 𝑡→∞, the solutions become
𝑅1 B
[(Aβ ·Cu)i ]
[(Aβ ·Cu)i ] + [(Aβ ·Cu)ii] =
𝑘2→1
𝑘1→2 + 𝑘2→1
, (3.84)
𝑅2 B
[(Aβ ·Cu)ii]
[(Aβ ·Cu)i ] + [(Aβ ·Cu)ii] =
𝑘1→2
𝑘1→2 + 𝑘2→1
. (3.85)
This allows the individual interconversion rates to be obtained from
𝑘1→2 = 𝑅2 × 𝑘r , (3.86)
𝑘2→1 = 𝑅1 × 𝑘r . (3.87)
It was found that there were two major phases with the reaction rates with
EDTA corresponding to the rates found previously for (Aβ ·Cu)i and (Aβ ·Cu)ii.
This suggests that any intermediary complex have lifetimes of much less than the
minimum delay time (50 ms). The results in figure 3.29 show that initially (Aβ ·Cu)i
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Figure 3.29: The relative change in amplitude of the two phases of freshly formed
labelled Aβ ·Cu reacted with 1 mm EDTA, after a set age time. The labelled Aβ ·Cu
complex was formed by mixing 50 nm of each. The fitted lines are single exponential,
to determine the relaxation rate 𝑘𝑟 . Using the relative proportion at equilibrium,
the interconversion rates 𝑘1→2 and 𝑘2→1 can be determined. See table 3.7 for the
determined rates.
𝑘𝑟 /s−1 𝑘1→2/s−1 𝑘2→1/s−1
Aβ16LysHL488 ·Cu 3.6(1) 1.68(5) 1.96(5)
Aβ16LysHL488 ·Cu at pH 8.0 6.1(3) 4.9(3) 1.22(8)
Aβ40Cys20HL488 ·Cu 3.6(6) 1.6(3) 2.1(4)
Murine Aβ16LysHL488 ·Cu 2.6(1) 1.98(8) 0.59(3)
Table 3.7: The relaxation 𝑘𝑟 and interconversion rates 𝑘1→2 and 𝑘2→1, obtained from
fits in figure 3.29.
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forms and that this then interconverts to (Aβ ·Cu)ii. This appears to be true for both
human and murine Aβ. The completed mechanism for a single Cu2+ binding to Aβ
is therefore
Aβ + Cu2+
𝑘on
𝑘off
(Aβ ·Cu)i 𝑘1→2
𝑘2→1
(Aβ ·Cu)ii , (3.88)
with interactions with the Aβ ·Cu complex, such as dimerisation, via (Aβ ·Cu)i.
When the experiment is performed in pH 8.0 Hepes NaCl, the (Aβ ·Cu)ii is dom-
inant, therefore the p𝐾a is between pH 7.5 and pH 8.0. The p𝐾a can be determined
using the Henderson-Hasselbalch relation, to be
p𝐾a = pH− lg
(︃
𝑘1→2
𝑘2→1
)︃
, (3.89)
assuming that there are only two states available, one protonated ((Aβ ·Cu)i), and
one not ((Aβ ·Cu)ii). These experiments and the previous set of EDTA experiments
give the mean p𝐾a for human Aβ to be 7.6(2), and for murine Aβ to be 6.9(4),
calculated from the data in table 3.8. The literature values for the p𝐾a are 7.8 & 6.2,
§3.7 §3.8
pH 6.5 pH 7.5 pH 7.5 pH 8.0
Aβ16LysHL488 7.8(6) 7.9(1) 7.57(2) 7.40(4)
Aβ40Cys20HL488 7.4(2) 7.73(3) 7.3(1)
mAβ16LysHL488 6.32(5) 6.88(5) 7.38(2)
Table 3.8: Calculated p𝐾a’s for the (Aβ ·Cu)i-(Aβ ·Cu)ii equilibrium. Calculated from
the 𝑘1→2’s and 𝑘2→1’s from the experiments in sections 3.7 and 3.8, using equation
3.89.
for human and murine Aβ, respectively. These are similar to the values obtained,
however the individually obtained values are somewhat scattered. It would be best
if the experiments in this section could be repeated with a shorter delay time for
better accuracy and precision of higher pH values. Varying the pH would also show
whether the relationship between the pH and lg(𝑘1→2/𝑘2→1) is flat, as predicted by
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the Henderson-Hasselbalch model.
3.9 Multiple Copper Binding to Aβ
It was shown in section 3.2 that multiple Cu2+ can bind to Aβ in equilibrium, with
the second Cu2+ binding at approximately 10 µm. In section 3.3.1 it was shown that
the second Cu2+ association rate constant was approximately 5× 105 m−1 s−1. How
does this fit into the single Cu2+ binding model found so far?
To probe the binding of the second Cu2+ binding to Aβ, double mixing was
used to mix 50 nm labelled Aβ16LysHL488 with CuCl2, under pseudo-first-order
conditions. This mixture was then mixed with 2 mm EDTA, also under pseudo-first-
order conditions. The resulting fluorescence recovery traces were globally fitted
with multiple exponentials, sharing the rates across data sets.
The data in figure 3.30 shows that there are four species of Cu2+ bound to
Aβ. There are two new species III & IV, not seen in the previous measurements.
These are therefore the Aβ with multiple Cu2+ species. Species III appears at much
shorter time scales than species IV. The relative amplitude of species III rises with
(Aβ ·Cu)ii, and therefore is formed via (Aβ ·Cu)i. This can also be seen from figure
3.7, the linear dependence of the apparent association rate of the second phase
with CuCl2. If species III formed via (Aβ ·Cu)ii, the rate limiting step would be
the interconversion, not the binding. Therefore, inserting the binding of Cu2+ to
(Aβ ·Cu)i to form (Aβ ·Cu2)iii in the mechanism gives
Aβ + Cu2+
𝑘on
𝑘off
(Aβ ·Cu)i +Cu
2+
𝑘1→3
(Aβ ·Cu2)iii
𝑘
1→
2
𝑘
2→
1
(Aβ ·Cu)ii
. (3.90)
This leaves the dissociation of Cu2+ from the (Aβ ·Cu2)iii. For this there are two
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Figure 3.30: Species distributions of multiple Cu2+ binding to 50 nm Aβ16HL488 in
time.
possible mechanisms
(Aβ ·Cu)i
(Aβ ·Cu)ii
(Aβ ·Cu2)iii
(Aβ ·Cu)i
(Aβ ·Cu)ii
(Aβ ·Cu2)iii
(3.91)
if it is assumed to reform as either (Aβ ·Cu)i, or (Aβ ·Cu)ii. However, there is also a
fourth species. Assuming that there are no intermediary species, given that they
are not seen in the data, there are therefore 9 different mechanisms of binding to
the three existing species. This brings the number of possible mechanisms to 18.
136
Ignoring their dependence on Cu2+, they are
Model 0
I
II
III
IV
Model 1
I
II
III
IV
Model 2
I
II
III
IV
Model 3
I
II
III
IV
Model 4
I
II
III
IV
Model 5
I
II
III
IV
Model 6
I
II
III
IV
Model 7
I
II
III
IV
Model 8
I
II
III
IV
(3.92)
Model 9
I
II
III
IV
Model 10
I
II
III
IV
Model 11
I
II
III
IV
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Model 12
I
II
III
IV
Model 13
I
II
III
IV
Model 14
I
II
III
IV
Model 15
I
II
III
IV
Model 16
I
II
III
IV
Model 17
I
II
III
IV
.
(3.93)
.
To determine which model most accurately predicted the data, they were all
fitted. The relative quenching of components I & II was set to 1, and for compon-
ents III & IV was set to 1.3, as determined from figure 3.2. They were fitted by
numerically solving the differential equations for each model, using the Runge-
Kutta-Dormand-Prince method. These solutions are then fitted using least-squares
regression, weighted by the errors obtained from fitting the raw data with multi-
exponentials. The errors in the fit are obtained similarly as in section 3.7. The code
used is shown in appendix A.3.
The fits for the models are shown in figure 3.31, with the fitted parameters shown
in table 3.9. The table shows that for models 0 through 8, that 𝑘1→2 > 𝑘2→1. This is
contradictory to the previous results, which show that at equilibrium (Aβ ·Cu)i is
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Figure 3.31: Part 1 of 3.
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Figure 3.31: Part 2 of 3.
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Figure 3.31: Part 3 of 3. Fitting of the models (Eqns. 3.92 & 3.93) to figure 3.30c.
Model
0 1 2 3 4 5 6 7 8
𝑘1→2 1.9(1) 1.9(1) 1.8(1) 2.0(3) 2.1(3) 2.0(3) 1.9(3) 2.0(3) 1.9(3)
𝑘2→1 0.9(1) 0.9(1) 0.8(1) 0.8(3) 1.1(3) 0.9(3) 1.0(3) 1.2(3) 1.0(3)
𝑘3 on 3.0(3) 3.0(3) 3.0(3) 3.1(6) 3.0(6) 3.2(7) 3.6(6) 3.6(7) 3.6(6)
𝑘3 off 1.7(2) 1.7(2) 1.8(2) 2.0(6) 1.9(6) 2.3(7) 2.2(7) 2.3(7) 2.3(7)
𝑘4 on 0.23(1) 0.23(1) 0.23(1) 0.26(5) 0.28(5) 0.25(5) 0.20(3) 0.20(3) 0.21(3)
𝑘4 off 0.16(2) 0.15(2) 0.15(2) 0.5(1) 0.5(1) 0.4(1) 0.28(6) 0.27(6) 0.29(7)
Model
9 10 11 12 13 14 15 16 17
𝑘1→2 1.5(2) 1.5(2) 1.5(2) 1.8(4) 1.8(4) 1.7(4) 1.4(4) 1.4(4) 1.4(4)
𝑘2→1 2.2(2) 2.3(3) 2.3(3) 2.6(8) 2.8(7) 2.8(8) 2.6(6) 2.8(6) 2.7(6)
𝑘3 on 3.1(3) 3.1(3) 3.1(3) 3.1(6) 3.1(6) 3.2(7) 3.5(6) 3.6(6) 3.6(6)
𝑘3 off 1.7(2) 1.7(2) 1.8(2) 2.0(6) 2.0(6) 2.3(7) 2.1(6) 2.1(6) 2.3(6)
𝑘4 on 0.24(1) 0.24(1) 0.24(1) 0.23(4) 0.24(4) 0.23(4) 0.21(3) 0.21(3) 0.22(3)
𝑘4 off 0.17(2) 0.17(2) 0.16(2) 0.4(1) 0.4(1) 0.4(0) 0.30(7) 0.30(6) 0.31(7)
Table 3.9: Fitting parameters for figure 3.31. 𝑘1→2, 𝑘2→1, 𝑘3 off and 𝑘4 off are rate
constants in s−1. 𝑘3 on is a rate in s−1. 𝑘4 on may be a rate or rate constant, in s−1.
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dominant at low Cu2+ concentrations. Those models based upon
(Aβ ·Cu)i
(Aβ ·Cu)ii
(Aβ ·Cu2)iii
(3.94)
which are models 9 though 17 are more correct. The rate constants for 𝑘3 on and
𝑘4 on for the models are 3.0× 105 m−1 s−1 to 3.6× 105 m−1 s−1 and 2.1× 104 m−1 s−1
to 2.4× 104 m−1 s−1. 𝑘3 on is similar to the rate constant obtained in section 3.3.1
(4.2(6)× 105 m−1 s−1). However, the dissociation rate is different (1.7(2) s−1 compared
to 7.3(7) s−1).
Of models 9 through 17, figure 3.31 shows that models 9 through 11 appear to
have the best fit. In these models
I
II
III
IV
I
II
III
IV
I
II
III
IV
,
(3.95)
(Aβ ·Cun)iv is formed via (Aβ ·Cu)i. These models allow for the non zero amplitude
of type IV to be fitted at short time scales.
To check these models and hypotheses, the copper was varied and the relative
amplitudes measured at equilibrium. 25 nm Aβ16LysHL488 was premixed with
various concentrations of CuCl2. This solution was then mixed with 4 mm EDTA, so
that the recovery amplitudes would be proportional to the population. The obtained
curves were globally fitted with a quintuple exponential, sharing the rates.
The results shown in figure 3.32 show that there were five exponentials visible,
unlike in the previous experiment (see Fig 3.30) where there were four. It appears
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Figure 3.32: Relative amplitudes and species population for different Cu2+ con-
centrations premixed with 25 nm Aβ16HL488, then mixed with 4 mm EDTA using
stopped flow. (a) The raw data was fitted with an offset quintuple exponential func-
tion with rates of 𝑘i = 234(4)s−1, 𝑘ii = 4.46(3)s−1, 𝑘iii = 19.9(2)s−1, 𝑘iv = 0.845(9)s−1
and 𝑘v = 0.331(4)s−1. (b) The data was normalised by subtracting the offset and
dividing by the sum of the amplitudes. (c) Relative amplitude of each of the expo-
nential phases. (d) The estimated relative population of each type, by factoring in
the apparent quenching of each phase. For types I & II relative quenching was taken
to be 1, whereas for types III, IV & V, 1.3 was used.
that an extra slow phase has appeared. There is further inconsistency between the
data figure 3.32 and the transient experiments in figure 3.30, in that the relative
amplitudes of the time points at approximately 20 s do not correspond well to the
equilibrium relative amplitudes. This may be due to the reaction being incomplete,
due to the maximal time difference in the transient experiments being approximately
20 s, whereas the equilibrium experiments had approximately 600 s.
To compare the models in the transient experiments against the equilibrium, it
was assumed that the both the formation of (Aβ ·Cu2)iii and (Aβ ·Cun)iv were copper
binding processes and the reaction was modeled as before. The amplitudes at
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1000 s were taken to be in equilibrium. These equilibrium relative amplitudes were
then plotted over the equilibrium data obtained in figure 3.32, with the associated
uncertainty from the fitting.
Figure 3.33 of the fitted models overlaying the data shows that none of the
models, fit well. In particular models 9 through 11 cannot be correct. This is because
with both III and IV form from I, therefore the models predict that [III] ∝ [IV].
Therefore the relative proportion of III cannot decrease at high Cu2+ concentrations,
as in the data. It is likely that an extra copper binding term would need to be
added to one of the models 9 through 11. This may then fit the small initial binding
to Type IV, whilst allowing for it to further increase in proportion at higher Cu2+
concentrations. However, all the models predict the association rate constant to Type
IV to be approximately 2× 104 m−1 s−1. This slow rate constant suggests that the
relevance of this species to the metal-Aβ hypothesis is questionable. That is unless
a location in which both Aβ and Cu2+ are freely available for extended periods of
time can be found, unlike in a synapse.
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Figure 3.33: Part 1 of 2.
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Figure 3.33: Part 2 of 2. Equilibrium predictions of models 9 through 17 (Eqn. 3.93)
with fitting parameters from table 3.9, overlaid onto the measurements from figure
3.32d.
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3.10 Summary
In this chapter it has been shown that the fluorescence of labelled Aβ can be
quenched, when Aβ binds to Cu2+. It was shown that the first Cu2+ binds to
form component I and it can bind with at least three Cu2+ with sufficiently high
Cu2+ concentrations (Approx. 𝐾d’s: 1 nm, 9 µm & 50 µm). The first copper binding
is near diffusion limited, with a low activation barrier. The lifetime of the Aβ ·Cu
complex is approximately 2 s. It was shown that at low Cu2+ concentrations two
Aβ ·Cu species exist, inter-converting on the second timescale. A second copper was
found to bind at a rate of approximately 105 m−1 s−1, to component I. Further Cu2+
binding species are apparent at higher Cu2+ concentrations.
Of the two Aβ ·Cu species that are likely to form at the low transient Cu2+
concentrations in the synapse, (Aβ ·Cu)i was shown to be more reactive. Copper
assisted dimerisation via component I is three orders of magnitude faster than
that without copper, and an order of magnitude faster than for murine Aβ. The
mechanism of Cu2+ binding to Aβ and dimerisation can be summarised as
Aβ + Cu2+
𝑘on
𝑘off
(Aβ ·Cu)i
𝑘 1
→
2
𝑘 2
→
1
(Aβ ·Cu)ii
(Aβ ·Cu2)iii
Aβ ·Cu ·Aβ Oligomers
𝑘3 off−Cu 2+
+Cu
2+
𝑘3 on
. (3.96)
It was found that compounds remove copper from Aβ ·Cu is via (Aβ ·Cu)i and the
removal rate was uncorrelated to 𝐾d. Using labelled Aβ and stopped-flow provides
a method of measuring the efficacy of drug candidates, which could be used to
better test the metal-Aβ hypothesis in vivo and develop new drug candidates.
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Chapter 4
Interactions of Amyloid-β with
Zn2+ and HSA
Having determined the kinetics of Cu2+ binding to Aβ, the focus is now moved
towards Zn2+. Zn2+ like Cu2+ has also been implicated in Alzheimer’s disease and
is released into the synaptic cleft during neurotransmission. Zn2+ is known to be
a neurotransmitter and is co-released with glutamate, but its role in Alzheimer’s
disease is still unclear.
The binding of Zn2+ to Aβ was first discovered in 1994 [76], with an equilibrium
dissociation constant (𝐾d) of approximately 100 nm. This estimate of the 𝐾d has
been revised to the range of 1 µm to 100 µm as the field has progressed. This range is
above that for the CSF Zn2+ concentration (approximately 100 nm) and below that
reached in the synaptic cleft (approximately 300 µm). Does the binding of Zn2+ to
Aβ occur in the synaptic cleft lead to the oligomerisation of Aβ?
The carrier protein human serum albumin (HSA), although having been shown
to bind metals, is also thought to bind Aβ with a 𝐾d of approximately 5 µm [166].
HSA’s 𝐾d with Aβ is similar to the concentration of HSA in the CSF (1 µm to 6 µm).
The binding of HSA to Aβ oligomers is thought to inhibit the association of Aβ [266]
and bind with 𝐾d’s in the range of 1 nm to 100 nm at multiple binding sites [267].
In these experiments, the binding of HSA to Aβ is studied using fluorescence
correlation spectroscopy (FCS). The aggregation of Aβ with Zn2+ is explored under
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equilibrium conditions using FCS and total internal reflection (TIRF) microscopy.
Finally, the kinetics of Zn2+ binding to Aβ and the formation of ternary Aβ ·Cu ·Zn
species is studied by applying the quenching of labelled Aβ by Cu2+ using stopped-
flow methodologies. Zn2+ itself does not quench the fluorophore complicating the
determination of its kinetics. Ternary Aβ ·Cu ·Zn complexes have been shown to
form in vivo, as well as both Zn2+ and Cu2+ being co-localised in amyloid plaques.
However, this area is less explored. The kinetics of both the formation of mixed
metal complexes and Aβ ·Zn is unknown.
4.1 Binding to HSA
HSA is a common protein in both the blood and the brain, which has been shown to
bind to Aβ. However, it is unclear from the literature as to whether HSA binds to
monomers [268], oligomers, or both.
To study the binding of Aβ monomers to HSA, FCS was used to measure the
mean diffusion time (𝜏D) with varying concentrations of HSA. 1.4 nm Aβ40HL488
was mixed with varying HSA concentrations from 0.03 gl−1 to 30 gl−1 (0.432 µm to
432 µm).
The data in table 4.1 shows that the binding of Aβ to HSA is not in the 0.4 µm to
40 µm range as the 𝜏D of HSA is approximately 0.37 ms (see §4.1.1), assuming that
Table 4.1: Diffusion times of 1.4 nm Aβ40HL488 with differing concentrations of
HSA, in Hepes NaCl. 0.3 gl−1 of HSA ≈ 4.32 µm
𝜏D/ms−1 𝐺(0)
HSA/gl−1 Run 1 Run 2 Run 1 Run 2
0 0.171 0.171 3.05 2.95
0.03 0.235 0.226 0.75 0.82
0.3 0.234 0.230 0.58 0.69
3 0.227 0.227 0.52 0.49
30 0.255 0.259 0.09 0.08
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the N-terminal dye label on Aβ does not affect the binding.
The fast diffusion without HSA is likely due to an average of the diffusion time
of monomeric Aβ and free dye. The concentration which proportional to the inverse
of amplitude of the correlation function (𝐺(0)) is approximately 5 times lower at
this point, compared to the other points. This suggests that Aβ may have adsorbed
to the surfaces of the container. The increase in 𝜏D at 30 gl−1 is likely due to the
increase in viscosity or aggregation of HSA due to the high concentration.
As a point of reference the 𝜏D of AL488 (Alexa Fluor 488) in Tris NaCl was
measured the previous day to be 130(3) µs with the same setup.
4.1.1 Mean Diffusion Time of BSA/HSA
To measure the 𝜏D of BSA so as to have a baseline for the previous experiment,
BSA-AL488 was purchased. BSA-AL488 has on average six AL488 per BSA. The 𝜏D
was measured using FCS using 10 nm BSA-AL488 in Hepes BSA. Hepes BSA was
used to prevent the labelled BSA adsorbing to surfaces. This gave a 𝜏D = 0.618(4)ms
which is larger than expected (range 0.4 ms to 0.5 ms). This is likely because the dyes
are attached via linkers to BSA making the molecule appear larger, overestimating
the 𝜏D of BSA.
Labelling HSA
To remedy this, HSA was labelled with HL488. HSA has one free cysteine on the
surface of the protein and therefore it should be possible to singularly label it with
a maleamide dye.
The labelling, purification and gel electrophoresis were performed by Chris-
topher McDonald. The HL488 dye was dissolved in DMSO and the HSA in Hepes
NaCl. 7.5 gl−1 (110 µm) HSA was mixed at a concentration ratio of approximately
1 : 5 : 10 for HSA : TCEP : HL488, with and without TCEP. TCEP is a reducing agent
that does not interfere with HL488, but breaks disulphide bridges. It is preferable
not to add TCEP as HSA naturally contains some disulphide bonds which may also
be broken. The dye, HSA and TCEP mixture was left for 2 h to react. The solution
was then dialysed in PBS at 4 ∘C overnight to remove some of the free dye. The
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filter used for dialysis was 10 kDa. HSA is approximately 67 kDa, whereas HL488
is approximately 600 Da. The apparent intensity of the solution after dialysis was
similar, as prior to dialysis. This suggests that the HSA blocked the pores in the
dialysis membrane preventing the dye from diffusing out.
(a) Fluorescence Image (b) Coomassie Blue Stained Image
Figure 4.1: Labelling of HSA by maleimide HL488, with and without the reducing
agent TCEP, prior to gel-filtration. The columns are 1) ladder, 2) 10 HSA, 3) HSA, 4)
HSA, 5) blank, 6) HSA with TCEP, 7) HSA with TCEP, 8) HSA with TCEP, where 10,
5 & 2 are the relative concentrations of each lane.
To check whether the HSA had been labelled with HL488, gel electrophoresis
was performed using an sodium dodecyl sulfate polyacrylamide gel. Figure 4.1
shows a fluorescence image of the gel and the gel stained with coomassie blue after
fluorescence image was taken. The stained gel shows the position of the HSA. The
fluorescence image shows that both with and without the TCEP the dye appears to
be localised with the protein suggesting that it is labelled. There also appears to
be ‘smaller’ labelled fragments further down the gel and some ‘larger’ aggregates
nearer the top. This suggests that there are impurities in the HSA, or that it may
have degraded during the labelling process.
After this, dye was further removed by using a tabletop gel-filtration chromato-
graphy column and different fractions collected.
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Measuring the 𝜏D of HSA and Quenching by Cu2+
The 𝜏D was measured by Martin Evans to be 0.357(5) ms, closer to the expected
value. Free AL488 dye was measured to be 0.127(1) ms. Martin also showed that
the dye is quenched when HSA binds to Cu2+. However, the dye labelling occludes
the Cu2+ binding site in some way, increasing the apparent 𝐾d and prevents the
kinetics of Cu2+ with HSA from being determined directly using this construct. The
only cysteine not in a disulfide bridge is residue 34 [269] and the N-terminal region
of HSA is thought to bind to Cu2+ [163]. However, the protein is folded, bringing the
N-terminus and Cys34 to within approximately 2 nm to 3 nm [269].
4.2 Aggregation of Aβ and HSA with Zn2+
To investigate the effect of Zn2+ on Aβ and HSA under near physiological conditions,
FCS was used to measure the change in 𝜏D of labelled Aβ in Hepes HSA or Hepes
BSA with differing concentrations of Zn2+.
Twice the concentration of the required final concentration of Aβ and Zn2+ were
diluted separately in either Hepes HSA or Hepes BSA. These two solutions were then
half and half mixed in an 8 well chambered cover glass (Lab-Tek). This is necessary
to minimise localised high concentrations of Zn2+ or Aβ which rapidly aggregates.
The wells were then covered and sealed with sellotape to reduce evaporation and left
overnight at room temperature to reach equilibrium. The 𝜏D was measured using
FCS over at least 2 min. Labelled particles on the cover glass were photobleached
before the measurement was taken, otherwise there is an exponential decay in the
baseline of the signal affecting the FCS curves.
Figure 4.2 and figure 4.3 show the results of the experiments with buffers
including HSA and BSA respectively. For labelled Aβ16 and Aβ40 at low Zn2+
concentrations there appears to be little change in 𝜏D, whereas after a critical Zn2+
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Figure 4.2: Mean diffusion times of various mixtures of labelled and unlabelled
Aβ at physiological concentrations (or ten times the concentration), with varying
concentrations of Zn2+ in Hepes HSA. The parameters for the fitted lines are shown
in table 4.2.
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Figure 4.3: Mean diffusion times of various mixtures of labelled Aβ at physiological
concentrations (1.4 nm) or 7.5 nm, with varying concentrations of Zn2+, in Hepes
BSA. The parameters for the fitted lines are shown in table 4.2.
concentration the 𝜏D appears to increase logarithmically. To fit this phenomenon
𝜏D = 𝑎+θ(𝑧 − 𝑐)×𝑚 ln
(︂𝑧
𝑐
)︂
(4.1)
was used, where 𝑧 is the concentration of Zn2+, 𝑎 is the monomer diffusion time,
𝑐 is the critical concentration, 𝑚 is the ‘gradient’, and θ is the Heaviside step
function. The fitted parameters are given in table 4.2. The critical concentrations
show that there is no significant dependence on the concentration of Aβ, and that
the aggregation is thus limited by the Zn2+ concentration. There appears to be no
significant difference for HSA and BSA. The mean critical concentration is 40(20) µm.
The similarity of the critical concentration for the N-terminally labelled and C-
terminal lysine Aβ suggests that N-terminal labelling has no effect on Zn2+ binding.
Thus the N-terminal amine group does not coordinate to Zn2+. This in agreement
with the proposed binding coordinations in the literature and opposite to what was
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Table 4.2: Summary of critical concentrations (𝑐), gradients (𝑚) and initial diffusion
times (𝑎) in figures 4.2 & 4.3.
Sample in Hepes HSA 𝑎/µs 𝑚/µs 𝑐/µm
Aβ16LysHL488 119(2) 23(4) 40(10) (n=4)
Aβ16LysHL488 (14 nm) 162(7) 40(10) 70(30) (n=1)
Aβ40HL488 218(1) 9(2) 60(20) (n=1)
Aβ40HL488 & Aβ42HL488 200(10) 40(10) 30(20) (n=1)
Aβ40HL488 & Aβ42 190(10) 50(10) 40(20) (n=1)
Sample in Hepes BSA 𝑎/µs 𝑚/µs 𝑐/µm
Aβ16LysHL488 156(1) 11(1) 70(10) (n=1)
Aβ40HL488 266(2) 50(4) 30(4) (n=1)
Aβ40HL488 (7.5 nm) 257(3) 45(5) 23(3) (n=1)
Aβ40HL488 & Aβ42HL488 265(4) 45(5) 32(8) (n=1)
seen with Cu2+ binding.
Aβ42 which is known to be more prone to aggregation, does not appear to
follow the trend of Aβ40 and displays a large variation in 𝜏D. This suggests that the
behaviour is more stochastic with the formation of larger oligomers. The addition of
Aβ40 to Aβ42 appears to reduce the variation of oligomer size, despite the increase
in total Aβ concentration.
One possibility is that the Zn2+ is causing the HSA to aggregate. However,
the literature also suggests that the HSA will not aggregate without heating [270].
Another suggestion is that the Aβ ·Zn complexes are actually forming Aβ ·Zn ·HSA
complexes, if the 𝐾d of Zn2+ to Aβ is greater than that of Aβ ·Zn with HSA.
4.3 Kinetics of Zn2+ Binding to Aβ
In the previous chapter it was shown that the binding of Cu2+ to Aβ is nearly
diffusion limited, which may be due to the electrostatic interactions between the
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positive Cu2+ ion and negative Aβ. Therefore the kinetics of binding between Zn2+
and Aβ may be similar to that of Cu2+ and Aβ. Determining the rate constants of
Zn2+ binding to Aβ will likewise allow for an assessment of the relative importance
of Aβ’s interactions with Zn2+ in the synaptic cleft.
The likely fast binding of Aβ to Zn2+ and a high 𝐾d of approximately 10 µm
prevents previous methodologies used to measure the 𝐾d from being applied to
investigating the kinetics. Likewise, the method used to determine the Cu2+ bind-
ing kinetics cannot be used directly because Zn2+ does not quench labelled Aβ.
Therefore, without a method of determining whether Aβ is bound to Zn2+ indirect
competition experiments must be used. There are two forms of competition experi-
ments possible: a mixture of Aβ and a Zn2+ indicator competing for Zn2+, and Zn2+
competing with Cu2+ for labelled Aβ.
The problem with the Aβ competing against a zinc indicator for Zn2+ is that
the concentration of Aβ and zinc indicator must be in a 20 fold excess of the
concentration of Zn2+ for the experiment to be under pseudo-first-order conditions.
Given that the literature 𝐾d is in the range of 1 µm to 100 µm, even stoichiometric
concentrations of Aβ would cause rapid aggregation, more so with a 20 fold excess.
Therefore the latter competition experiment was used.
If the model of Aβ binding to a mixture of Zn2+ and Cu2+ is taken to be
Aβ + Zn2+ + Cu2+
𝑘z
𝑘 -z
Aβ ·Zn + Cu2+
𝑘c
Aβ ·Cu + Zn2+
, (4.2)
and the experiment is under pseudo-first-order conditions, such that [Cu2+] ≫
[Aβ]≪ [Zn2+], then the solution for Aβ ·Cu is of the form
[Aβ ·Cu] = [Aβ]
⃒⃒⃒
𝑡=0
2𝛽2
⎛⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎝
2𝛽2
+𝛽(𝑘c[Cu
2+]− 𝑘z[Zn2+]− 𝑘-z − 𝛽)e− 𝑡2 (𝛼−𝛽)
−𝛽(𝑘c[Cu2+]− 𝑘z[Zn2+]− 𝑘-z + 𝛽)e− 𝑡2 (𝛼+𝛽)
⎞⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎠ , (4.3)
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where
𝛼 = 𝑘c[Cu
2+] + 𝑘z[Zn
2+] + 𝑘-z , (4.4)
𝛽 =
√︁
𝛼2 − 4𝑘-z𝑘c[Cu2+] , (4.5)
and the initial conditions applied are
[Aβ ·Zn]⃒⃒⃒
𝑡=0
= [Aβ ·Cu]⃒⃒⃒
𝑡=0
= 0 . (4.6)
Therefore the solution is a double exponential with the rates
𝑘 =
1
2
(𝛼 ± 𝛽) (4.7)
=
1
2
(︃
𝑘c[Cu
2+] + 𝑘z[Zn
2+] + 𝑘-z ±
√︁
(𝑘c[Cu2+] + 𝑘z[Zn2+] + 𝑘-z)2 − 4𝑘c[Cu2+]𝑘-z
)︃
.
(4.8)
In this model there are many implicit assumptions in the model (Eqn. 4.2). The
reaction of Aβ ·Cu −−−→ Aβ + Cu2+ is ignored as the rate is approximately 0.5 s−1,
much slower than the observed binding rates (20 s−1 to 100 s−1). The reaction
Aβ ·Cu + Zn2+ −−−→ Aβ ·Cu ·Zn is ignored as the rate constant is 3× 103 m−1 s−1 (see
§4.4). At the highest Zn2+ concentration the rate is 0.6 s−1. The reaction Aβ ·Zn +
Cu2+ −−−→ Aβ ·Cu ·Zn is ignored because in order for the reaction to have a rate of at
least 10 s−1, a rate constant of 2× 107 m−1 s−1 or greater is required. This is deemed
unlikely given the Aβ ·Cu+Zn2+ −−−→ Aβ ·Cu ·Zn rate constant is 3× 103 m−1 s−1 and
Aβ ·Cu + Cu2+ −−−→ Aβ ·Cu ·Cu is 1× 105 m−1 s−1. Aβ ·Cu + Cu2+ −−−→ Aβ ·Cu ·Cu is
therefore also too slow to participate (0.05 s−1). By the same reasoning the Aβ ·Zn +
Zn2+ −−−→ Aβ ·Zn ·Zn is also ignored. This leaves the above model (Eqn. 4.2), the
second simplest competition model.
To measure 𝑘 predicted by the model, 500 nm CuCl2 was premixed with various
concentrations of ZnCl2 which were then mixed with 25 nm Aβ16LysHL488 using
stopped-flow and the fluorescence quenching traces recorded. The traces were fitted
with a double exponential from 2 ms to 0.1 s, without weights. The rate of the fastest
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phase was then fitted with
𝑘 =
1
2
(︃
𝑘Cu + 𝑘z[Zn
2+] + 𝑘z𝐾d −
√︁
(𝑘Cu + 𝑘z[Zn2+] + 𝑘z𝐾d)2 − 4𝑘Cu
)︃
, (4.9)
where the 𝑘Cu is the association rate of 500 nm Cu2+ to Aβ under pseudo first order
conditions (𝑘Cu = 𝑘c[Cu2+]) and 𝐾d is the equilibrium dissociation constant of Aβ
with Zn2+.
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Figure 4.4: Apparent rate of Cu2+ binding to Aβ (𝑘) when competing against Zn2+.
25 nm Aβ16LysHL488 was mixed using stopped flow with a solution of 500 nm Cu2+
and varying concentrations of Zn2+, in Hepes NaCl. The solid line is the fit from
equation 4.9 with 𝑘Cu = 160(20)s−1, 𝑘z = 1.9(3)× 106m−1 s−1, and 𝐾d = 58(9)µm.
The fit in figure 4.4 gives 𝑘Cu to be 160(20) s−1, 𝑘z to be 1.9(3)× 106 m−1 s−1 and
the𝐾d to be 58(9) µm. Therefore 𝑘-z is 110(20) s−1. 𝑘Cu is within error of the expected
value, i.e. 150 s−1 (see §3.3).
The 𝐾d is within the expected range from the literature (1 µm to 100 µm). How-
ever, the value was obtained with 50 mm Hepes and 100 mm NaCl. This may increase
the 𝐾d by reducing 𝑘z as with Cu2+ where it was a factor of approximately 2. The 𝐾d
is within error of the critical concentration for the onset of Aβ aggregation obtained
in section 4.2. Given that the concentration of Aβ in the experiments was 1.4 nm,
this suggests that the affinity of Aβ for Aβ ·Zn is nanomolar or less and thus that
zinc assisted Aβ dimers are more stable than Aβ ·Zn alone. The binding of Zn2+ to
oligomers or fibrils may be important for their growth.
It is surprising that 𝑘z is approximately two orders of magnitude less than the
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association rate constant of Aβ with Cu2+. This suggests that Aβ may not be able to
bind to Zn2+ before it diffuses out of the synapse. The dissociation rate of Aβ ·Zn
suggests that the complex would have a lifetime of approximately 9 ms (half-life
of 6 ms). For Zn2+ assisted dimerisation to occur, the binding of free Aβ to Aβ ·Zn
without free Zn2+ in the CSF would require a rate constant at least an order of
magnitude above the limit by diffusion (109 m−1 s−1), 1.1× 1010 m−1 s−1 for 10 nm
Aβ, which is highly unlikely. For comparison the dimerisation rate of Aβ with
Aβ ·Cu would need to be above 5× 107 m−1 s−1. This is also unlikely suggesting that
dimerisation does not occur in the CSF, and that sustained high concentrations of
metals or Aβ would be required. However, the relative parameters to find limits for
the dimerisation on the synaptic membrane are unknown.
4.4 Kinetics of Mixed Metal Aβ ·Cu ·Zn Species
An extension to the amyloid-metal hypothesis seen in the literature is that mixed
Aβ ·Cu ·Zn may be involved in the pathways of Alzheimer’s disease. To measure
the associated parameters with this process, the displacement of Cu2+ in Aβ ·Cu by
Zn2+ is studied.
To measure the interactions of Zn2+ with Aβ ·Cu, 100 nm Aβ16LysHL488 was
premixed with 100 nm CuCl2 to form Aβ ·Cu. This solution was then mixed with
varying concentrations of ZnCl2. The recorded fluorescence recovery traces were
fitted with a double exponential fit. A slow dominant phase with a rate of 0.47(3) s−1
and a minor fast phase with rate of 5.2(2) s−1 were observed. The slow rate corres-
ponds to the rate of dissociation of Aβ ·Cu. This suggests that the slow process is
related to
Aβ ·Cu + Zn2+ −−−⇀↽−− Aβ + Cu2+ + Zn2+ −−−⇀↽−− Aβ ·Zn + Cu2+ , (4.10)
which is unrelated to Zn2+’s interaction with Aβ ·Cu.
Figure 4.5 shows the apparent rate of the fast phase. The rate appears independ-
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Figure 4.5: Apparent rate of the fast phase (𝑘) of the displacement of Cu2+ by
varying concentrations of Zn2+ in 50 nm Aβ ·Cu, in Hepes NaCl. The solid line is the
average 5.2(2) s−1, uncertainty not shown.
ent of Zn2+ concentration. Therefore, if the model of the experiment is
Aβ ·Cu + Zn2+ −−−⇀↽−− Aβ ·Cu ·Zn⏟                                  ⏞                                  
Quenched
−−−⇀↽−− Aβ ·Zn + Cu2+⏟           ⏞           
Fluorescent
(4.11)
this rate corresponds to the rate limiting step, i.e. the removal of Cu2+ from
Aβ ·Cu ·Zn and Aβ ·Cu ·Zn −−−→ Aβ ·Cu + Zn2+. This rate constant is related to the
lifetime of the Aβ ·Cu ·Zn complex. However, the lifetime may be dominated by
the removal of the Zn2+ instead. In this model, to determine the rate constant of
Aβ ·Cu + Zn2+ −−−→ Aβ ·Cu ·Zn, it is required to be slow compared to the other steps,
otherwise there will be little difference in the fluorescence change contributed by
it. Theoretically, this rate could be slowed by reducing the concentration of Zn2+.
However, this is impractical due to the small amplitude of the fast phase which
would decrease further with a reduced Zn2+ concentration. Therefore an alternative
approach is required.
For intramolecular processes such as dissociations, typically the Arrhenius pre-
exponential factor is much larger than that of intermolecular processes. This is
due to the relation between the pre-exponential factor and the ‘collision frequency’.
Therefore, at sufficiently high temperatures, the rates of intermolecular processes
may be slower than those of internal processes. By studying the underlying energet-
ics of the process, it may be possible to extrapolate the association rate constant of
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Aβ ·Cu + Zn2+ −−−→ Aβ ·Cu ·Zn at 25 ∘C.
To test this hypothesis, 100 nm Aβ16LysHL488 was premixed with 100 nm CuCl2
to form Aβ ·Cu. This was then mixed with 600 µm ZnCl2 varying the temperature
of the reaction. The fluorescence recovery data was fitted with a multi-exponential,
and the rate of the fastest phase was taken.
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Figure 4.6: Arrhenius plot of the apparent rate of the fastest phase (𝑘) of 50 nm
Aβ16LysHL488, with 300 µm ZnCl2. The solid line is a fit of equation 4.12, and the
dotted line is an extension of the piecewise parts of equation 4.12. The intersection
of the two lines is at 34(2) ∘C.
Figure 4.6 shows that there appears to be a bend in the Arrhenius plot as the
rate limiting step changes. To fit the data, two Arrhenius equations are used in a
continuous piecewise manner, such that
ln(𝑘) =
⎧⎪⎪⎪⎨⎪⎪⎪⎩ 𝑇
−1 ≤ 𝑅(𝑐1−𝑐2)𝐸a1−𝐸a2 , 𝑐1 −
𝐸a1
𝑅𝑇
otherwise , 𝑐2 − 𝐸a2𝑅𝑇
, (4.12)
where 𝑘 is the apparent reaction rate, 𝑇 is the temperature, 𝑅 is the ideal gas
constant, the 𝑐’s are the natural log of the Arrhenius pre-exponential factor of the
two phases, and the 𝐸a’s are the activation energies of the two phases. This shows
that the transition temperatures between the two regimes is 34(2) ∘C, suggesting that
for concentrations of ZnCl2 less than or equal to 300 µm and temperatures above
34(2) ∘C, the Zn2+ binding can be studied as it would be the dominant process. It
should be noted that this transition temperature should change for different Zn2+
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concentrations.
To confirm that for temperatures near and above 34(2) ∘C the Aβ ·Cu+Zn2+ −−−⇀↽−−
Aβ ·Cu ·Zn is the limiting process and to measure the binding rate constant, 100 nm
Aβ16LysHL488 was premixed with 100 nm CuCl2 to form Aβ ·Cu. This was then
mixed with different concentrations of ZnCl2 (200 µm to 600 µm, twice the final
concentration) at different temperatures (35 ∘C to 55 ∘C). The resulting fluorescence
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Figure 4.7: Temperature dependence of addition displacement of Cu2+ from 50 nm
Aβ ·Cu by Zn2+. (a) The dependence of the apparent binding rate (𝑘Appon ) on temper-
ature and Zn2+. (b) The temperature dependence of the association rate constant
(𝑘on), determined from the gradient of the fits in (a). Extrapolating this to 25 ∘C
gives 𝑘on = 3(1)× 103m−1 s−1.
recovery data was fitted with a multi-exponential, and the fastest rate taken to be
due to the association process (see Fig. 4.7a). The rates for each temperature point
were taken and linearly fitted (see Fig. 4.7a). The gradient of the fit is taken as the
Aβ ·Cu + Zn2+ −−−→ Aβ ·Cu ·Zn association rate constant (𝑘on). The Arrhenius plot
of 𝑘on in figure 4.7b was fitted with the Arrhenius equation. This fit can then be
used to extrapolate 𝑘on at 25 ∘C, giving 3(1)× 103 m−1 s−1. The error at 25 ∘C was
calculated by shifting the data by 𝑇 −1 ↦→ 𝑇 −1 − (25∘C)−1 and refitting so as not to
overestimate the error at this point.
The 3(1)× 103 m−1 s−1 association rate constant is extremely slow, two orders of
magnitude slower than the second Cu2+ binding and thus Aβ ·Cu ·Zn species are
unlikely to form from Aβ ·Cu in vivo.
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4.5 Summary
In this chapter it has been shown that Zn2+ may bind to Aβ and may form mixed
Aβ ·Cu ·Zn complexes. Dye labelled monomeric Aβ has been shown not to bind to
HSA.
At physiological concentrations of Aβ and HSA there is a critical point of ap-
proximately 40(20) µm for the onset of aggregation with Zn2+. This is well below
the 300 µm Zn2+ released during synaptic transmission. The critical point of aggreg-
ation under these conditions appears to depend only on Zn2+ concentration and not
on the concentration of Aβ when the Aβ concentrations are in the low nanomolar
regime. The aggregates may or may not contain HSA. The critical point also provides
an estimate for the 𝐾d of Aβ binding to Zn2+ or HSA ·Zn.
The kinetics of Aβ with Zn2+ were determined to be
Aβ + Zn2+
1.9(3)× 106 m−1 s−1
110 s−1
Aβ ·Zn , (4.13)
with 𝐾d of 58(9) µm, uncorrected for buffer effects. The association rate constant of
Zn2+ with Aβ is two orders of magnitude lower than that for Cu2+ and further from
the diffusion limit, so it is harder to deduce the magnitude and possible relevance
of Aβ binding to Zn2+ during synaptic transmission. The short lifetime of the
Aβ ·Zn complexes suggests that Aβ ·Zn cannot dimerise in free solution with CSF
concentrations of Aβ, without sustained high concentrations of Zn2+.
The kinetics binding of Zn2+ to Aβ ·Cu is very slow,
Aβ ·Cu + Zn2+ 3(1)× 10
3 m−1 s−1
Aβ ·Cu ·Zn , (4.14)
but the complete mechanism is unclear. With a slow association rate constant
of 3(1)× 103 m−1 s−1 mixed Aβ ·Cu ·Zn complexes are likely to be irrelevant in
physiology or to the dimerisation of Aβ.
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Chapter 5
Interactions of Amyloid-β with
Model Lipid Membranes
Having determined some of the kinetics for Cu2+ and Zn2+ binding to Aβ as para-
meters to test the metal-amyloid hypothesis in the synapse, this leaves the effect
of the synapse itself on the hypothesis. The C-terminal region of Aβ is known to
bind to membranes, in particular to lipid rafts containing the ganglioside GM1. The
effects of Aβ being bound to a membrane on the binding to Cu2+ are unknown.
In the previous chapters, it was predicted that metal assisted Aβ dimerisation
was unlikely to occur in solution for Cu2+. This is because for the concentration of Aβ
in the CSF a rate constant of > 107m−1 s−1 was required for the rate of the reaction
to be greater than the dissociation rate of Aβ ·Cu. The measured rate was only
105 m−1 s−1. This leaves the possibility that Aβ dimerisation occurs on the surface of
synaptic membranes. To make an equivalent prediction for the dimerisation rate on
membranes, surface density of Aβ, its metal assisted dimerisation rate constant and
the kinetic parameters of Cu2+ binding to membrane bound Aβ would be required.
Here the binding of Aβ to model lipid membranes is studied, leading to an order
of magnitude estimate of the concentration on membranes. This is done by counting
labelled Aβ observed through TIRF microscopy. The kinetics of Cu2+ binding to
Aβ bound to GM1 micelles are measured using stopped flow for comparison to the
Aβ/Cu2+ kinetics obtained in chapter 3.
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5.1 Binding of Aβ to Sodium Dodecyl Sulfate Micelles
Sodium dodecyl sulfate (SDS) can be used as a membrane mimic due to its very
polar head group and hydrophobic tail (see Fig. 5.1). In aqueous solutions they
O
S
OO
O− Na+
Figure 5.1: Chemical structure of sodium dodecyl sulfate.
spontaneously form micelles when above the critical micelle concentration (CMC)
of 8.2 mm [271]. The micelles formed are approximately 60 units of SDS, however it
may increases in strong electrolyte solutions [272].
To investigate the incorporation of Aβ40 into SDS micelles, SDS was dissolved
in PBS buffer at 20 mm to form micelles. The 20 mm SDS solution was diluted to
the required concentration and mixed with 2.3 nm Aβ40HL488. The mean diffusion
time of the label was measured with FCS.
0.2
0.25
0.3
0.35
0.4
0.45
0.5
0.1 1 10
τ D
/m
s
[SDS]/mm
Figure 5.2: Mean diffusion time of 2.3 nm Aβ40HL488 with varying concentrations
of SDS. The data is fitted with a Hill function with, 𝐴 = −0.21(4)ms, 𝐾d = 0.2(1)mm,
𝑐 = 0.45(2)ms, with 𝛼 fixed at 1.
Figure 5.2 shows the data fitted with a Hill function. The fit gives the 𝐾d to
be in the low hundreds of micromolar (200(100) µm for SDS molecules, or equival-
ently 3(2) µm for SDS micelles). The mean diffusion time of the bound complex is
0.45(2) ms, which may be used to estimate the number of SDS units per micelle. If
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the micelle is assumed to be spherical and the density (𝜌) of the micelle and Aβ are
similar, then
𝑚 = 𝜌𝑉 , 𝑉 =
4
3
𝜋𝑟3 , 𝑅H =
𝑘B𝑇
6𝜋𝜂𝐷
and 𝜏D =
𝜔20
4𝐷
, (5.1)
where 𝑉 is the volume, 𝑟 is the radius of a sphere, 𝑅H ≡ 𝑟 is the hydrodynamic
radius, 𝑇 is the temperature, 𝜂 is the viscosity, 𝐷 is the diffusion constant and 𝜔20 is
the beam waist of the confocal volume, which can be used to show the that 𝜏3D ∝∼𝑚.
From this the number of units (𝑛) can be approximated from(︃
𝜏D Aβ ·micelle
𝜏D Aβ
)︃
=
𝑚Aβ +𝑚SDS ×𝑛
𝑚Aβ
. (5.2)
Using the fitted diffusion with the micelle (0.45(2) ms) and the free Aβ40 diffusion
time (0.254 ms), this estimates the size to be approximately 70 SDS units, similar to
that in the literature.
5.2 Binding of Aβ to GM1 micelles
Aβ is known to bind tightly to GM1 ganglioside, a lipid found in the plasma
membrane of cells which is concentrated in lipid rafts [273]. The binding of Aβ to
GM1 is thought to promote structural changes and oligomerisation.
GM1, like SDS, spontaneously forms micelles when the concentration is above
the critical micelle concentration of approximately 1 µm [147]. They have a hydro-
dynamic radius of 5.4 nm and are made up of 168(4) GM1 units (approximately
260 kDa). The C-terminal region of Aβ has been shown to be the region bind-
ing to GM1 micelles leaving the N-terminal metal binding region exposed to the
extracellular spaces, such as the synaptic cleft.
5.2.1 Formation of Micelles
To make BODIPY(texas red) labelled micelles, GM1 and GM1 labelled with BODIPY
are dissolved in methanol as stock solutions. The GM1 and labelled GM1 are
mixed at a molar ratio of approximately 1 : 200 in methanol to allow for the lipids
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to mix evenly. The methanol solution is left to evaporate to dryness. Aqueous
buffer is added to the dried mixture of labelled and unlabelled GM1, such that the
concentration is greater than 1 µm (620 µm, or 3.7 µm of micelles). This solution
is then diluted to the required concentration. The 1 : 200 mixture of labelled to
unlabelled lipids in the micelles should follow a Poisson distribution. Therefore
the probability (𝑃 (𝑛)) of number of dyes per micelle (𝑛) is: 𝑃 (0) = 43%, 𝑃 (1) = 36%,
𝑃 (2) = 15%, 𝑃 (> 2) = 5%, and thus the proportion of singularly labelled to multiply
labelled micelles is 63 %. For unlabelled micelles the same steps were followed, but
without adding dye labelled GM1.
To determine whether micelles were formed, the diffusion time of labelled
micelles was measured in Tris NaCl buffer. 𝜏D was measured to be 0.61(2) ms, signi-
ficantly larger than for Aβ40 (approximately 0.25 ms). Using a similar calculation
to that in section 5.2, this gives the number of units in a GM1 micelle to be 40(20).
The literature value of the hydrodynamic radius of Aβ is approximately 0.9 nm [50].
This gives the GM1 micelles a radius of 2.2 nm, approximately half the literature
value of 5.4 nm [147].
5.2.2 Binding of Aβ to GM1 Micelles
Aβ ·GM1 micelle complexes were prepared at higher concentrations and diluted
for the FCS measurement. This is because the binding of Aβ40 to Aβ ·GM1 micelles
complexes was too slow at low concentrations. 100 µm GM1 (667 nm micelles)
was mixed with 500 nm Aβ40HL488 and diluted by a factor of 200 for the FCS
measurement in PBS.
The 𝜏D of the micelles was measured to be approximately 0.51 ms, suggesting
that binding had occurred. However, the literature states that the 𝐾d is approxim-
ately 1 µm, so the complex should start to dissociate after dilution. Measuring the
dissociation rate was attempted using FCS, but the concentration of fluorescence
particles dropped over the course of 150 min, suggesting that upon dissociation the
Aβ40 was adsorbing to the glass/plastic surface of the well.
In order to measure the kinetics, order of magnitude higher concentrations are
required. However this would be too high for FCS measurements.
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Anisotropy
Aβ40Cys20HL488 was shown to bind micelles using fluorescence anisotropy. The
anisotropy of 2 µm Aβ40Cys20HL488 was measured with and without 2 µm GM1
micelles, using the fluorometer. The anisotropy increased from 0.04(1) to 0.193(2).
This shows binding of the labelled Aβ to GM1 micelles. The binding occurred
within 20 s, so the kinetics are too fast to be measured by the fluorometer, so require
the change in anisotropy to be measured by stopped flow.
The fluorescence anisotropy (𝐴) is defined as
𝐴 =
𝑟0
1 + 𝜏𝜑
, (5.3)
where 𝑟0 is the intrinsic anisotropy of the fluorophore, 𝜏 is the fluorescence lifetime
of the fluorophore (4.1 ns), and 𝜑 is the rotational time constant. The Stokes-
Einstein-Debye equation
𝜑−1 = 𝑘B𝑇
𝜂𝑉
(5.4)
relates 𝜑 to the temperature 𝑇 (298 K), the viscosity 𝜂 (8.9× 10−4 kgm−1 s−2 for
water), and the molecular volume 𝑉 . Using the hydrodynamic radius of Aβ (0.9 nm)
and its anisotropy (0.04), 𝑟0 was determined to be 0.29. This gives the hydrodynamic
radius of Aβ ·GM1 micelle to be 2.1 nm, approximately half the literature value.
5.2.3 Labelled Micelles are not Quenched by Cu2+
To investigate the interactions of Cu2+ with GM1 micelles, 100 nm of labelled mi-
celles were mixed with 10 µm Cu2+ and the fluorescence was measured before and
after using the fluorometer. There was no apparent change in fluorescence.
As a possible positive control 1 µm unlabelled Aβ40 was mixed with 1 µm GM1
micelles and 10 µm Cu2+ was added. There was no apparent change in fluorescence.
This suggests that Cu2+ bound to Aβ on the micelle or Cu2+ bound to the
surface of the micelle is unable to interact with the dye on the lipid tail of the GM1
inside of the micelle. Therefore BODIPY labelled GM1 micelles with a label on the
hydrophobic tail of GM1 cannot be used to investigate copper binding to micelles
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or unlabelled Aβ.
5.3 Binding of Aβ to Vesicles of GM1, Sphingomyelin and
Cholesterol
To test the binding Aβ to a more physiologically relevant system of lipids, a mixture
of GM1, Sphingomyelin and Cholesterol was used to create vesicles of approximately
100 nm in size. Varying the composition of the lipids in the system will vary the
properties of the membrane that Aβ binds, such as curvature, surface tension and
fluidity.
The vesicles were prepared such that the molar ratio of GM1:Cholesterol:Sphin-
gomyelin is 1:2:1 with concentration of 140 µm:270 µm:140 µm in 1 mL of Tris NaCl.
For labelled vesicles 0.8 % of the GM1 was replaced with GM1 Bodipy. Initially the
lipids were dissolved in methanol to facilitate the mixing of the lipids and evapor-
ated to dryness. The mixture of lipids was then hydrated in buffer, making large
multilamellar vesicles. This solution was extruded through a 100 nm polycarbonate
membrane filter (LipsoFast, Avestin) 15 times, to ensure that the solution used had
passed through the membrane [274].
Figure 5.3 shows some of the vesicles (diffraction limited bright spots) on the
glass cover slip. This shows that the vesicles have formed and have stuck to the
surface.
Figure 5.4a shows that there are vesicles in solution using confocal microscopy.
The bright spikes are the vesicles diffusing slowly through the confocal volume.
To test whether Aβ binds to the vesicles, FRET from the GM1 Bodipy in the
vesicles to the Aβ40HLTR was measured. Figure 5.4b shows the fluorescence spectra
of labelled vesicles with different ratios of Aβ40HLTR to GM1 Bodipy. The figure
shows that there is a FRET peak at approximately 620 nm, showing that the Aβ
is close to the GM1 Bodipy. The FRET peak increases up until the ratio of 4.54
after which there is a decrease in the FRET efficiency. This is likely due a high
density of Aβ40HLTR binding to the vesicles allowing for Homo-FRET to occur. The
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Figure 5.3: Labelled vesicles on a glass surface using TIRF microscopy. The colour
denotes the pixel brightness of the CCD camera.
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Figure 5.4: (a) Fluorescence trace of labelled vesicles diffusing through the confocal
volume. (b) Emission spectrum of acceptor labelled Aβ40 with donor labelled
vesicles, with different ratios of Aβ40HLTR to GM1 Bodipy. The sample is excited at
488 nm.
169
emission peak of GM1 Bodipy continues to decrease with the increased proportion
of Aβ40HLTR as expected.
5.4 Estimate of the Surface Density of Aβ
The number of Aβ molecules and the diffusion constant when bound to the synapse
are important biophysical quantity for predicting whether dimerisation can occur
on the membrane. Although the diffusion constant of Aβ monomers on some
membranes has been measured, there has been no attempt to quantify the surface
concentration of Aβ.
To obtain an order of magnitude estimate of the surface density of Aβ40 on
model membranes, two disparate forms of membranes were formed on a large glass
bottomed dish (WillCo-Dish, GWSt-5040) and then TIRF microscopy was used to
image the bottom of the well so that the single molecules could be counted.
The membranes were formed of POPC & POPG, or GM1, Sphingomyelin &
Cholesterol. The POPC & POPG membrane was formed by dissolving POPG and
POPC in chloroform and then mixing them in a glass vial such that 1 mg of each
was in the vial in chloroform. This was left to evaporate to dryness. 1.3 ml of Hepes
NaCl was added to the dried powder and left for a few hours. The white cloudy
solution was sonicated for approximately 30 min until the solution had become
clear. This was then pipetted into a glass bottomed dish and a further 4.3 ml Hepes
NaCl was added. The solution was left at 5 ∘C overnight to allow the vesicles to
collapse onto the surface. After this the solution was removed and the dish rinsed
gently with Hepes NaCl buffer to the remove vesicles that had not collapsed. For
the GM1, Sphingomyelin & Cholesterol membrane, 0.5 mg, 0.5 mg and 1 mg, were
prepared respectively in methanol and left to evaporate to dryness. After that, the
same procedure was followed.
For the TIRF measurements, 10 pm Aβ40Cys20HL488 was added into the glass
bottomed dish such that the total volume was 6 ml. The solution was left for a few
hours to reach equilibrium. 40 frames of 80 ms exposure time were taken using
the EMCCD with a laser power of approximately 4.4 mW. The molecules were
170
counted in each frame by hand and fitted with exponentials as expected for the
photobleaching processes.
As a possible control to see whether membranes had formed, the experiment
was also performed on glass. Figure 5.5 shows that with only glass the surface has
a very high coverage in which it is difficult to identify single molecules until most
of the fluorophores have photobleached. For comparison, when the membrane has
been prepared the number of molecules was significantly lower showing that the
membranes had formed (see Fig. 5.6 & 5.7). However, it does not show the thickness
of the membrane or the number of layers that may had formed. This also suggests
that coating surfaces with a membrane could be used to reduce surface adsorption.
In particular with POPC, as Aβ is not thought to bind to POPC membranes.
Figure 5.8 shows the number of spots on each of the two membranes as the
fluorophores bleach in time. The bleaching of the spots on the POPC & POPG
membrane appears more exponential than that with the GM1, Sphingomyelin &
Cholesterol membrane. This suggests that on the GM1 containing membrane the
Aβ molecules are more localised and possibly have formed oligomers. Extrapolating
to frame 0 gives the number of spots to be 270 for POPC & POPG, and 280 for
GM1, Sphingomyelin & cholesterol. This is surprisingly consistent for such differing
membranes suggesting that the solution concentration may be a limiting factor. The
area of frames is approximately 20 µm by 20 µm, giving a surface number density
of approximately 7× 1011 m−2 (11 fmoldm−2). The bottom of the well is 40 mm in
diameter giving the total number of molecules adsorbed to the surface as 3.5× 109,
whereas the total number of molecules in the dish is expected to be 3.6× 1010, so
approximately 10 % are bound. The Langmuir isotherm
𝜃 =
[P]
𝐾d + [P]
(5.5)
relates the fractional surface coverage 𝜃, to the solution concentration [P] via the 𝐾d.
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(a) Frame 1 (b) Frame 4
(c) Frame 16 (d) Frame 32
Figure 5.5: Photobleaching of Aβ40Cys20HL488 on glass. Frame one appears blank
as it is overexposed due to the high surface density of Aβ40Cys20HL488 on the glass.
The colour denotes the pixel brightness of the CCD camera.
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(a) Frame 1 (b) Frame 4
(c) Frame 16 (d) Frame 32
Figure 5.6: Photobleaching of Aβ40Cys20HL488 on a membrane of GM1, Sphin-
gomyelin and Cholesterol.The colour denotes the pixel brightness of the CCD
camera.
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(a) Frame 1 (b) Frame 4
(c) Frame 16 (d) Frame 32
Figure 5.7: Photobleaching of Aβ40Cys20HL488 on a membrane of POPC and POPG.
The colour denotes the pixel brightness of the CCD camera.
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Figure 5.8: Photobleaching of 10 pm Aβ40Cys20HL488 bound to a model lipid
membrane (either POPC & POPG, or GM1, Sphingomyelin & Cholesterol). 400 µm2
images were taken, using TIRF microscopy and the particles were counted manually.
The membrane components were of an equal mass ratio. Fitting with a single
exponential, with the error estimated by the square root of the particle number,
gives approximately 270 & 280 molecules for the two membranes (POPC & POPG,
or GM1, Sphingomyelin & Cholesterol, respectively). Therefore the surface density
of Aβ is estimated to be approximately 1 pmolm−2 (7× 1011 m−2).
As the proportion bound is relatively low, this suggests that [𝑃 ]≪ 𝐾d and thus
𝜃 ∝ [P] . (5.6)
Given that the diameter of a synapse is approximately 300 nm, at 10 pm there are
approximately 0.05 /synapse. Therefore at physiological concentrations (1 nm to
10 nm) there are likely be approximately 5 /synapse to 50 /synapse. For comparison
there are approximately up to 20 NMDA receptors per synapse and up to 200 AMPA
receptors [275].
5.5 Kinetics of Cu2+ Binding to Aβ on GM1 Micelles
The kinetics of Cu2+ binding to Aβ were measured in solution in chapter 3. However,
Aβ may be bound to the synaptic termini when the Cu2+ is released rather than in
solution which may affect its kinetics.
To investigate its kinetics methods similar to those in sections 3.3, 3.7 & 3.8 were
used. Instead of labelled Aβ, Aβ40Cys20HL488 bound to unlabelled GM1 micelles
was used, prepared as in section 5.2.1.
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5.5.1 Association
To measure the association of Cu2+ to Aβ40Cys20HL488 ·GM1 micelles, 500 nm
CuCl2 was mixed with 50 nm Aβ40Cys20HL488 ·GM1 micelles in Hepes NaCl, using
stopped flow. The concentration of Hepes was varied such that the weak interactions
between the Cu2+ and the Hepes in the buffer may be extrapolated away.
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Figure 5.9: Determination of the Hepes independent association rate constant.
25 nm Aβ40Cys20HL488 ·GM1 micelles was reacted with 500 nm Cu2+ in various
Hepes concentrations and 100 nm NaCl. The solid line is a fitted zero centred
parabola (𝑘−1on(App) = 𝐴[Hepes]
2 +𝐶), to the first six points. Extrapolating to zero give
the Hepes independent association rate constant 𝑘on to be 8(2)× 108 m−1 s−1.
Figure 5.9 shows that the data appears to be parabolic in shape and is fitted
with a zero centered parabola, similarly to as was found when Aβ was not bound
to micelles. The first six points were fitted to give 𝑘on = 8(2)× 108m−1 s−1 and
𝐴 = 2.5(8)mm−2 s. The 𝑘on is not significantly different from the 5× 108 m−1 s−1
obtained when Aβ is not bound to micelles.
5.5.2 Interconversion and Dissociation
To measure the rate of interconversion and dissociation of Aβ ·Cu on GM1 micelles,
100 nm of Aβ40Cys20HL488 ·GM1 micelles was premixed with 100 nm CuCl2, which
was then mixed with various concentrations of EDTA using stopped flow. The
fluorescence recovery traces are then fitted with exponentials and the rates and
relative amplitudes are fitted to the model in equation 3.28.
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Figure 5.10: Apparent rates and relative amplitudes of the two major phases seen in
the dissociation and removal by EDTA of Cu2+ from Aβ40Cys20HL488 ·Cu on GM1
micelles, in Hepes NaCl at pH 7.5, fitted with the model in 3.28 (solid lines). Model
parameters are shown in table 5.1
Figure 5.10 appears quite different from the figures in section 3.7. In particular
at the highest EDTA concentrations, the rate of interaction with the fastest phase
is an order of magnitude lower and this effect shifts the behaviour of the relative
amplitude curves to higher EDTA concentrations. The fitted parameters in table 5.1
give the removal rate from (Aβ ·Cu)i to be approximately two orders of magnitude
slower when bound to micelles, whereas the removal rate from (Aβ ·Cu)ii is slower
but similar. This suggests that the Aβ ·Cu complex on the surface may be protected
from ligands in solution. This may be in part due to the very polar head group
of GM1 being negatively charged, thus electrostatic interactions may repel the
negatively charged EDTA and possibly other Cu2+ binding ligands. As to whether
there is a similarly large decrease in the rate of removal of Cu2+ from Aβ ·Cu when
the ligand is also bound to the surface is an open question. This may have an effect
on the possibility of metal assisted Aβ dimerisation on membranes.
The interconversion between (Aβ ·Cu)i and (Aβ ·Cu)ii on GM1 micelles is slower
but similar to when Aβ is not bound to GM1 micelles. 𝑘1→2 and 𝑘2→1 gives the
relative proportion of the two species to be 64 : 36 (Aβ ·Cu)i to (Aβ ·Cu)ii, similar to
that without micelles. One issue of the fit is the relative brightness (Γ ) between the
two species being 0.4(1) when it is expected to be close to 1. Refitting with Γ fixed to
1 (see Fig. 5.11) gives the relative proportion of the two species to be 74 : 26, similar
to the measurements without micelles. There are no other significant differences
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Sample Aβ40 ·GM1 Micelle
𝑘1off/s−1 0.78(5) 0.71(4)
𝑘1Loff/m−1 s−1 3.4(3) × 103 3.6(3) × 103
𝑘1→2/s−1 0.52(9) 0.25(2)
𝑘2Loff/m−1 s−1 70(50) 170(60)
𝑘2→1/s−1 0.91(6) 0.71(3)
Γ 0.4(1) 1
𝑘
App
off /s
−1 0.39(3) 0.40(2)
Figure 5.10 5.11
Table 5.1: Summary of fitting for the model (Eqn. 3.28) for the dissociation and
removal by EDTA of Cu2+ from Aβ40Cys20HL488 ·Cu on GM1 micelles.
between the two fitting’s parameters.
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Figure 5.11: Apparent rates and relative amplitudes of the two major phases seen in
the dissociation and removal by EDTA of Cu2+ from Aβ40Cys20HL488 ·Cu on GM1
micelles, in Hepes NaCl at pH 7.5, fitted with the model in 3.28 (solid lines) with Γ
fixed to 1. Model parameters are shown in table 5.1.
5.5.3 Interconversion and Binding Pathway
To confirm the rate constants of interconversion, the experiments from section 3.8
were repeated for the Aβ40Cys20HL488 ·GM1 micelles construct. However, due to
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the slower rate of Cu2+ removal from Aβ ·Cu ·GM1 micelles (see Fig. 5.10) a higher
concentration of EDTA (4 mM) was used to remove the copper at a sufficiently fast
rate.
To measure the rates of interconversion, 100 nm Aβ40Cys20HL488 ·GM1 micelles
was mixed with 2 µm CuCl2 to form approximately 50 nm Aβ ·Cu on GM1 micelles.
After a chosen delay time this solution was mixed with 8 mm EDTA and the fluores-
cence recovery traces were recorded. All was performed in Hepes NaCl.
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Figure 5.12: The relative change in amplitude of the two phases of freshly formed
25 nm Aβ40Cys20HL488 ·Cu on GM1 micelles reacted with 4 mm EDTA, after a set
age time. The fitted lines are single exponential with the rate of 1.3(1) s−1. Using
the relative proportion at equilibrium gives interconversion rates to be 𝑘1→2 =
0.74(6)s−1 and 𝑘2→1 = 0.94(8)s−1 (assuming Γ = 1).
Fitting the data in figure 5.12 gives 𝑘1→2 + 𝑘2→1 = 1.3(1)s−1, similar to the sum
of the rates in table 5.1. This confirms that the interconversion is indeed impeded
when bound to the membrane and suggests that the Aβ ·Cu complex spends more
time in the more reactive component I state (Aβ ·Cu)i.
5.6 Summary
In this chapter it has been shown that Aβ binds to SDS micelles and GM1 micelles,
as has been shown in the literature. It is therefore likely that Aβ is bound in the
synaptic cleft to the membranes of the synaptic termini. An order of magnitude
estimate surface density of Aβ in the synapse was made to be in the low 10’s of Aβ
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per synapse range.
The kinetics of the Aβ ·Cu complex and its formation and dissociation on GM1
micelles is similar to that when not bound to micelles. The interconversion kinetics
between the two components are a factor of two slower, suggesting that Aβ will
spend more time in the more reactive (Aβ ·Cu)i form. The major difference in the
kinetics is the removal rate constant of Cu2+ from Aβ ·Cu. With EDTA it is two
orders of magnitude slower when Aβ ·Cu is membrane bound, compared to when
Aβ ·Cu is free in solution. This suggests that membrane bound Aβ ·Cu may be
protected from Cu2+ ligands in solution. Whether there is a similar protection
against membrane bound ligands is unknown.
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Chapter 6
Simulation of the Synapse during
Neurotransmission
Having determined some of the kinetics of Cu2+ and Zn2+ binding to Aβ in solution
and on membranes, some perspective is required for the magnitude of the paramet-
ers and whether the parameters allow metal ion binding to Aβ to may play a role in
physiology or in Alzheimer’s disease. To gain this perspective a toy model of the
synapse is created applying the mechanisms and parameters determined from the
previous chapters.
r=0 r=20nm
40nm
Cu2+
rr
20nm
Figure 6.1: Schematic of the diffusion of Cu2+ into the synaptic cleft. The green
discs with holes represent HSA. The red lines represent Aβ. The small blue circles
represent Cu2+.
A model of the synapse where the synapse appears two dimensional is used
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(see Fig. 6.1). Cu2+ or Zn2+ is released into the centre of the synapse completely
filling a cylinder of radius 20 nm with 30 µm Cu2+ or 300 µm Zn2+. These are
close to the physiological concentrations of Cu2+ and Zn2+ thought to be released
into the synapse. Physiological synaptic vesicles are thought to be approximately
40 nm in diameter [276] with the distance between post- and pre-synaptic terminal
at approximately 10 nm to 25 nm [277]. It is because of the above that the cylinder
approximation is used. The metal ions diffuse with a diffusion coefficient (𝐷) of
𝐷Zn2+ = 𝐷Cu2+ = 650nm
2 µs−1. The toy model is then built up to include the inter-
actions of 3 nm Aβ (𝐷Aβ = 304nm2 µs−1) and 5 µm HSA (𝐷HSA = 61nm2 µs−1 [278]).
Finally the model is extended to include multiple pulses of metal ions into the
synapse.
This may give insight into the role of Aβ in physiology and pathology of the
brain’s 8(1)× 1010 neurons [279] with approximately 7000 synapses each [280].
6.1 Method
To simulate the diffusion of metal ions and Aβ in the synapse, Fick’s second law
with constant diffusion coefficient
𝜕𝑡𝜙 = 𝐷∇2𝜙 (6.1)
is used, where 𝜙 is a scalar field of the concentration, 𝑡 is the time and 𝐷 is the
diffusion coefficient. In cylindrical coordinates the operator
∇2 = 𝜕2𝑟 + 𝑟−1𝜕𝑟 + 𝑟−2𝜕2𝜃 +𝜕2𝑧 , (6.2)
where 𝑟 is the distance from the origin, 𝜃 is the angle from a reference direction, and
𝑧 is the distance above a reference plane. 𝑟, 𝜃 and 𝑧 are orthogonal. To simplify the
calculation of the solutions to Fick’s law, it will be assumed there exists a rotational
symmetry (perpendicular to 𝑧) and translational symmetry (along 𝑧) in 𝜙, that is
𝜙(𝑟,𝜃,𝑧) = 𝜙(𝑟,𝜃 + 𝑎,𝑧+ 𝑏) ∀ 𝑎,𝑏 ∈R . (6.3)
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Therefore
𝜕𝜃𝜙 = lim
𝛿𝑥→0
𝜙(𝑟,𝜃 + 𝛿𝑥,𝑧)−𝜙(𝑟,𝜃,𝑧)
𝛿𝑥
= lim
𝛿𝑥→0
𝜙(𝑟,𝜃,𝑧)−𝜙(𝑟,𝜃,𝑧)
𝛿𝑥
= 0 (6.4)
and thus higher order derivatives are also 0. Likewise 𝜕2𝑧𝜙 = 0. This simplifies the
diffusion equation to be
𝜕𝑡𝜙 = 𝐷∇2𝜙 = 𝐷(𝜕2𝑟 + 𝑟−1𝜕𝑟 )𝜙 (6.5)
which can be solved in one dimension to give the solutions for three dimensional
space. To solve this equation numerically, the equation needs to be discretized. For
the temporal term the Euler method is applied. For the spatial term the central
finite difference methods are applied to 𝜕2r and 𝜕r in a backwards manor. This gives
𝜙𝑡+δ𝑡𝑟 −𝜙𝑡𝑟
δ𝑡
= 𝐷
⎛⎜⎜⎜⎜⎝𝜙𝑡+δ𝑟𝑟+δ𝑟 − 2𝜙𝑡+δ𝑡𝑟 +𝜙𝑡+δ𝑡𝑟−δ𝑟(δ𝑟)2 + 𝜙
𝑡+δ𝑡
𝑟+δ𝑟 −𝜙𝑡+δ𝑡𝑟−δ𝑟
2𝑟δ𝑟
⎞⎟⎟⎟⎟⎠ . (6.6)
Equation 6.6 can be rearranged to give
𝜙𝑡𝑟 = 𝜙
𝑡+δ𝑡
𝑟−δ𝑟
𝐷δ𝑡
δ𝑟
(︂ 1
2𝑟
− 1
δ𝑟
)︂
+𝜙𝑡+δ𝑡𝑟
(︃
1 +
2𝐷δ𝑡
(δ𝑟)2
)︃
−𝜙𝑡+δ𝑡𝑟+δ𝑟
𝐷δ𝑡
δ𝑟
(︂ 1
2𝑟
+
1
δ𝑟
)︂
, (6.7)
which forms a set of equations for the next time step. In this function there is a
pole at 𝑟 = 0. Therefore the function needs to be moved off the axis by mapping
𝑟 ↦→ 𝑟 + δ𝑟/2 in the implementation, thus becoming
𝜙𝑡𝑟 = 𝜙
𝑡+δ𝑡
𝑟−δ𝑟
𝐷δ𝑡
δ𝑟
(︂ 1
2𝑟 + δ𝑟
− 1
δ𝑟
)︂
+𝜙𝑡+δ𝑡𝑟
(︃
1 +
2𝐷δ𝑡
(δ𝑟)2
)︃
−𝜙𝑡+δ𝑡𝑟+δ𝑟
𝐷δ𝑡
δ𝑟
(︂ 1
2𝑟 + δ𝑟
+
1
δ𝑟
)︂
.(6.8)
For the boundary conditions at the centre of the disc (𝑟 = 0), the boundary
condition used is
𝜙𝑡0 = 𝜙
𝑡+δ𝑡
0
(︃
1 +
2𝐷δ𝑡
(δ𝑟)2
)︃
−𝜙𝑡+δ𝑡δ𝑟
𝐷δ𝑡
δ𝑟
(︂ 1
2𝑟 + δ𝑟
+
1
δ𝑟
)︂
. (6.9)
At the edge of the disc (𝑟 = 𝑅), there are two main options. The concentration of the
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ring outside of the disc (𝑅+ δ𝑟) is set to 0, that is
𝜙𝑡𝑅 = 𝜙
𝑡+δ𝑡
𝑅−δ𝑟
𝐷δ𝑡
δ𝑟
(︂ 1
2𝑅+ δ𝑟
− 1
δ𝑟
)︂
+𝜙𝑡+δ𝑡𝑅
(︃
1 +
2𝐷δ𝑡
(δ𝑟)2
)︃
. (6.10)
This will cause the molecules to ‘leak’ off the edge of the simulation. Although this
is suitable for metals diffusing from the centre, it is not suitable for a homogeneous
concentration of Aβ as the Aβ will diffuse off the disc. To counteract this, the edge
of the disc may be connected to itself. This can be done by mapping 𝜙𝑡+δ𝑡𝑅+δ𝑟 ↦→ 𝜙𝑡+δ𝑡𝑅−δ𝑟 ,
giving the boundary conditions to be
𝜙𝑡𝑅 = −𝜙𝑡+δ𝑡𝑅−δ𝑟
2𝐷δ𝑡
(δ𝑟)2
+𝜙𝑡+δ𝑡𝑅
(︃
1 +
2𝐷δ𝑡
(δ𝑟)2
)︃
. (6.11)
To incorporate reactions into the model, the rate of change of the concentration
due to reactions (R(𝜙)) is added to the change due to diffusion, thus becoming
𝜕𝑡𝜙 = 𝐷∇2𝜙 + R(𝜙) . (6.12)
For example in the reaction
A + B
𝑘on
𝑘off
C , (6.13)
if the scalar fields of the concentrations of A, B & C, are 𝜙, 𝜓 & 𝜒, respectively. This
gives the change in concentration due to reactions to be
𝑅(𝜙) = 𝑘off𝜒 − 𝑘on𝜙 ∘𝜓 , 𝑅(𝜓) = 𝑘off𝜒 − 𝑘on𝜙 ∘𝜓 & 𝑅(𝜒) = 𝑘on𝜙 ∘𝜓 − 𝑘off𝜒 .
(6.14)
Hence with discretising these and applying the Euler method, the full set of equa-
tions to be solved are
𝜙𝑡𝑟 =− δ𝑡(𝑘off𝜒𝑡𝑟 − 𝑘on𝜙𝑡𝑟𝜓𝑡𝑟 )
+𝜙𝑡+δ𝑡𝑟−δ𝑟
𝐷δ𝑡
δ𝑟
(︂ 1
2𝑟 + δ𝑟
− 1
δ𝑟
)︂
+𝜙𝑡+δ𝑡𝑟
(︃
1 +
2𝐷δ𝑡
(δ𝑟)2
)︃
−𝜙𝑡+δ𝑡𝑟+δ𝑟
𝐷δ𝑡
δ𝑟
(︂ 1
2𝑟 + δ𝑟
+
1
δ𝑟
)︂
(6.15)
𝜓𝑡𝑟 =− δ𝑡(𝑘off𝜒𝑡𝑟 − 𝑘on𝜙𝑡𝑟𝜓𝑡𝑟 )
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+𝜓𝑡+δ𝑡𝑟−δ𝑟
𝐷δ𝑡
δ𝑟
(︂ 1
2𝑟 + δ𝑟
− 1
δ𝑟
)︂
+𝜓𝑡+δ𝑡𝑟
(︃
1 +
2𝐷δ𝑡
(δ𝑟)2
)︃
−𝜓𝑡+δ𝑡𝑟+δ𝑟
𝐷δ𝑡
δ𝑟
(︂ 1
2𝑟 + δ𝑟
+
1
δ𝑟
)︂
(6.16)
𝜒𝑡𝑟 =− δ𝑡(𝑘on𝜙𝑡𝑟𝜓𝑡𝑟 + 𝑘off𝜒𝑡𝑟 )
+𝜒𝑡+δ𝑡𝑟−δ𝑟
𝐷δ𝑡
δ𝑟
(︂ 1
2𝑟 + δ𝑟
− 1
δ𝑟
)︂
+𝜒𝑡+δ𝑡𝑟
(︃
1 +
2𝐷δ𝑡
(δ𝑟)2
)︃
−𝜒𝑡+δ𝑡𝑟+δ𝑟
𝐷δ𝑡
δ𝑟
(︂ 1
2𝑟 + δ𝑟
+
1
δ𝑟
)︂
(6.17)
with the boundary conditions produced similarly.
In the reaction-diffusion equations (Eqn. 6.12 onwards) the reaction and diffu-
sion parts may be treated separately in each time step simplifying the implement-
ation, as the reaction only depends on the concentrations at particular 𝑟 and the
diffusion depends on all 𝑟 but only for the concentration in one field. It can therefore
be easily parallelized using OpenMP∗.
The discretized solution for 𝜙 is of the matrix form
𝜙𝑡 + 𝛿𝑡𝑅(𝜙,𝜓,𝜒) = 𝑀𝜙𝑡+1 , (6.18)
where 𝑀 is a matrix of coefficients related to diffusion (similarly for 𝜓 and 𝜒). This
gives the procedural order to be: get the concentration fields, perform the reactions,
and then calculate the concentrations at the next time step from diffusion. The
concentrations of the next time step can be obtained from
𝜙𝑡+1 = 𝑀−1(𝜙𝑡 + 𝛿𝑡𝑅(𝜙,𝜓,𝜒)) . (6.19)
However, equation 6.15 shows that 𝑀 is tridiagonal, therfore solving for 𝜙𝑡+1 may
be done more efficiently than via matrix inversion. The gsl_linalg_solv_tridiag
routine is used from the GSL†.
For the simulation, the time steps were chosen to be exponentially increasing
after the second time step 𝑡1 (𝑡0 = 0), calculated by
𝑡(𝑖+1) = 𝑡1 × 10lg(𝑇 /𝑡1)×𝑖/(𝑁t−1) , (6.20)
where 𝑇 is the maximum time of the simulation, 𝑡1 is the first non-zero time step, 𝑁t
∗Open Multiprocessing API (2.5) http://openmp.org.
†GNU Scientific Library (1.16) http://www.gnu.org/software/gsl/.
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is the number of time steps, and 𝑖 is an integer from 0 to𝑁t. Exponentially increasing
time steps allows the long timescale behaviour to be seen without exponentially
increasing processing power. For the space steps linear spacing is used as it not
possible to use exponentially increasing steps with the central finite difference
method, as it requires 𝛿𝑟 to be constant across the simulation.
The simulation was written in C++, using the GSL and the OpenMP API, and
compiled using GCC∗ (see App. A.4).
Occasionally numerical error caused the concentration to become negative (at
concentrations of approximately 10−11 µm). This causes the simulation to become
very unstable. In simulations in which this occurred the negative concentrations
were set to zero.
6.1.1 Multiple Pulses
To simulate the periodic nature of the release of neurotransmitter by neurons at each
release, the concentration of metal ions at the centre (20 nm radius) of the simulation
was reset to the initial concentration. However, this would cause a problem with
the exponentially spaced time step. To counteract this when the system pulses, the
exponential spacing of the time steps is reset, that is
𝑡𝑖+1 = 𝑇p
⌊︃
𝑖
𝑁s
⌋︃
+ 𝑡1 × 10lg(𝑇p/𝑡1)×(𝑖 mod 𝑁s)/(𝑁s−1) , (6.21)
where 𝑇p is the pulse period, 𝑁s is the number of steps per pulse, and mod is the
modulo operator. Then when
𝑖 mod 𝑁𝑠 = 0 (6.22)
the central 20 nm of the simulation is reset to the initial concentration of metal ions.
6.2 Diffusion of Cu2+ & Zn2+
The rate of chemical reactions depends on the concentrations of the reactants.
However, the concentration of metal ions released into the synapse decreases due
∗GNU Compiler Collection (4.9.1) https://gcc.gnu.org/.
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not only to reactions but also due to diffusion. This effect cannot be simulated using
stopped flow experiments. Simulating the diffusion of Cu2+ or Zn2+ in the synapse
gives a indication of the concentration profile in time.
10−3 10−2 10−1 100 101 102 103 104 105
Time/µs
100
101
102
103
104
105
R
ad
iu
s/
n
m
10−3
10−2
10−1
100
101
102
[C
u
2+
]/
µ
m
(a) Diffusion of Cu2+
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(b) Diffusion of Zn2+
Figure 6.2: Diffusion of 30 µm Cu2+ and 300 µm Zn2+ in a simulated synapse. The
contour lines correspond to the molar concentrations that are powers of 10.
Figure 6.2 shows that the concentration of Cu2+ drops below nanomolar con-
centrations (𝐾d ≈ 1nm) after a few milliseconds. Whereas Zn2+ drops below 10’s of
micromolar concentrations (𝐾d ≈ 60µm) in less than 1 µs. Once the concentration
of metal ions or Aβ drops below their respective 𝐾d, the rate of binding becomes
less than the rate of dissociation. However, this is insufficient to quantify the pro-
portion of metal bound Aβ. For this, the association of Cu2+ or Zn2+ with Aβ in the
simulation is required.
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6.3 Reactions of Cu2+ or Zn2+ with Aβ
To simulate the binding and unbinding of metal ions to Aβ, 30 µm Cu2+ or 300 µm
Zn2+ is released into a 20 nm cylinder in the centre with 3 nm Aβ, using the rate con-
stants obtained in the previous chapters. Due to the unknown temporal separation
of the release of Zn2+ and Cu2+ as part of synaptic transition, the limiting case will
be considered in which both are independent.
6.3.1 Cu2+ & Aβ
The model used for the reactions of Aβ binding to Cu2+ is
Aβ + Cu2+
𝑘on
𝑘off
(Aβ ·Cu)i
𝑘 1
→
2
𝑘 2
→
1
(Aβ ·Cu)ii
(Aβ ·Cu2)iii
𝑘3 off−Cu 2+
+Cu
2+
𝑘3 on
, (6.23)
where 𝑘on = 3× 108m−1 s−1, 𝑘off = 0.8s−1, 𝑘1→2 = 0.9s−1, 𝑘2→1 = 2.22s−1, 𝑘3 on =
4.2× 105m−1 s−1, and 𝑘3 off = 1.7s−1.
The simulation in figure 6.3 shows that during one pulse of Cu2+ approximately
0.1 % of the total Aβ forms Aβ ·Cu, at timescales of 1 µs to 10 ms. Most of the
Aβ ·Cu is (Aβ ·Cu)i, with (Aβ ·Cu)ii reaching approximately 0.01 % at timescales of
0.3 ms to tens of millisecond. In equilibrium ,the ratio of (Aβ ·Cu)i to (Aβ ·Cu)ii is
approximately 70 : 30, but due to the diffusion of Cu2+ out of the synapse in the
simulation, the kinetics greatly favour the formation of only (Aβ ·Cu)i. In contrast
(Aβ ·Cu2)iii only reaches tens of attomolar concentrations (approximately 10−6 % of
total Aβ), on millisecond timescales.
Binding of Cu2+ to Aβ ·Cu
To investigate the maximal amount of Cu2+ binding to Aβ ·Cu, the limiting case
when all Aβ is already bound to copper forming the two species of Aβ ·Cu (and
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(c) Reaction-diffusion of (Aβ ·Cu)i
Figure 6.3: Part 1 of 2
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(d) Reaction-diffusion of (Aβ ·Cu)ii
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(e) Reaction-diffusion of (Aβ ·Cu2)iii
Figure 6.3: Part 2 of 2. Simulation of the diffusion and reaction of 30 µm Cu2+ re-
leased from a 40 nm diameter cylinder into a reservoir of 3 nm Aβ, with the reactions
shown in equation 6.23. The contours correspond to the molar concentrations that
are powers of 10.
is prevented from dissociating), would give an estimate for the maximal possible
formation of (Aβ ·Cu2)iii in a single Cu2+ pulse. The model used is
(Aβ ·Cu)i
𝑘 1
→
2
𝑘 2
→
1
(Aβ ·Cu)ii
(Aβ ·Cu2)iii
𝑘3 off−Cu 2+
+Cu
2+
𝑘3 on
, (6.24)
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where 𝑘1→2 = 0.9s−1, 𝑘2→1 = 2.22s−1, 𝑘3 on = 4.2× 105m−1 s−1, and 𝑘3 off = 1.7s−1.
The initial concentrations of Aβ ·Cu are set to
[(Aβ ·Cu)i ]|𝑡=0 = 3nm× 𝑘2→1𝑘1→2 + 𝑘2→1 , (6.25)
[(Aβ ·Cu)ii]|𝑡=0 = 3nm× 𝑘1→2𝑘1→2 + 𝑘2→1 , (6.26)
i.e. assuming that (Aβ ·Cu)i and (Aβ ·Cu)ii have reached equilibrium before the
simulation had started.
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Figure 6.4: Diffusion and reaction of 30 µm Cu2+ released from a 40 nm diameter
cylinder into a reservoir of 3 nmAβ ·Cu, with the concentrations split across (Aβ ·Cu)i
and (Aβ ·Cu)ii as expected in equilibrium. The contour lines correspond to the molar
concentrations that are powers of 10.
Figure 6.4 shows that in this limiting case (Aβ ·Cu2)iii reaches low of femto-
molar concentrations, approximately 10−4 % of total Aβ. Given the low number
of Aβ molecules per synapse, this suggests that (Aβ ·Cu2)iii does not play a role in
physiology.
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6.3.2 Zn2+ & Aβ
The model used for the reactions of Aβ binding to Zn2+ is
Aβ + Zn2+
1.9× 106 m−1 s−1
110 s−1
Aβ ·Zn . (6.27)
The results are shown in figure 6.5. At the timescale of milliseconds there is
instability in the numerical solution and thus should be ignored. The figures show
that Aβ ·Zn reaches hundreds of attomolar concentrations across timescales of 0.5 µs
to 30 ms (approximately 10−5 %). This suggests that it is unlikely that Zn2+ binds to
Aβ during synaptic release. However, it may be possible for the Aβ ·Zn to build up
from repetitive release during transmissions.
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(c) Reaction-diffusion of Aβ ·Zn
Figure 6.5: Diffusion and reaction of 300 µm Zn2+ released from a 40 nm diameter
cylinder into a reservoir of 3 nm Aβ, based on equation 6.27. The contour lines
correspond to the molar concentrations that are powers of 10.
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6.3.3 Cu2+ & HSA
The binding of HSA to Cu2+ may have an effect on the levels of Cu2+ during neur-
otransmission, given that it is at micromolar concentrations in the CSF and binds
quickly and strongly to Cu2+.
To simulate the effect of 5 µm HSA on the diffusion of 30 µm Cu2+ after release,
the model
HSA + Cu2+
1× 108 m−1 s−1
HSA ·Cu (6.28)
was used. The dissociation of HSA ·Cu is ignored as it is likely to take longer than the
timescales of the simulation. One caveat to this model is that free diffusion of HSA
is assumed. However, the distance between the synaptic termini are approximately
10 nm to 25 nm [277], whereas the HSA is approximately 10 nm [281], so the diffusion
is unlikely to be free.
Figure 6.6 shows that nanomolar concentrations of HSA ·Cu are formed, however
it also attenuates the Cu2+ pulse. Without HSA, it drops below nanomolar after
approximately 30 ms, whereas with HSA it drops after 3 ms. Due the high concen-
trations of HSA, this dominates the rate of the reaction once the concentration of
Cu2+ is less than the concentration of HSA. This appears to cause an accelerated
drop off in the concentration of Cu2+, compared to Cu2+ diffusion without HSA
(see Fig. 6.3a). If HSA can enter the synapse, the modulation of the profile of
the Cu2+ concentration will likely affect the binding to Aβ, reducing the maximal
concentrations of Aβ ·Cu reached.
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(b) Reaction-diffusion of HSA
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(c) Reaction-diffusion of HSA ·Cu
Figure 6.6: Diffusion and reaction of 30 µm Cu2+ released from a 40 nm diameter
cylinder into a reservoir of 5 µm HSA, based on equation 6.28. The contour lines
correspond to the molar concentrations that are powers of 10.
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6.3.4 Cu2+, HSA & Aβ
To investigate the binding of Aβ to Cu2+ with the presence of HSA, the model
Aβ + Cu2+
𝑘on
𝑘off
(Aβ ·Cu)i
𝑘 1
→
2
𝑘 2
→
1
(Aβ ·Cu)ii
(Aβ ·Cu2)iii
𝑘3 off−Cu 2+
+Cu
2+
𝑘3 on
(6.29)
HSA + Cu2+
𝑘HSA
HSA ·Cu (6.30)
was used, where 𝑘on = 3× 108m−1 s−1, 𝑘off = 0.8s−1, 𝑘1→2 = 0.9s−1, 𝑘2→1 = 2.22s−1,
𝑘3 on = 4.2× 105m−1 s−1, 𝑘3 off = 1.7s−1, and 𝑘HSA = 1× 108m−1 s−1.
Figure 6.7 shows that the inclusion of HSA into the model has little effect
on the maximal concentration of (Aβ ·Cu)i and a factor of 60 drop for (Aβ ·Cu)ii.
However, there is a large effect on the temporal profile. The length of time that
the concentration of (Aβ ·Cu)i is above picomolar is reduced by approximately two
orders of magnitude.
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Figure 6.7: Part 1 of 2.
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Figure 6.7: Part 2 of 2. Diffusion and reaction of 30 µm Cu2+ released from a 40 nm
diameter cylinder into a reservoir of 5 µm HSA and 3 nm Aβ, based on equations 6.29
& 6.30. The contour lines correspond to the molar concentrations that are powers of
10.
6.4 Reaction-Diffusion of Aβ with Pulsed Cu2+ & Zn2+
In the previous sections, the reaction-diffusion of Aβ with metal ions was studied
for a single pulse of metal ions. However, in the brain, neurons can fire multiple
times releasing metal ions into the synapse in quick succession.
To investigate the effect of repetitive release of metal ions into the synaptic cleft,
the central 40 nm of the concentration of metal ions simulation was reset to the
initial concentration, at a chosen frequency. The upper limit firing rate frequency of
neurons is approximately 200Hz [282], so the range of 1 Hz to 100 Hz was simulated.
To obtain the mean concentration of Aβ-Metal ion complexes in the synapse of
radius, the average concentration (of 𝜙) is
?¯? =
𝑅∑︁
𝑖=0
𝜙𝑖(𝑟
2
𝑖−1 − 𝑟2𝑖 )
𝑟2𝑅
, (6.31)
where 𝜙𝑖 is the concentration from the simulation with radius 𝑟𝑖 , 𝑟−1 = 0, and where
𝑅 (the maximal 𝑖) is such that 𝑟𝑅 > 300nm & 𝑟𝑅−1 < 300nm. This is to account for
the cylindrical geometry of the simulation.
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6.4.1 Zn2+
The reaction
Aβ + Zn2+
1.9× 106 m−1 s−1
110 s−1
Aβ ·Zn (6.32)
was simulated with multiple pulses of Zn2+. Figure 6.8 shows the average concen-
tration in the synapse after 10 s. The concentration appears to be monomial with
frequency. However, at the highest frequency (100 s−1) the concentration reaches
low picomolar, 0.1 % of the total Aβ concentration. This suggests that Zn2+ binding
to Aβ is a relatively rare event. Figure 6.9 shows the temporal variation of Aβ ·Zn
at different radii for different pulse frequencies. The figure shows that at this low
frequency range, there is little increase in the maximum transient concentration
of Aβ ·Zn. This is due to the 110 s−1 dissociation rate constant of Aβ ·Zn. However,
there is an increase in the minimum transient concentration of Aβ ·Zn after each
pulse. For a sizeable build up of Aβ ·Zn between pulses, the pulse rate would need
to be greater than the dissociation rate.
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Figure 6.8: Mean concentration of Aβ ·Zn in the central 300 nm after 10 s at different
pulse frequencies of 300 µm Zn2+. The data points were empirically fitted with
𝑓 ↦→ 𝑎𝑓 𝑐. In the fit 𝑐 was 1.208(3), and 𝑎 was 8.01(9)× 10−9 µm sc. See figure 6.9 for
time traces.
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Figure 6.9: Concentration of Aβ ·Zn for different pulse frequencies of 300 µm Zn2+,
at different radii.
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6.4.2 Cu2+
The model used for the reactions of Aβ binding to Cu2+ is
Aβ + Cu2+
𝑘on
𝑘off
(Aβ ·Cu)i
𝑘 1
→
2
𝑘 2
→
1
(Aβ ·Cu)ii
(Aβ ·Cu2)iii
𝑘3 off−Cu 2+
+Cu
2+
𝑘3 on
, (6.33)
where 𝑘on = 3× 108m−1 s−1, 𝑘off = 0.8s−1, 𝑘1→2 = 0.9s−1, 𝑘2→1 = 2.22s−1, 𝑘3 on =
4.2× 105m−1 s−1, and 𝑘3 off = 1.7s−1.
Figure 6.10 shows the average concentration in the synapse after 10 s. The
concentrations appears to approximately follow the form of 𝑓 ↦→ 𝑐𝑓𝑎+𝑓 , for a frequency
𝑓 . However, this form is an approximation, given that for the fitting 𝑐(Aβ ·Cu)i +
𝑐(Aβ ·Cu)ii = 5nm, which is greater than the total concentration of Aβ (3 nm). Across
the frequency range simulated, there is factor of slightly greater than 3 higher
concentration of (Aβ ·Cu)i, than (Aβ ·Cu)ii. If all Aβ is bound to Cu2+, in equilibrium
a factor of 2.47 = 𝑘2→1𝑘1→2 is expected. Therefore repetitive neurotransmission may
cause a decrease in the concentration of (Aβ ·Cu)ii, relative to (Aβ ·Cu)i.
The concentrations of (Aβ ·Cu)i and (Aβ ·Cu)ii obtained are significant, reaching
0.80 nm for (Aβ ·Cu)i and 0.26 nm for (Aβ ·Cu)ii, a sizeable fraction of the total Aβ
concentration. This suggests that Aβ may bind to Cu2+ released during neurotrans-
mission. The rate of Cu2+ assisted Aβ dimer formation would be maximal at equal
proportions of Aβ and (Aβ ·Cu)i.
After 10 s (Aβ ·Cu2)iii had reached concentrations of 240 fm, suggesting that
(Aβ ·Cu2)iii is unlikely to form under physiological conditions and thus lacks a role
in physiology.
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Figure 6.10: Mean concentration after 10 s of the central 300 nm at different pulse
frequencies of Cu2+. The data points were empirically fitted with 𝑓 ↦→ 𝑐𝑓𝑎+𝑓 , where
𝑓 is the pulse frequency, 𝑐 is the concentration as 𝑓 →∞, and 𝑎 is the frequency at
which half are bound. The obtained parameters were 𝑎 = 360(20)s−1 & 𝑐 = 3.7(1)nm
for (Aβ ·Cu)i, and 𝑎 = 407(5)s−1 & 𝑐 = 1.32(1)nm for (Aβ ·Cu)ii. See figures 6.11 &
6.12.
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Figure 6.11: Concentration of (Aβ ·Cu)i at different radii for different pulse frequen-
cies of 30 µm Cu2+.
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Figure 6.12: Concentration of (Aβ ·Cu)ii at different radii for different pulse frequen-
cies of 30 µm Cu2+. The curves for the different radii are nearly superimposed
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6.5 Summary
In this chapter the reactions of Aβ with Cu2+ and Zn2+ have been simulated in a toy
model of the synapse. This is to gain some perspective on the parameters obtained
from the previous chapters and estimate the importance of reactions in physiology.
The results suggest that the binding of Zn2+ to Aβ in the synapse is minimal,
from 10−3 % of the Aβ forming Aβ ·Zn from a single pulse, to 10−1 % of Aβ when
pulsing is at 100 Hz. Given the low probability of Aβ ·Zn forming and its fast
dissociation, this suggests that Aβ ·Zn is unlikely to play a role in the oligomerisation
of Aβ or in physiology.
The results for the binding of Cu2+ to Aβ show that a sizable proportion of
Aβ may form Aβ ·Cu, from 0.1 % during a single pulse to approximately 1/3 when
pulsing is at 100 Hz. During repetitive releases of copper the ratio of (Aβ ·Cu)i
to (Aβ ·Cu)ii is 75 : 25, with more (Aβ ·Cu)i than is expected in equilibrium. This
suggests that Aβ ·Cu may indeed form under physiological conditions, suggesting
that the Aβ-metal hypothesis may still be valid as the cause of Alzheimer’s disease
for Aβ with Cu2+.
The consequences of oligomerisation may be an increase in affinity for metal
ions including Cu2+ and Zn2+. This in turn may cause the trapping and removal
of Cu2+ and Zn2+ from the brain’s pool of metals. Trapping of Cu2+ by Aβ may
produce reactive oxygen species close to the neuronal membranes damaging itself
Aβ, proteins or lipids in the membrane. Oligomerisation of Aβ may slow the diffu-
sion of Aβ on the membranes preventing any physiological roles [283]. Alternatively,
oligomers may decrease the ability of proteases to break down Aβ, upsetting Aβ
homeostasis.
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Chapter 7
Conclusion
Chemical kinetics allows the temporal behaviour of chemical reactions to be pre-
dicted. The main aim of this thesis was to determine the kinetic rate constants of
Aβ’s interactions with metal ions and elucidate their mechanisms which would allow
for a closer examination of the amyloid-metal hypothesis of Alzheimer’s disease.
This thesis describes both experimental and computational approaches to achieve
this aim.
It was found that the binding of Aβ to Cu2+ was nearly diffusion limited, with
apparent dissociation on the second time scale, giving a low nanomolar 𝐾d. The 𝐾d
is within the expected range and is the first measurement deriving the 𝐾d from the
underlying kinetics of the system. This combined with the toy simulations of the
synapse suggest that Aβ ·Cu is able to form under physiological conditions. How-
ever, measurements of the Cu2+ assisted dimerisation rate constant suggests that
dimerisation is unlikely to occur in the CSF. This also suggests that future research
should focus on Aβ-metal-membrane interactions. The long lived formation Aβ ·Cu
also lends support to the hypothesis that redox cycling and reactive oxygen species
(ROS) production may occur. However, the relevant kinetic parameters to determine
the magnitude of this effect compared to basal levels are missing from the literature.
Damage to Aβ by ROS may increase the stability of dimers, possibly by allowing
covalent cross-linking.
The two components of Aβ ·Cu were identified by their different reactivities, as
seen in the literature where they were distinguished by their electron paramagnetic
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resonance signatures. It was shown that they interconvert on the second timescale
with the derived equilibrium population close to the literature values. Furthering
this, (Aβ ·Cu)i was found to be significantly more reactive with Cu2+ binding ligands
than (Aβ ·Cu)ii. The ability to measure the reactivity offers a new methodology for
the optimisation of therapeutics and allowing the amyloid-metal hypothesis to be
investigated in vivo.
The binding of Aβ to Zn2+ was found to be much lower than the diffusion limit
unlike Aβ binding Cu2+ and the complex is very shorter lived. Although Zn2+ can
cause Aβ at CSF concentrations to aggregate when the concentration of Zn2+ is
greater than 40(20) µm, the simulations suggest that Zn2+ has little opportunity
to do so under the transient Zn2+ concentrations in the synapse. Therefore the
binding of Zn2+ to Aβ is unlikely to occur and is unlikely to be relevant in the initial
oligomer formation or in physiology. However, it may have a role in the formation
and growth of larger aggregates and fibrils.
Although Aβ bound to multiple metal ions have been observed the formation
rate constant for Zn2+ or Cu2+ binding to Aβ ·Cu are very low. This, along with the
simulations suggest that it is unlikely that Aβ monomers could bind with more
than one metal ion in the synapse and thus have little relevance in physiology or
Alzheimer’s disease.
Possible Role of Amyloid-β in Physiology
Given the near diffusion limited binding of Cu2+ to Aβ’s N-terminal region, the
membrane-binding properties of Aβ’s hydrophobic C-terminal region, and the abil-
ity of Aβ ·Cu to react with ligands, the kinetics suggest that Aβ’s role in physiology
may be to capture Cu2+ that has been released into the synaptic cleft and transport
it to other membrane proteins (see Fig. 7.1). The fast binding of Aβ to Cu2+ as
shown in the simulations, is required for Aβ to compete against other Cu2+ binding
ligands and against the diffusion of Cu2+ out of the synaptic cleft after release.
Membrane binding allows locally high surface concentrations of Aβ. It has been
shown that diffusion in two dimensions can enhance reaction rates of ligands with
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receptors [284]. A mechanism as such may reduce the quantities of Cu2+ required
by neurons which would be beneficial given the toxicity of Cu2+. The life-time
for Aβ ·Cu (on the second timescale) could allow time for interactions with other
components on the membrane.
One candidate for the final destination of Cu2+ is to modulate NMDA receptor
response, which has a role in synaptic plasticity. NMDA receptors are known to
be modulated by reactions involving Cu2+ causing conformational change. The
pathway by which Cu2+ gets to NMDA receptors is currently unclear. However, it
has been suggested that the it is via cellular prion protein (PrPc) which complex
with Cu2+ and bind to NMDA receptors [285;286].
Aβ·Cu
Cu2+
NMDA
receptor
2D Diffusion
on Membrane
Membrane Bound
Aβ·Cu
Lipid Raft
Transfer
of Cu2+ to NMDAr
K+Na+
Figure 7.1: Hypothesis that Aβ’s role in physiology is to capture and transport Cu2+
on neuronal synaptic membranes and transfer by some pathway to NMDA receptors
(NMDAr).
Within this hypothesis, oligomers formed on the membrane would be problem-
atic in that they may disrupt the membrane, slow the diffusion of Aβ [283], and bind
more tightly to Cu2+. This would prevent the movement of Cu2+ on the synaptic
membrane to its receptor causing synaptic dysfunction. Aβ oligomers have been
shown to interfere with PrPc-Cu modulation of NMDA receptors [287].
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Chapter 8
Further Work
The work in this thesis mainly focused on the kinetics studies of Aβ with Cu2+ and
Zn2+. Below are listed some possible extensions to the work of this thesis.
Measuring the Dissociation Rate of Aβ ·Cu ·Aβ
In section 3.5 the copper assisted dimerisation rate constant of Aβ was measured.
However, the corresponding dissociation rate could not be obtained. This is likely
due to Aβ ·Cu ·Aβ not being populated under those conditions. It may be possible
to increase the population in the Aβ ·Cu ·Aβ by increasing the concentration of Aβ.
Zinc-Aβ Kinetics on GM1 Micelles
As GM1 micelles are likely negatively charged, therefore Zn2+ may become loosely
associated with them. This may enhance the binding rate constant of Zn2+ with Aβ
when Aβ is bound to membranes. The Cu2+-Zn2+ competition experiment could be
repeated to compare the binding rate constants of Zn2+ with Aβ when bound and
not bound to GM1 micelles.
Studying the Folding and Binding of Aβ on Membranes
In section 3.6.1 it was shown that labelled Aβ was quenched on the time scale of a
few Hertz when ethanol or DMSO was added. However, at these time scales with
the very high concentrations of ethanol & DMSO added (given their quite different
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structures) the quenching is unlikely due to ethanol or DMSO but instead may be
due to folding of the Aβ. Therefore it may be possible to use the quenching to study
the kinetics of folding on model membranes using stopped-flow as Aβ has been
shown to adopt an α-helical conformation.
It was shown in section 5.2.2 that there is a measurable change in anisotropy
when labelled Aβ binds to GM1. It may be possible to measure the binding kinetics
of Aβ to GM1 micelles using stopped-flow anisotropy. This, along with the 𝐾d in
the literature, may be used to help predict the surface density of Aβ in vivo.
Measuring the Surface Concentration of Aβ on Living Cells
In section 5.4, an estimate of the surface density of Aβ on cells was made using POP-
C/POPG or GM1/Cholesterol/Sphingomyelin membranes. This could be extended
to live cells to see if the density is still similar.
Copper Assisted Dimerisation on a Membrane
Although Cu2+ binding was studied on GM1 micelles, it is an incompatible system
to study the dimerisation of Aβ, due to its geometry and that high concentrations
of Aβ disrupt micelles. It may be possible to study the dimerisation of labelled Aβ
on membranes using TIRF microscopy under equilibrium conditions with Cu2+ in
solution. This could be extended to non-equilibrium conditions by using an electric
field across a nanopipette to push pulses of Cu2+ out at locally high concentrations
near a membrane.
Measuring Diffusion Within a Synapse
In the simulation chapter (Ch. 6) it was assumed that diffusion within the synapse
is free, with an apparent viscosity similar to that in water. However, the synaptic
cleft is likely very crowded with surface bound proteins and receptors. It may be
possible to measure the viscosity within a synapse by using fluorescent dye and
STED-FCS to measure the diffusion coefficient. This may be useful in studies of
neurotransmitter release.
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Using labelled Aβ, the simulations suggest it may be possible to measure the
concentration profile of Cu2+ in the synapse, by measuring the quenching when
Cu2+ binds to Aβ by applying super-resolution techniques.
Amyloid-β Peptides with Familial Alzheimer’s disease Mutations
There are a number of mutant variants of Aβ [77–79] to which the work in this thesis
could be applied, in particular the Cu2+ binding studies. Finding differences would
lend support to the amyloid-metal hypothesis for Alzheimer’s disease and the
mechanisms behind it.
A Systematic Study of the Kinetics of Aβ with Fe2+
Although Fe2+ is an important ion in physiology and is the other metal ion thought
to be involved in the amyloid-metal hypothesis, the kinetics of Aβ with Fe2+ were
not studied. This is due to the fast oxidation of Fe2+ to Fe3+. It may be possible to
study the binding of Fe2+ to Aβ by using an reducing agent to prevent the formation
of Fe3+. Fe2+ (like Cu2+) is paramagnetic so should also directly quench fluorophore
labelled Aβ and thus the experiments in this thesis could be repeated for Fe2+.
Studying the Kinetics of Copper Redox Cycling
The quenching of dye labeled Aβ by Cu2+ is due to the paramagnetic properties of
Cu2+. However, Cu+ is not paramagnetic, therefore it should be possible to study
the kinetics of the redox cycling of copper by physiologically relevant reducing
and oxidizing agents. A kinetic understanding of the redox cycling of copper and
iron would allow for a quantitative judgement on the magnitude of reactive oxygen
species production, testing this hypothesis of Alzheimer’s disease.
With an understanding of the kinetics of the redox cycling of Aβ with copper,
it may then be possible to prepare Cu+ with reducing agents, whilst knowing the
reaction rate of reducing agents with Aβ ·Cu2+. Then it may be possible to measure
the kinetics of Aβ binding to Cu+, in a similar way to with Zn2+ (see §4.3), if the
reaction rate of the reducing agent with Aβ ·Cu2+ is sufficiently slow.
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It was shown that copper assisted dimerisation of Aβ was too slow to occur
at CSF concentrations in solution. However in fibrils, Aβ has been found to be
damaged which may form more stable oligomers. Mixing Aβ, Cu2+, reducing agents,
and oxidizing agents could be used to damage the Aβ in a systematic way. The
experiments in section 3.5 could then be repeated to see if there is a substantial
effect on the lifetime of the Aβ ·Cu ·Aβ complexes formed. The effect of production
of redox species on tyrosine cross-linked dimers could also be studied.
MPAC Optimisation
In section 3.6, a method was described to measure the effectiveness of CQ and
L2-b to remove Cu2+ from Aβ ·Cu. This method could be applied to discover and
optimise drug candidates for the removal of Cu2+ from Aβ ·Cu, which could then be
used to test the ‘metal-protein attenuating compounds’ (MPACs) treatment strategy.
Extending the Methodology to Cu2+ Binding Kinetics of Other Systems
The quenching of a dye label when a protein or peptide binds Cu2+ has not been
exploited much in the literature. This system could also be used to find the kinetics
of Cu2+ binding to other proteins found in neurodegenerative diseases, such as PrPc
(prion disease) and α-synuclein (Parkinson’s disease), but also to other Cu2+ binding
proteins in physiology, such as HSA.
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Appendix A
Code Listings
A.1 Competition of Aβ and HSA for Cu2+∗
Python 3 code to simulate the binding of Cu2+ to a mixture of Aβ and HSA. The
code was run using Python 3.4.3, with the libraries csv 1.0, matplotlib 1.4.3, numpy
1.9.2, and scipy 0.15.1 . The code is used in section 3.4.1, to generate the data for
figure 3.12.
A.1.1 ABHSAcompetition.py
1 # HSA & AB Competing for Cu
2
3 import csv
4 import matplotlib.pyplot as plt
5 import numpy as np
6 import scipy as sp
7 from scipy.integrate import odeint
8
9
10 def leftab(HSA,AB,Cu,ka,kh):
11 # Differential Equations
12 def f(t,y):
13 cu = y[0]
14 ab = y[1]
15 hsa = y[2]
16 dcu = -ka*cu*ab -kh*cu*hsa
17 dab = -ka*cu*ab
18 dhsa = -kh*cu*hsa
19 return [dcu,dab,dhsa]
20
21 # Initial conditions
22 y0 = [Cu,AB,HSA]
23 t0 = 0
24 t1 = 1
25 # Solve DE's
26 solver = sp.integrate.ode(f).set_integrator('dopri5')
27 solver.set_initial_value(y0,t0).set_f_params()
28 while solver.t < t1:
29 solver.integrate(t1,step=True)
∗Archive of source code:
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30
31 return solver.y[1]
32
33 def main():
34 plt.ion()
35
36 HSA = 5E-6 # M
37 AB = 5E-9 # M
38 ka = 3E8 # M^-1 s^-1
39 Cus = np.linspace(0,7.5,1000) * 1E-6 # [M]
40 khs = np.logspace(-1,1,7)*ka # [M^-1 s^-1]
41
42 propAB = [[1-leftab(HSA,AB,c,ka,k)/AB for c in Cus] for k in khs]
43
44 fig = plt.figure()
45 for l in range(len(propAB)):
46 plt.plot(Cus/1E-6,propAB[l])
47 plt.xlabel('[Cu] / uM')
48 plt.ylabel('[AB.Cu]/AB] / M')
49
50 propAB = np.transpose(np.array([Cus]+propAB)).tolist()
51 with open('output.dat','w') as csvfile:
52 wrtr = csv.writer(csvfile,delimiter='\t')
53 wrtr.writerow(['#Cu'] + khs.tolist())
54 wrtr.writerows(propAB)
55
56 plt.show(block=True)
57
58 main()
A.2 Removal of Cu2+ by EDTA∗
Matlab code to fit the apparent amplitudes and rates of when Cu2+ is removed from
Aβ ·Cu by a ligand (EDTA). The code is used in section 3.7.
The main.m should be run to perform the analysis, the other files contain helper
functions. Lines 9 through 16 contain the initial fitting parameters. The variable
file is a CSV (comma separated variable, tabs were used as the separating character)
file containing the data. The columns should be [EDTA / µm, 𝐴1/(𝐴1+𝐴2), 𝜎𝐴1/(𝐴1+𝐴2),
𝑘1, 𝜎𝑘1 , 𝐴2/(𝐴1 +𝐴2), 𝜎𝐴2/(𝐴1+𝐴2), 𝑘2, 𝜎𝑘2]. Whether the fitting parameters are variable
may be changed in the array tofit on line 49. The output is saved to the input file
name with .fit.csv appended.
A.2.1 main.m
1 %% Initialisation
2 clear; close all;
3 clc; % Clear Command Window
4 concat = @(xs)(reshape(xs,[],1));
5
6
7 %% Model Parameters
8 % Kinetic Parameters
∗Archive of source code:
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9 K1off = 0.5; % Hz
10 K1EDTA = 1E5; % Hz M^-1
11 K1to2 = 0.5; % Hz
12 K2EDTA = 1E3; % Hz M^-1
13 K2off = 0; % Hz
14 K2to1 = 1; % Hz
15 AB = 50E-9; % M
16 gamma = 1; % Correction Factor for brightnesses of quenched states
17
18
19 %% Fitting Data
20 %file = '130408WeightedData.csv';
21 %
22 file = '131015-SimFormat.csv';
23 %file = '131025-AB40Cys20HL488-VaryEDTA-50nMAB50nMCu.csv';
24 %file = '131024-AB16LysHL488Rat-VaryEDTA-50nMAB50nMCu.csv';
25 %file = '131030-AB40Cys20HL488-VaryEDTA-50nMAB50nMCu.csv';
26 %file = '131029-AB16LysHL488Rat-VaryEDTA-50nMAB50nMCu.csv';
27 %file = '131113-AB16LysHL488Rat-VaryEDTA-50nMAB50nMCu.csv';
28 %file = '131203-AB16LysHL488Rat-pH6.5VaryEDTA-50nMAB50nMCu.csv';
29 %file = '131205-AB16LysHL488-pH6.5VaryEDTA-50nMAB50nMCu.csv';
30 %file = '131204-AB40Cys20HL488-pH6.5VaryEDTA-50nMAB50nMCu.csv';
31 %file = '131129-AB40Cys20HL488Micelles-VaryEDTA-50nMABGM150nMCu.csv';
32 data = importdata(file);
33 data = data.data;
34 datax = data(:,1)*1E-6; % [EDTA]: uM -> M
35 dataA1 = data(:,2); % A1/A
36 dataA1e = data(:,3); % A1/A error
37 dataK1 = data(:,4); % K1
38 dataK1e = data(:,5); % K1 error
39 dataA2 = data(:,6); % A2/A
40 dataA2e = data(:,7); % A2/A error
41 dataK2 = data(:,8); % K2
42 dataK2e = data(:,9); % K2 error
43 dataconcaty = concat([dataA1 dataK1 dataK2 ]);
44 dataconcatye = concat([dataA1e dataK1e dataK2e]);
45
46 %% Perform Fit
47 % Initial Parameters
48 fit = [K1off K1EDTA K1to2 K2off K2EDTA K2to1 gamma];
49 tofit = [true true true false true true true ];
50
51 % Fiting Parameters
52 opts = statset('nlinfit'); opts.Display = 'iter' ;
53 opts.MaxIter = 100000 ; opts.UseParallel = true;
54
55 % Perform Fit
56 [fit(:), residuals, jacobian, convB, MSE] ...
57 = nlinfitsome ...
58 ( datax ... % X points
59 , dataconcaty ... % Y points
60 , @(A,t)(concat(DoSolving ... % Fitting Function
61 ( abs(A(1)) ... % K1off
62 , abs(A(2)) ... % K1EDTA
63 , abs(A(3)) ... % K1to2
64 , abs(A(4)) ... % K2off
65 , abs(A(5)) ... % K2EDTA
66 , abs(A(6)) ... % K2to1
67 , t ... % EDTA
68 , AB ... % AB
69 , abs(A(7)) ... % gamma
70 , false ... % Calculate Errors
71 ))) ...
72 , fit ... % Fitting Parameters
73 ,~tofit ... % Fixed Parameters
74 , opts ... % Options
75 ,'Weights', 1./dataconcatye.^2 ...
76 );
77
78
79 %% Calculate Errors
80 % http://www.mathworks.co.uk/support/solutions/en/data/1-X92KR/ (16/07/13)
81 fite = zeros(size(fit));
82 ci = nlparci(fit(tofit),residuals,'jacobian',jacobian);% 95% confidence
intervals
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83 t = tinv(1-0.05/2,length(dataconcaty)-length(datax));
84 fite(tofit)= transpose((ci(:,2)-ci(:,1)) ./ (2*t)); % Standard Error
85 residuals = reshape(residuals,[],3);
86
87
88 %% Get the values out of the fitted value array
89 [K1off ,K1EDTA ,K1to2 ,K2off ,K2EDTA ,K2to1 ,gamma ] = ...
90 PatternMatch(abs(fit ));
91 [K1offe,K1EDTAe,K1to2e,K2offe,K2EDTAe,K2to1e,gammae] = ...
92 PatternMatch(abs(fite));
93
94
95 %% Calculate the Apparent Dissociation Rate
96 %Appoff = 0.5*(K1to2 + K2to1 + K1off + K2off ...
97 % - sqrt(4*K1to2*K2to1 ...
98 % +(K1to2 - K2to1 + K1off - K2off)^2) ...
99 % );
100 Appofff= @(A)(...
101 0.5*(A(1) + A(2) + A(3) + A(4) ...
102 - sqrt(4*A(1)*A(2) ...
103 +(A(1) - A(2) + A(3) - A(4))^2)) ...
104 );
105 Appoff= Appofff([K1to2 K2to1 K1off K2off]);
106
107 CFD = CentralFiniteDifference ...
108 ( Appofff ...
109 , 1E-6 ... % relative StepSize
110 , 1E-8 ... % Minimium StepSize
111 , K1to2, K2to1 ...
112 , K1off, K2off ...
113 );
114
115 Appoffe = ...
116 ( (K1to2e *cell2mat(CFD(1))).^2 ...
117 + (K2to1e *cell2mat(CFD(2))).^2 ...
118 + (K1offe *cell2mat(CFD(3))).^2 ...
119 + (K2offe *cell2mat(CFD(4))).^2 ...
120 ).^0.5;
121
122 %% Print Fitted Values
123 fprintf('\n%s\n',file);
124 fprintf('K1off \t=\t%±g%g (%0.2g%%)\n',K1off ,K1offe ,100*K1offe /K1off );
125 fprintf('K1EDTA\t=\t%±g%g (%0.2g%%)\n',K1EDTA,K1EDTAe,100*K1EDTAe/K1EDTA);
126 fprintf('K1to2 \t=\t%±g%g (%0.2g%%)\n',K1to2 ,K1to2e ,100*K1to2e /K1to2 );
127 fprintf('K2off \t=\t%±g%g (%0.2g%%)\n',K2off ,K2offe ,100*K2offe /K2off );
128 fprintf('K2EDTA\t=\t%±g%g (%0.2g%%)\n',K2EDTA,K2EDTAe,100*K2EDTAe/K2EDTA);
129 fprintf('K2to1 \t=\t%±g%g (%0.2g%%)\n',K2to1 ,K2to1e ,100*K2to1e /K2to1 );
130 fprintf('gamma \t=\t%±g%g (%0.2g%%)\n',gamma ,gammae ,100*gammae /gamma );
131 fprintf('Appoff\t=\t%±g%g (%0.2g%%)\n',Appoff,Appoffe,100*Appoffe/Appoff);
132
133 %% Modelling the Data from Fitted parameters and get Errors for Plotting
134 numModelPoints = 300;
135 xPoints = Logspacelist(1E-6,2.5E-3,numModelPoints); %% [EDTA]
136 solveddata = DoSolving ( K1off, K1EDTA, K1to2 ...
137 , K2off, K2EDTA, K2to1 ...
138 , xPoints ... %% EDTA
139 , AB ...
140 , gamma ...
141 , true ... %% Errors
142 , K1offe, K1EDTAe, K1to2e ...
143 , K2offe, K2EDTAe, K2to1e ...
144 , gammae ...
145 );
146
147
148 %% Plot Data and Fits
149 warning('off','MATLAB:Axes:NegativeDataInLogAxis');
150
151 xPoints = transpose(xPoints);
152 fitA1 = solveddata(:,1); fitA1e = solveddata(:,4);
153 fitK1 = solveddata(:,2); fitK1e = solveddata(:,5);
154 fitK2 = solveddata(:,3); fitK2e = solveddata(:,6);
155 fitA2 = 1-fitA1 ; fitA2e = fitA1e;
156
157 scrsz = get(0,'ScreenSize');
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158 % Plot
159 figure('Name','K1','Position',[1 1 scrsz(3)/2 scrsz(4)/2]);
160 hold all;
161 plot(xPoints,fitK1); % K1
162 errorbar(datax,dataK1,dataK1e,'.');
163 plot(xPoints,fitK1+fitK1e); % K1
164 plot(xPoints,fitK1-fitK1e); % K1
165 hold off;
166 legend('K1', 'K1 Data', 'Location', 'NorthWest');
167
168 % Plot
169 figure('Name','K2','Position',[scrsz(3)/2 1 scrsz(3)/2 scrsz(4)/2]);
170 hold all;
171 plot(xPoints,fitK2); % K2
172 errorbar(datax,dataK2,dataK2e,'.');
173 plot(xPoints,fitK2+fitK2e); % K2
174 plot(xPoints,fitK2-fitK2e); % K2
175 hold off;
176 legend('K2', 'K2 Data', 'Location', 'NorthWest');
177
178 % Plot
179 figure('Name','A_i/A','Position',[1 scrsz(4)/2 scrsz(3)/2 scrsz(4)/2]);
180 hold all;
181 semilogx(xPoints,fitA1); % A1/A
182 errorbar(datax,dataA1,dataA1e,'.');
183 semilogx(xPoints,fitA2); % A2/A
184 errorbar(datax,dataA2,dataA2e,'.');
185 semilogx(xPoints,fitA1+fitA1e); % A1/A
186 semilogx(xPoints,fitA1-fitA1e); % A1/A
187 semilogx(xPoints,fitA2+fitA2e); % A2/A
188 semilogx(xPoints,fitA2-fitA2e); % A2/A
189 hold off;
190 legend('A1/A', 'A1/A Data', 'A2/A', 'A2/A Data');
191
192 % Plot
193 figure('Name','K_i','Position',[1 scrsz(4)/4 scrsz(3)/2 scrsz(4)/2]);
194 loglog(xPoints,fitK1); % K1
195 hold all;
196 errorbar(datax,dataK1,dataK1e,'.');
197 loglog(xPoints,fitK2); % K2
198 errorbar(datax,dataK2,dataK2e,'.');
199 loglog(xPoints,fitK1+fitK1e); % K1
200 loglog(xPoints,fitK1-fitK1e); % K1
201 loglog(xPoints,fitK2+fitK2e); % K2
202 loglog(xPoints,fitK2-fitK2e); % K2
203 hold off;
204 legend('K1', 'K1 Data','K2', 'K2 Data', 'Location', 'NorthWest');
205
206 % Plot
207 figure('Name','A_i/A','Position',[scrsz(3)/2 scrsz(4)/4 scrsz(3)/2 scrsz(4)/2])
;
208 semilogx(xPoints,fitA1); % A1/A
209 hold all;
210 errorbar(datax,dataA1,dataA1e,'.');
211 semilogx(xPoints,fitA2); % A2/A
212 errorbar(datax,dataA2,dataA2e,'.');
213 semilogx(xPoints,fitA1+fitA1e); % A1/A
214 semilogx(xPoints,fitA1-fitA1e); % A1/A
215 semilogx(xPoints,fitA2+fitA2e); % A2/A
216 semilogx(xPoints,fitA2-fitA2e); % A2/A
217 hold off;
218 legend('A1/A', 'A1/A Data', 'A2/A', 'A2/A Data', 'Location', 'West');
219
220
221 %% Save Simulated Data
222 outfile = strcat(file, '.fit.csv');
223 fid = fopen (outfile,'w');
224 fprintf(fid,'#%s\n',file);
225 fprintf(fid,'#K1off \t=\t%±g%g (%0.2g%%)\n',K1off ,K1offe ,100*K1offe /K1off );
226 fprintf(fid,'#K1EDTA\t=\t%±g%g (%0.2g%%)\n',K1EDTA,K1EDTAe,100*K1EDTAe/K1EDTA);
227 fprintf(fid,'#K1to2 \t=\t%±g%g (%0.2g%%)\n',K1to2 ,K1to2e ,100*K1to2e /K1to2 );
228 fprintf(fid,'#K2off \t=\t%±g%g (%0.2g%%)\n',K2off ,K2offe ,100*K2offe /K2off );
229 fprintf(fid,'#K2EDTA\t=\t%±g%g (%0.2g%%)\n',K2EDTA,K2EDTAe,100*K2EDTAe/K2EDTA);
230 fprintf(fid,'#K2to1 \t=\t%±g%g (%0.2g%%)\n',K2to1 ,K2to1e ,100*K2to1e /K2to1 );
231 fprintf(fid,'#gamma \t=\t%±g%g (%0.2g%%)\n',gamma ,gammae ,100*gammae /gamma );
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232 fprintf(fid,'#Appoff\t=\t%±g%g (%0.2g%%)\n',Appoff,Appoffe,100*Appoffe/Appoff);
233 fprintf(fid,'#\n#[EDTA] \t A1/A \t K1 \t A2/A \t K2 \t (A1/A)e \t K1e \t (A2/A)e \t
K2e \n');
234 fclose (fid);
235 dlmwrite(outfile ...
236 ,[xPoints fitA1 fitK1 fitA2 fitK2 fitA1e fitK1e fitA2e fitK2e] ...
237 ,'delimiter','\t','-append')
The variable gamma overwrites the matlab function gamma.
A.2.2 nlinfitsome.m
1 %%Based on http://www.mathworks.com/matlabcentral/answers/96392
2 function [varargout] = nlinfitsome(x,y,fun,beta0,fixed,varargin)
3 % "fixed" indicats which values of beta0 should not change
4
5 % Get separate arrays of coefficients to fix and to estimate
6 bfixed = beta0(fixed); beta0 = beta0(~fixed);
7
8 % Estimate only the non-fixed ones
9 [varargout{1:max(1,nargout)}] = nlinfit(x,y,@localfit,beta0,varargin{:});
10
11 % Re-create array combining fixed and estimated coefficients
12 b(~fixed) = varargout{1};
13 b(fixed) = bfixed;
14 varargout{1} = b;
15
16 % Nested function takes just the parameters to be estimated as inputs
17 % It inherits the following from the outer function:
18 % fixed = logical index for fixed elements
19 % bfixed = fixed values for these elements
20 % but its input is the
21 function y=localfit(beta,x)
22
23 b(fixed) = bfixed;
24 b(~fixed) = beta;
25 y = fun(b,x);
26 end
27 end
A.2.3 DoSolving.m
1 function out = DoSolving ( K1off, K1EDTA, K1to2 ...
2 , K2off, K2EDTA, K2to1 ...
3 , EDTA ...
4 , AB ... % Intial Conditions
5 , epsilon ... % Correction for different brightnesses
6 , varargin... % see varargs below
7 ... , errors ... % Optional Arguments for Errors
8 ... , K1offe, K1EDTAe, K1to2e ...
9 ... , K2offe, K2EDTAe, K2to1e ...
10 ... , epsilone...
11 )
12
13 %DOSOLVING The solutions for the model:
14 % AB+Cu <---- (AB.Cu)_1 ----> AB + Cu.EDTA
15 % || /\ ||
16 % || /||\ ||
17 % || || ||
18 % || \||/ ||
19 % || \/ ||
20 % AB+Cu <---- (AB.Cu)_2 ----> AB + Cu.EDTA
21
22 if (nargin <1 || varargin{1} == false)
23 errors = false;
24 numout = 3;
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25 else
26 errors = true; % varargin{1}
27 numout = 8;
28 K1offe = varargin{2};
29 K1EDTAe = varargin{3};
30 K1to2e = varargin{4};
31 K2offe = varargin{5};
32 K2EDTAe = varargin{6};
33 K2to1e = varargin{7};
34 epsilone = varargin{8};
35 end
36
37 out = zeros ( length(EDTA) ...
38 , numout ...
39 );
40
41 AC1at0 = AB*(K2to1/(K1to2+K2to1)); % AB.Cu Species 1
42 AC2at0 = AB*(K1to2/(K1to2+K2to1)); % AB.Cu Species 2
43
44 alpha = K1to2 + K2to1 + K1off + K2off + EDTA*(K1EDTA + K2EDTA);
45 beta = sqrt(K1to2^2 ...
46 + 2*K1to2*(K2to1 + K1off - K2off + EDTA*(K1EDTA - K2EDTA)) ...
47 + (K2to1 - K1off + K2off - EDTA*(K1EDTA - K2EDTA)).^2);
48 gamma = K1to2 - K2to1 + K1off - K2off + EDTA*(K1EDTA - K2EDTA);
49 delta = sqrt(-4 *(K2to1 * (K1off + EDTA*K1EDTA) ...
50 + (K1to2 + K1off + EDTA*K1EDTA).*(K2off + EDTA*K2EDTA)) + alpha.^2);
51
52 A1 = ( (beta + gamma)*AC1at0 - 2*K2to1*AC2at0 ...
53 +((beta - gamma)*AC2at0 - 2*K1to2*AC1at0)* epsilon ...
54 )./(2*delta);
55 K1 = (alpha + beta)/2;
56 A2 = ( (beta - gamma)*AC1at0 + 2*K2to1*AC2at0 ...
57 +((beta + gamma)*AC2at0 + 2*K1to2*AC1at0)* epsilon ...
58 )./(2*delta);
59 K2 = (alpha - beta)/2;
60
61 A = A1 + A2;
62 out(:,1) = A1./A;
63 out(:,2) = K1;
64 out(:,3) = K2;
65
66 if (errors)
67 K1eAnalytical = sqrt( ...
68 ( K1to2e ^2.*(1+( K1to2 + K2to1 + K1off - K2off + EDTA*(K1EDTA -
K2EDTA))./(beta)).^2 ...
69 + K2to1e ^2.*(1+( K1to2 + K2to1 - K1off + K2off - EDTA*(K1EDTA -
K2EDTA))./(beta)).^2 ...
70 + K1offe ^2.*(1+( K1to2 - K2to1 + K1off - K2off + EDTA*(K1EDTA -
K2EDTA))./(beta)).^2 ...
71 + K2offe ^2.*(1+(-K1to2 + K2to1 - K1off + K2off - EDTA*(K1EDTA -
K2EDTA))./(beta)).^2 ...
72 +(EDTA*K1EDTAe).^2.*(1+( K1to2 - K2to1 + K1off - K2off + EDTA*(K1EDTA -
K2EDTA))./(beta)).^2 ...
73 +(EDTA*K2EDTAe).^2.*(1+(-K1to2 + K2to1 - K1off + K2off - EDTA*(K1EDTA -
K2EDTA))./(beta)).^2 ...
74 ))./2;
75 K2eAnalytical = sqrt( ...
76 ( K1to2e ^2.*(1-( K1to2 + K2to1 + K1off - K2off + EDTA*(K1EDTA -
K2EDTA))./(beta)).^2 ...
77 + K2to1e ^2.*(1-( K1to2 + K2to1 - K1off + K2off - EDTA*(K1EDTA -
K2EDTA))./(beta)).^2 ...
78 + K1offe ^2.*(1-( K1to2 - K2to1 + K1off - K2off + EDTA*(K1EDTA -
K2EDTA))./(beta)).^2 ...
79 + K2offe ^2.*(1-(-K1to2 + K2to1 - K1off + K2off - EDTA*(K1EDTA -
K2EDTA))./(beta)).^2 ...
80 +(EDTA*K1EDTAe).^2.*(1-( K1to2 - K2to1 + K1off - K2off + EDTA*(K1EDTA -
K2EDTA))./(beta)).^2 ...
81 +(EDTA*K2EDTAe).^2.*(1-(-K1to2 + K2to1 - K1off + K2off - EDTA*(K1EDTA -
K2EDTA))./(beta)).^2 ...
82 ))./2;
83
84 CFD = CentralFiniteDifference(@(A)(DoSolving(A(1) ... % K1off
85 , A(2) ... % K1EDTA
86 , A(3) ... % K1to2
87 , A(4) ... % K2off
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88 , A(5) ... % K2EDTA
89 , A(6) ... % K2to1
90 , EDTA ... % EDTA
91 , AB ... % AB
92 , A(7) ... % Gamma
93 , false... % Calculate Errors
94 )) ...
95 , 1E-6 ... % relative StepSize
96 , 1E-8 ... % Minimium StepSize
97 , K1off, K1EDTA, K1to2 ...
98 , K2off, K2EDTA, K2to1 ...
99 , epsilon ...
100 );
101 errs = ...
102 ( (K1offe *cell2mat(CFD(1))).^2 ...
103 + (K1EDTAe *cell2mat(CFD(2))).^2 ...
104 + (K1to2e *cell2mat(CFD(3))).^2 ...
105 + (K2offe *cell2mat(CFD(4))).^2 ...
106 + (K2EDTAe *cell2mat(CFD(5))).^2 ...
107 + (K2to1e *cell2mat(CFD(6))).^2 ...
108 + (epsilone*cell2mat(CFD(7))).^2 ...
109 ).^0.5;
110
111 out(:,4) = errs(:,1); % A1/A error
112 out(:,5) = K1eAnalytical; % K1 error analytical
113 out(:,7) = errs(:,2); % K1 error numerical
114 out(:,6) = K2eAnalytical; % K2 error analytical
115 out(:,8) = errs(:,3); % K2 error numerical
116 end
117
118
119 end
A.2.4 CentralFiniteDifference.m
1 function out = CentralFiniteDifference( Function ...
2 , stepSize ... % relative StepSize
3 , minStepSize...
4 , varargin)
5 %Central Finite Difference
6 %varargin the point arround the function
7 %returns cells use cell2mat() to get matrix
8
9 varargin = cell2mat(varargin);
10 js = -4:4;
11 f = cell(length(js));
12 out= cell(length(varargin));
13
14 for arg = 1:length(varargin)
15 for j = 1:length(js)
16 tmp = varargin;
17 if abs(tmp(arg)*stepSize) > minStepSize
18 tmp(arg) = tmp(arg)*(1 + js(j)*stepSize);
19 else
20 tmp(arg) = tmp(arg) + js(j)*minStepSize;
21 end
22 f(j) = {Function(tmp)};
23 end
24 diff = ( 1/280 *cell2mat(f(1))...
25 - 4/105 *cell2mat(f(2))...
26 + 1/ 5 *cell2mat(f(3))...
27 - 4/ 5 *cell2mat(f(4))...
28 - 00000 *cell2mat(f(5))...
29 + 4/ 5 *cell2mat(f(6))...
30 - 1/ 5 *cell2mat(f(7))...
31 + 4/105 *cell2mat(f(8))...
32 - 1/280 *cell2mat(f(9))...
33 ) ;
34
35 if abs(tmp(arg)*stepSize) > minStepSize
36 diff = diff ./ (tmp(arg)*stepSize);
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37 else
38 diff = diff ./ minStepSize;
39 end
40 out(arg) = {diff};
41 end
42
43
44
45 end
A.2.5 PatternMatch.m
1 function [a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z] ...
2 = PatternMatch(in)
3 %PATTERNMATCH Pattern match a list into variables
4 % If number of output variables is greater than input list,
5 % values set to NaN
6 numvalues = 27-length(in);
7 in=[in zeros([1 numvalues])];
8 in(numvalues:27) = NaN;
9 a=in(1) ;b=in(2) ;c=in(3) ;d=in(4) ;e=in(5) ;f=in(6) ;g=in(7) ;h=in(8) ;
10 i=in(9) ;j=in(10);k=in(11);l=in(12);m=in(13);n=in(14);o=in(15);p=in(16);
11 q=in(17);r=in(18);s=in(19);t=in(20);u=in(21);v=in(22);w=in(23);x=in(24);
12 y=in(25);z=in(26);
13 end
A.2.6 Logspacelist.m
1 function [ point ] = Logspacelist( max, min, numpoints)
2 %LOGSPACE Summary of this function goes here
3 % Detailed explanation goes here
4
5 point = zeros(1, numpoints);
6 for n = drange(1:numpoints)
7 point(n) = 10^((n-1)/(numpoints-1)*log10(max/min)+log10(min));
8 end
9 end
A.3 Multiple Binding of Cu2+ to Aβ∗
Matlab code to fit the relative populations of the different phases for different age
times of when {{Aβ⊗Cu2+}⊗EDTA} (main.m), and code to take the fitting parameters
from main.m and generate the relative equilibrium populations of Cu2+ bound Aβ
species and plot them over equivalent experimental data (main2.m). The code is used
in section 3.9. The follow files are not included in the listing below as they appear
in section A.2: Logspacelist.m (§A.2.6), nlinfitsome.m (§A.2.2), PatternMatch.m
(§A.2.5), and CentralFiniteDifference.m (§A.2.4).
∗Archive of source code:
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main.m The initial parameters for fitting are lines 8 through 13, with lines 14
through 17 as the relative quenching of the different amplitudes. Whether the fitting
parameters are variable is declared in the array tofit (line 26). The variable AB is
the concentration of Aβ (line 18), and Cu is the concentration of Cu2+ (line 30). Line
22 selects which models to fit from model2dot.m. The experimental data should
be in a CSV file with columns [Age Time / s, 𝐴1/𝐴, 𝜎𝐴1/𝐴, 𝐴2/𝐴, 𝜎𝐴2/𝐴, 𝐴3/𝐴, 𝜎𝐴3/𝐴,
𝐴4/𝐴, 𝜎𝐴4/𝐴], where 𝐴 = 𝐴1 +𝐴2 +𝐴3 +𝐴4. The output parameters are saved to the
input file name with .fit., the model number and .csv appended.
main2.m It takes the base name (without .fit.modelnum.csv) file outputted
from main.m in the variable fittedfilebase with the concentration of Cu2+ to
calculate rate constants and experimental data in file (line 9) in the format [Cu
/ µm, 𝐴1/𝐴, 𝐴2/𝐴, 𝐴3/𝐴, 𝐴4/𝐴, 𝐴5/𝐴], where 𝐴 = 𝐴1 +𝐴2 +𝐴3 +𝐴4 +𝐴5. Line 16
selects which models to fit from model2dot.m. The output is saved to the base name
with .fit.modelnum.csv.fit.varyCu.csv appended.
A.3.1 main.m
1 %% Initialisation
2 clear;% close all;
3 clc; % Clear Command Window
4 concat = @(xs)(reshape(xs,[],1));
5
6 %% Model Parameters
7 % Kinetic Parameters
8 k12 = 1.1; % Hz
9 k21 = 3.1; % Hz
10 k3on = 10; % Hz
11 k3off = 4; % Hz
12 k4on = 0.01; % Hz
13 k4off = 0.25; % Hz
14 rA1 = 1;
15 rA2 = 1;
16 rA3 = 1.3;
17 rA4 = 1.3;
18 AB = 50E-9; % M
19 initial = AB*[1 0 0 0]; % [M M M M]
20
21 model = 2; % model number in model2dot.m
22 for model = 0:17
23
24 %% Initial Parameters
25 fit = [k12 ,k21 ,k3on ,k3off,k4on ,k4off,rA1 ,rA2 ,rA3 ,rA4 ];
26 tofit = [true ,true ,true ,true ,true ,true ,false,false,false,false];
27
28 %% Fitting Data
29 %
30 file ='140324-AB16LysHL488-VaryTime-10uMCu100nMAB2mMEDTA.csv';Cu=10E-6;%M
31 % file ='140325-AB16LysHL488-VaryTime-5uMCu100nMAB2mMEDTA.csv';Cu=5E-6;%M
32 % file ='140325-AB16LysHL488-VaryTime-2uMCu100nMAB2mMEDTA.csv';Cu=2E-6;%M
33 % file ='140409-AB16LysHL488-VaryTime-2uMCu100nMAB2mMEDTA.csv';Cu=2E-6;%M
34 data = importdata(file);
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35 data = data.data;
36 datat = data(:,1);
37 dataA1 = data(:,2);
38 dataA1e = data(:,3);
39 dataA2 = data(:,4);
40 dataA2e = data(:,5);
41 dataA3 = data(:,6);
42 dataA3e = data(:,7);
43 dataA4 = data(:,8);
44 dataA4e = data(:,9);
45 dataconcaty = concat([dataA1 dataA2 dataA3 dataA4 ]);
46 dataconcatye = concat([dataA1e dataA2e dataA3e dataA4e]);
47
48 %% Perform Fit
49 % Fiting Parameters
50 opts = statset('nlinfit'); opts.Display = 'iter' ;
51 opts.MaxIter = 200 ; opts.UseParallel = true;
52
53
54 % Perform Fit
55 [fit(:), residuals, jacobian, convB, MSE] ...
56 = nlinfitsome ...
57 ( datat ... % X points
58 , dataconcaty ... % Y points
59 , @(A,t)(concat(model2 ... % Fitting Function
60 ( model ...
61 , abs(A(1)) ... % k12
62 , abs(A(2)) ... % k21
63 , abs(A(3)) ... % k3on
64 , abs(A(4)) ... % k3off
65 , abs(A(5)) ... % k4on
66 , abs(A(6)) ... % k4off
67 , abs(A(7)) ... % rA1
68 , abs(A(8)) ... % rA2
69 , abs(A(9)) ... % rA3
70 , abs(A(10))... % rA4
71 , t ... % time
72 , Cu ... % Copper
73 , initial ... % Starting Conditions
74 , false ... % errors
75 ))) ...
76 , fit ... % Fitting Parameters
77 ,~tofit ... % Fixed Parameters
78 , opts ... % Options
79 ,'Weights', 1./dataconcatye.^2 ...
80 );
81
82
83
84 %% Calculate Errors
85 % http://www.mathworks.co.uk/support/solutions/en/data/1-X92KR/ (16/07/13)
86 fite = zeros(size(fit));
87 ci = nlparci(fit(tofit),residuals,'jacobian',jacobian);% 95% confidence
intervals
88 t = tinv(1-0.05/2,length(dataconcaty)-length(datat));
89 fite(tofit)= transpose((ci(:,2)-ci(:,1)) ./ (2*t)); % Standard Error
90 residuals = reshape(residuals,[],3);
91
92
93 %% Get the values out of the fitted value array
94 [k12 ,k21 ,k3on ,k3off ,k4on ,k4off ,rA1 ,rA2 ,rA3 ,rA4 ] = ...
95 PatternMatch(abs(fit ));
96 [k12e,k21e,k3one,k3offe,k4one,k4offe,rA1e,rA2e,rA3e,rA4e] = ...
97 PatternMatch(abs(fite));
98
99
100 %% Print Fitted Values
101 fprintf('\n%s\n',file);
102 fprintf('k12 \t=\t%±g%g (%0.2g%%)\n',k12 ,k12e ,100*k12e/k12 );
103 fprintf('k21 \t=\t%±g%g (%0.2g%%)\n',k21 ,k21e ,100*k21e/k21 );
104 fprintf('k3on \t=\t%±g%g (%0.2g%%)\n',k3on ,k3one ,100*k3on/k3on );
105 fprintf('k3off \t=\t%±g%g (%0.2g%%)\n',k3off,k3offe,100*k3offe/k3off);
106 fprintf('k4on \t=\t%±g%g (%0.2g%%)\n',k4on ,k4one ,100*k4one/k4on );
107 fprintf('k4off \t=\t%±g%g (%0.2g%%)\n',k4off,k4offe,100*k4offe/k4off);
108 fprintf('rA1 \t=\t%±g%g (%0.2g%%)\n',rA1 ,rA1e ,100*rA1e/rA1 );
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109 fprintf('rA2 \t=\t%±g%g (%0.2g%%)\n',rA2 ,rA2e ,100*rA2e/rA2 );
110 fprintf('rA3 \t=\t%±g%g (%0.2g%%)\n',rA3 ,rA3e ,100*rA3e/rA3 );
111 fprintf('rA4 \t=\t%±g%g (%0.2g%%)\n',rA4 ,rA4e ,100*rA4e/rA4 );
112
113 %% Modelling the Data from Fitted parameters and get Errors for Plotting
114 numModelPoints = 300;
115 xPoints = transpose(Logspacelist(100,1E-3,numModelPoints)); %% time
116 solveddata = model2 ... % Fitting Function
117 ( model ...
118 , k12 , k21 , k3on , k3off , k4on , k4off ...
119 , rA1 , rA2 , rA3 , rA4 ...
120 , xPoints ... % time
121 , Cu ... % Copper
122 , initial ... % Initial Conditions
123 , true ... % errors
124 , k12e, k21e, k3one, k3offe, k4one, k4offe ...
125 , rA1e, rA2e, rA3e, rA4e ...
126 );
127
128
129 %% Plot Data and Fits
130 warning('off','MATLAB:Axes:NegativeDataInLogAxis');
131
132 fitA1 = solveddata(:,1);
133 fitA2 = solveddata(:,2);
134 fitA3 = solveddata(:,3);
135 fitA4 = solveddata(:,4);
136 fitA1e = solveddata(:,5);
137 fitA2e = solveddata(:,6);
138 fitA3e = solveddata(:,7);
139 fitA4e = solveddata(:,8);
140
141 scrsz = get(0,'ScreenSize');
142 %plot
143 figure('Name',sprintf('Ai/A (Cu = %0.2g M)',Cu));
144 semilogx(xPoints,fitA1);
145 hold all;
146 semilogx(xPoints,fitA1+fitA1e);
147 semilogx(xPoints,fitA1-fitA1e);
148 errorbar(datat,dataA1,dataA1e,'.');
149 semilogx(xPoints,fitA2);
150 semilogx(xPoints,fitA2+fitA2e);
151 semilogx(xPoints,fitA2-fitA2e);
152 errorbar(datat,dataA2,dataA2e,'.');
153 semilogx(xPoints,fitA3);
154 semilogx(xPoints,fitA3+fitA3e);
155 semilogx(xPoints,fitA3-fitA3e);
156 errorbar(datat,dataA3,dataA3e,'.');
157 semilogx(xPoints,fitA4);
158 semilogx(xPoints,fitA4+fitA4e);
159 semilogx(xPoints,fitA4-fitA4e);
160 errorbar(datat,dataA4,dataA4e,'.');
161 hold off;
162 legend('A1/A', 'A1/A Data', 'A2/A', 'A2/A Data', 'A3/A', 'A3/A Data', 'A4/A', '
A4/A Data');
163
164 outfile = strcat(file, '.fit.', num2str(model), '.csv');
165 fid = fopen (outfile,'w');
166 fprintf(fid,'\n#%s\n',file);
167 fprintf(fid,'#k12 \t=\t%±g%g (%0.2g%%)\n',k12 ,k12e ,100*k12e/k12 );
168 fprintf(fid,'#k21 \t=\t%±g%g (%0.2g%%)\n',k21 ,k21e ,100*k21e/k21 );
169 fprintf(fid,'#k3on \t=\t%±g%g (%0.2g%%)\n',k3on ,k3one ,100*k3on/k3on );
170 fprintf(fid,'#k3off \t=\t%±g%g (%0.2g%%)\n',k3off,k3offe,100*k3offe/k3off);
171 fprintf(fid,'#k4on \t=\t%±g%g (%0.2g%%)\n',k4on ,k4one ,100*k4one/k4on );
172 fprintf(fid,'#k4off \t=\t%±g%g (%0.2g%%)\n',k4off,k4offe,100*k4offe/k4off);
173 fprintf(fid,'#rA1 \t=\t%±g%g (%0.2g%%)\n',rA1 ,rA1e ,100*rA1e/rA1 );
174 fprintf(fid,'#rA2 \t=\t%±g%g (%0.2g%%)\n',rA2 ,rA2e ,100*rA2e/rA2 );
175 fprintf(fid,'#rA3 \t=\t%±g%g (%0.2g%%)\n',rA3 ,rA3e ,100*rA3e/rA3 );
176 fprintf(fid,'#rA4 \t=\t%±g%g (%0.2g%%)\n',rA4 ,rA4e ,100*rA4e/rA4 );
177 fprintf(fid,'#\n#[time] \t A1/A \t A2/A \t A3/A \t A4/A \t (A1/A)e \t (A2/A)e \t (
A3/A)e \t (A4/A)e\n');
178 fclose (fid);
179 dlmwrite(outfile ...
180 ,[xPoints fitA1 fitA2 fitA3 fitA4 fitA1e fitA2e fitA3e fitA4e] ...
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181 ,'delimiter','\t','-append')
182 end
A.3.2 main2.m
1 %% Initialisation
2 clear; % close all;
3 clc; % Clear Command Window
4 concat = @(xs)(reshape(xs,[],1));
5
6 %% Model Parameters
7 %file = '130128-ABCu+2mMEDTA-VaryCu-4phaseanalysis.csv';
8 %
9 file = '140429-AB16LysHL488-VaryCu-25nMAB-2mMEDTA.csv';
10 fittedfilebase = '140324-AB16LysHL488-VaryTime-10uMCu100nMAB2mMEDTA.csv'; Cu = 10E
-6;
11
12 AB = 50E-9; % M
13 initial = AB*[1 0 0 0]; % [M M M M]
14
15
16 for model = 9:17
17 %% Get Fitted Parameters
18 fittedfile = strcat(fittedfilebase, '.fit.', num2str(model), '.csv');
19 [params, paramse] = importfile(fittedfile);
20 [k12 ,k21 ,k3on ,k3off ,k4on ,k4off ,rA1 ,rA2 ,rA3 ,rA4 ] = ...
21 PatternMatch(transpose(params ));
22 [k12e,k21e,k3one,k3offe,k4one,k4offe,rA1e,rA2e,rA3e,rA4e] = ...
23 PatternMatch(transpose(paramse));
24 k3on = k3on / Cu; k3one = k3one / Cu;
25 k4on = k4on / Cu; k4one = k4one / Cu;
26
27 %% Do modelling
28 numpoints = 50;
29 npoints = 50;
30 tPoints = transpose(Logspacelist(1000,1E-3,npoints)); %% time
31 fitA1=[];fitA2=[];fitA3=[];fitA4=[];
32 fitA1e=[];fitA2e=[];fitA3e=[];fitA4e=[];
33
34 outx = Logspacelist(200E-6, 0.05E-6,numpoints);
35 parfor i = 1:numpoints
36 fprintf('%d\n',i);
37 Copper = outx(i);
38
39 solveddata = model2 ... % Fitting Function
40 ( model + 100 ...% +100 for models with explicit Cu
41 , k12 , k21 , k3on , k3off , k4on , k4off ...
42 , rA1 , rA2 , rA3 , rA4 ...
43 , tPoints ... % time
44 , Copper ... % Copper
45 , initial ... % Starting Conditions
46 , true ... % Errors
47 , k12e , k21e , k3one , k3offe , k4one , k4offe ...
48 , rA1e , rA2e , rA3e , rA4e ...
49 );
50
51 fitA1 = [fitA1 , solveddata(:,1)];%#ok<*AGROW>% npoints-1,1);
52 fitA2 = [fitA2 , solveddata(:,2)];%#ok<*AGROW>% npoints-1,2);
53 fitA3 = [fitA3 , solveddata(:,3)];%#ok<*AGROW>% npoints-1,3);
54 fitA4 = [fitA4 , solveddata(:,4)];%#ok<*AGROW>% npoints-1,4);
55 fitA1e = [fitA1e, solveddata(:,5)];%#ok<*AGROW>% npoints-1,1);
56 fitA2e = [fitA2e, solveddata(:,6)];%#ok<*AGROW>% npoints-1,2);
57 fitA3e = [fitA3e, solveddata(:,7)];%#ok<*AGROW>% npoints-1,3);
58 fitA4e = [fitA4e, solveddata(:,8)];%#ok<*AGROW>% npoints-1,4);
59 end
60
61 figure1 = figure;
62 colormap('winter');
63 axes1 = axes ...
64 ('Parent',figure1 ...
65 ,'YScale','log','YMinorTick','on'...
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66 ,'XScale','log' ...
67 ,'XMinorTick','on');
68 view(axes1,[16.5 42]);
69 hold(axes1,'all');
70 surf( repmat(tPoints,1,numpoints) ...
71 , repmat(outx,npoints,1) ...
72 , fitA1 ...
73 )
74 surf( repmat(tPoints,1,numpoints) ...
75 , repmat(outx,npoints,1) ...
76 , fitA2 ...
77 )
78 surf( repmat(tPoints,1,numpoints) ...
79 , repmat(outx,npoints,1) ...
80 , fitA3 ...
81 )
82 surf( repmat(tPoints,1,numpoints) ...
83 , repmat(outx,npoints,1) ...
84 , fitA4 ...
85 )
86 xlabel('Time / s','HorizontalAlignment','right');
87 ylabel('[Cu] / M','HorizontalAlignment','left');
88 zlabel('Ai/A');
89
90
91
92 data = importdata(file);
93 data = data.data;
94 dataCu = data(:,1)./1E6; %uM -> M
95 dataA1 = data(:,2);
96 dataA2 = data(:,3);
97 dataA3 = data(:,4);
98 dataA4 = data(:,5);
99 dataA5 = data(:,6);
100
101 figure2 = figure('name','t=1000');
102 axes1 = axes('Parent',figure2,'XScale','log','XMinorTick','on');
103 xlim(axes1,[5e-07 5e-5]);
104 semilogx(outx,fitA1(length(outx),:));
105 hold all;
106 semilogx(outx,fitA2(length(outx),:));
107 semilogx(outx,fitA3(length(outx),:));
108 semilogx(outx,fitA4(length(outx),:));
109 semilogx(dataCu,dataA1,'.')
110 semilogx(dataCu,dataA2,'.')
111 semilogx(dataCu,dataA3,'.')
112 semilogx(dataCu,dataA4+dataA5,'.')
113 semilogx(outx,fitA1(length(outx),:)+fitA1e(length(outx),:));
114 semilogx(outx,fitA1(length(outx),:)-fitA1e(length(outx),:));
115 semilogx(outx,fitA2(length(outx),:)+fitA2e(length(outx),:));
116 semilogx(outx,fitA2(length(outx),:)-fitA2e(length(outx),:));
117 semilogx(outx,fitA3(length(outx),:)+fitA3e(length(outx),:));
118 semilogx(outx,fitA3(length(outx),:)-fitA3e(length(outx),:));
119 semilogx(outx,fitA4(length(outx),:)+fitA4e(length(outx),:));
120 semilogx(outx,fitA4(length(outx),:)-fitA4e(length(outx),:));
121 hold off;
122 legend('A1/A', 'A2/A', 'A3/A', 'A4/A');
123
124 outfile = strcat(fittedfile, '.fit.varyCu.csv');
125 fid = fopen (outfile,'w');
126 fprintf(fid,'#[Cu] \t A1/A \t A2/A \t A3/A \t A4/A \t (A1/A)e \t (A2/A)e \t (A3
/A)e \t (A4/A)e\n');
127 fclose (fid);
128 dlmwrite(outfile ...
129 ,[transpose(outx) transpose(fitA1(length(outx),:)) transpose(fitA2(length(
outx),:)) transpose(fitA3(length(outx),:)) transpose(fitA4(length(outx),:))
transpose(fitA1e(length(outx),:)) transpose(fitA2e(length(outx),:)) transpose(
fitA3e(length(outx),:)) transpose(fitA4e(length(outx),:))] ...
130 ,'delimiter','\t','-append')
131 end
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A.3.3 importfile.m
1 function [VarName3,VarName4] = importfile(filename, startRow, endRow)
2 % Auto-generated by MATLAB on 2014/09/05 16:49:57
3
4 delimiter = {'\t','(','±'};
5 if nargin<=2
6 startRow = 3;
7 endRow = 12;
8 end
9 formatSpec = 'sfileID = fopen(filename,’r’);dataArray = textscan(fileID, formatSpec,
endRow(1)-startRow(1)+1, ’Delimiter’, delimiter, ’HeaderLines’, startRow(1)-1,
’ReturnOnError’, false);for
block=2:length(startRow)frewind(fileID);dataArrayBlock = textscan(fileID,
formatSpec, endRow(block)-startRow(block)+1, ’Delimiter’, delimiter,
’HeaderLines’, startRow(block)-1, ’ReturnOnError’, false);for
col=1:length(dataArray)dataArraycol =
[dataArraycol;dataArrayBlockcol];endendfclose(fileID);VarName3 = dataArray:,
1;VarName4 = dataArray:, 2;
A.3.4 model2.m
1 function out = model2 ...
2 ( modelnum ...
3 , k12 , k21 , k3on , k3off , k4on , k4off ...
4 , rA1 , rA2 , rA3 , rA4 ...
5 , time ...
6 , Cu ...
7 , initial ...
8 , varargin ...
9 ... , errors ... % Optional Arguments for Errors
10 ... , k12e, k21e, k13e, k31e, k34e, k43e ...
11 ... , rA1e, rA2e, rA3e, rA4e ...
12 )
13 %MODEL2
14 if (nargin <1 || varargin{1} == false)
15 errors = false;
16 else
17 errors = true; % varargin{1}
18 k12e = varargin{2};
19 k21e = varargin{3};
20 k3one = varargin{4};
21 k3offe = varargin{5};
22 k4one = varargin{6};
23 k4offe = varargin{7};
24 rA1e = varargin{8};
25 rA2e = varargin{9};
26 rA3e = varargin{10};
27 rA4e = varargin{11};
28 end
29
30
31 odeoptions = odeset( 'Reltol',1e-6 ...
32 , 'Abstol',1e-30 ...
33 );
34 [T,Y] = ode45(@(t,A)(model2dot ...
35 ( modelnum ...
36 , k12, k21, k3on, k3off, k4on, k4off ...
37 , Cu ...
38 , A(1), A(2), A(3), A(4) ... %rA's
39 )...
40 ) ...
41 , [0; time] ... % Put in Initial time point
42 , initial ... % Starting Conditions
43 , odeoptions ... % Simulation Options
44 );
45 out = Y(2:length(T),:); % Remove in Initial time point
46 out = out .* repmat([rA1, rA2, rA3, rA4], size(out,1),1); % Rel Brightness
47 total = repmat(transpose(sum(transpose(out))), 1,size(out,2));
48 out = out ./ total;
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49
50 if (errors)
51 CFD = CentralFiniteDifference(@(A)(model2 ... % Fitting Function
52 ( modelnum ...
53 , A(1) ... % k12
54 , A(2) ... % k21
55 , A(3) ... % k3on
56 , A(4) ... % k3off
57 , A(5) ... % k4on
58 , A(6) ... % k4off
59 , A(7) ... % rA1
60 , A(8) ... % rA2
61 , A(9) ... % rA3
62 , A(10) ... % rA4
63 , time ... % time
64 , Cu ... % Copper
65 , initial ... % Starting Conditions
66 , false ... % errors
67 ) ...
68 ) ...
69 , 1E-6 ... % relative StepSize
70 , 1E-8 ... % Minimium StepSize
71 , k12, k21, k3on, k3off, k4on, k4off ...
72 , rA1, rA2, rA3, rA4 ...
73 );
74
75 errs = ...
76 ( (k12e *cell2mat(CFD(1))).^2 ...
77 + (k21e *cell2mat(CFD(2))).^2 ...
78 + (k3one *cell2mat(CFD(3))).^2 ...
79 + (k3offe*cell2mat(CFD(4))).^2 ...
80 + (k4one *cell2mat(CFD(5))).^2 ...
81 + (k4offe*cell2mat(CFD(6))).^2 ...
82 + (rA1e *cell2mat(CFD(7))).^2 ...
83 + (rA2e *cell2mat(CFD(7))).^2 ...
84 + (rA3e *cell2mat(CFD(7))).^2 ...
85 + (rA4e *cell2mat(CFD(7))).^2 ...
86 ).^0.5;
87
88 out(:,5) = errs(:,1); % A1/A error
89 out(:,6) = errs(:,2); % A2/A error
90 out(:,7) = errs(:,3); % A3/A error
91 out(:,8) = errs(:,4); % A4/A error
92
93 end
94 end
A.3.5 model2dot.m
1 function dy = model2dot ...
2 ( model ...
3 , k12, k21, k3n, k3f, k4n, k4f ...
4 , Cu ...
5 , A1, A2, A3, A4 ...
6 )
7 %MODEL2
8 %[k12 k21 k13 k31 k34 k43 ]
9 dy = zeros(4,1);
10 switch(model)
11 case 0
12 dy(1) = - A1*k12 + A2*k21 - A1*k3n + A3*k3f - A1*k4n + A4*k4f;
13 dy(2) = + A1*k12 - A2*k21;
14 dy(3) = + A1*k3n - A3*k3f;
15 dy(4) = + A1*k4n - A4*k4f;
16
17 case 1
18 dy(1) = - A1*k12 + A2*k21 - A1*k3n + A3*k3f - A1*k4n ;
19 dy(2) = + A1*k12 - A2*k21 + A4*k4f;
20 dy(3) = + A1*k3n - A3*k3f;
21 dy(4) = + A1*k4n - A4*k4f;
22
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23 case 2
24 dy(1) = - A1*k12 + A2*k21 - A1*k3n + A3*k3f - A1*k4n ;
25 dy(2) = + A1*k12 - A2*k21;
26 dy(3) = + A1*k3n - A3*k3f + A4*k4f;
27 dy(4) = + A1*k4n - A4*k4f;
28
29 case 3
30 dy(1) = - A1*k12 + A2*k21 - A1*k3n + A3*k3f + A4*k4f;
31 dy(2) = + A1*k12 - A2*k21 - A2*k4n;
32 dy(3) = + A1*k3n - A3*k3f;
33 dy(4) = + A2*k4n - A4*k4f;
34
35 case 4
36 dy(1) = - A1*k12 + A2*k21 - A1*k3n + A3*k3f;
37 dy(2) = + A1*k12 - A2*k21 - A2*k4n + A4*k4f;
38 dy(3) = + A1*k3n - A3*k3f;
39 dy(4) = + A2*k4n - A4*k4f;
40
41 case 5
42 dy(1) = - A1*k12 + A2*k21 - A1*k3n + A3*k3f;
43 dy(2) = + A1*k12 - A2*k21 - A2*k4n;
44 dy(3) = + A1*k3n - A3*k3f + A4*k4f;
45 dy(4) = + A2*k4n - A4*k4f;
46
47 case 6
48 dy(1) = - A1*k12 + A2*k21 - A1*k3n + A3*k3f + A4*k4f;
49 dy(2) = + A1*k12 - A2*k21;
50 dy(3) = + A1*k3n - A3*k3f - A3*k4n;
51 dy(4) = + A3*k4n - A4*k4f;
52
53 case 7
54 dy(1) = - A1*k12 + A2*k21 - A1*k3n + A3*k3f;
55 dy(2) = + A1*k12 - A2*k21 + A4*k4f;
56 dy(3) = + A1*k3n - A3*k3f - A3*k4n;
57 dy(4) = + A3*k4n - A4*k4f;
58
59 case 8
60 dy(1) = - A1*k12 + A2*k21 - A1*k3n + A3*k3f;
61 dy(2) = + A1*k12 - A2*k21;
62 dy(3) = + A1*k3n - A3*k3f - A3*k4n + A4*k4f;
63 dy(4) = + A3*k4n - A4*k4f;
64
65 case 9
66 dy(1) = - A1*k12 + A2*k21 - A1*k3n - A1*k4n + A4*k4f;
67 dy(2) = + A1*k12 - A2*k21 + A3*k3f;
68 dy(3) = + A1*k3n - A3*k3f;
69 dy(4) = + A1*k4n - A4*k4f;
70
71 case 10
72 dy(1) = - A1*k12 + A2*k21 - A1*k3n - A1*k4n;
73 dy(2) = + A1*k12 - A2*k21 + A3*k3f + A4*k4f;
74 dy(3) = + A1*k3n - A3*k3f;
75 dy(4) = + A1*k4n - A4*k4f;
76
77 case 11
78 dy(1) = - A1*k12 + A2*k21 - A1*k3n - A1*k4n;
79 dy(2) = + A1*k12 - A2*k21 + A3*k3f;
80 dy(3) = + A1*k3n - A3*k3f + A4*k4f;
81 dy(4) = + A1*k4n - A4*k4f;
82
83 case 12
84 dy(1) = - A1*k12 + A2*k21 - A1*k3n + A4*k4f;
85 dy(2) = + A1*k12 - A2*k21 + A3*k3f - A2*k4n;
86 dy(3) = + A1*k3n - A3*k3f;
87 dy(4) = + A2*k4n - A4*k4f;
88
89 case 13
90 dy(1) = - A1*k12 + A2*k21 - A1*k3n;
91 dy(2) = + A1*k12 - A2*k21 + A3*k3f - A2*k4n + A4*k4f;
92 dy(3) = + A1*k3n - A3*k3f;
93 dy(4) = + A2*k4n - A4*k4f;
94
95 case 14
96 dy(1) = - A1*k12 + A2*k21 - A1*k3n;
97 dy(2) = + A1*k12 - A2*k21 + A3*k3f - A2*k4n ;
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98 dy(3) = + A1*k3n - A3*k3f + A4*k4f;
99 dy(4) = + A2*k4n - A4*k4f;
100
101 case 15
102 dy(1) = - A1*k12 + A2*k21 - A1*k3n + A4*k4f;
103 dy(2) = + A1*k12 - A2*k21 + A3*k3f;
104 dy(3) = + A1*k3n - A3*k3f - A3*k4n;
105 dy(4) = + A3*k4n - A4*k4f;
106
107 case 16
108 dy(1) = - A1*k12 + A2*k21 - A1*k3n;
109 dy(2) = + A1*k12 - A2*k21 + A3*k3f + A4*k4f;
110 dy(3) = + A1*k3n - A3*k3f - A3*k4n;
111 dy(4) = + A3*k4n - A4*k4f;
112
113 case 17
114 dy(1) = - A1*k12 + A2*k21 - A1*k3n;
115 dy(2) = + A1*k12 - A2*k21 + A3*k3f;
116 dy(3) = + A1*k3n - A3*k3f - A3*k4n + A4*k4f;
117 dy(4) = + A3*k4n - A4*k4f;
118
119 case 109
120 dy(1) = - A1*k12 + A2*k21 - A1*Cu*k3n - A1*Cu*k4n + A4*k4f;
121 dy(2) = + A1*k12 - A2*k21 + A3*k3f;
122 dy(3) = + A1*Cu*k3n - A3*k3f;
123 dy(4) = + A1*Cu*k4n - A4*k4f;
124
125 case 110
126 dy(1) = - A1*k12 + A2*k21 - A1*Cu*k3n - A1*Cu*k4n;
127 dy(2) = + A1*k12 - A2*k21 + A3*k3f + A4*k4f;
128 dy(3) = + A1*Cu*k3n - A3*k3f;
129 dy(4) = + A1*Cu*k4n - A4*k4f;
130
131 case 111
132 dy(1) = - A1*k12 + A2*k21 - A1*Cu*k3n - A1*Cu*k4n;
133 dy(2) = + A1*k12 - A2*k21 + A3*k3f;
134 dy(3) = + A1*Cu*k3n - A3*k3f + A4*k4f;
135 dy(4) = + A1*Cu*k4n - A4*k4f;
136
137 case 112
138 dy(1) = - A1*k12 + A2*k21 - A1*Cu*k3n + A4*k4f;
139 dy(2) = + A1*k12 - A2*k21 + A3*k3f - A2*Cu*k4n;
140 dy(3) = + A1*Cu*k3n - A3*k3f;
141 dy(4) = + A2*Cu*k4n - A4*k4f;
142
143 case 113
144 dy(1) = - A1*k12 + A2*k21 - A1*Cu*k3n;
145 dy(2) = + A1*k12 - A2*k21 + A3*k3f - A2*Cu*k4n + A4*k4f;
146 dy(3) = + A1*Cu*k3n - A3*k3f;
147 dy(4) = + A2*Cu*k4n - A4*k4f;
148
149 case 114
150 dy(1) = - A1*k12 + A2*k21 - A1*Cu*k3n;
151 dy(2) = + A1*k12 - A2*k21 + A3*k3f - A2*Cu*k4n ;
152 dy(3) = + A1*Cu*k3n - A3*k3f + A4*k4f;
153 dy(4) = + A2*Cu*k4n - A4*k4f;
154
155 case 115
156 dy(1) = - A1*k12 + A2*k21 - A1*Cu*k3n + A4*k4f;
157 dy(2) = + A1*k12 - A2*k21 + A3*k3f;
158 dy(3) = + A1*Cu*k3n - A3*k3f - A3*Cu*k4n;
159 dy(4) = + A3*Cu*k4n - A4*k4f;
160
161 case 116
162 dy(1) = - A1*k12 + A2*k21 - A1*Cu*k3n;
163 dy(2) = + A1*k12 - A2*k21 + A3*k3f + A4*k4f;
164 dy(3) = + A1*Cu*k3n - A3*k3f - A3*Cu*k4n;
165 dy(4) = + A3*Cu*k4n - A4*k4f;
166
167 case 117
168 dy(1) = - A1*k12 + A2*k21 - A1*Cu*k3n;
169 dy(2) = + A1*k12 - A2*k21 + A3*k3f;
170 dy(3) = + A1*Cu*k3n - A3*k3f - A3*Cu*k4n + A4*k4f;
171 dy(4) = + A3*Cu*k4n - A4*k4f;
172
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173 otherwise
174 error 'model2dot: case not found';
175 end
176 end
A.4 Simulation of Cu2+, Zn2+ and Aβ in the Synapse∗
C++ code to simulate the reaction and diffusion of metals and Aβ in the synapse.
The code may be compiled using the make file.
The experiments are listed in experiments.h, and may be selected on line 9
of main.cpp. For the pulsed diffusion simulations timeSteps = 200000 was used,
and the pulseRate was set to {1,2,5,10,20,50,100}. The code is currently setup to
perform the single release simulations.
getr.hs (§A.4.10) is haskell code that allows for the extraction of different radii
from the output files produced by the C++ program.
A.4.1 makefile
1 BIN = Diff
2 GPP = g++ -Wall -Wextra -W -std=c++0x -g #-fprofile-arcs #-ftest-coverage
3
4 OPTI = -O2 -fopenmp #-ffast-math #-mfpmath=sse #-funroll-loops
5
6 CFLAGS = `pkg-config --cflags gsl`
7 LIBS = `pkg-config --libs gsl`
8 FLAGS =
9
10
11 all: Diff
12
13 Diff: main.o gslvec.o diftrimat.o diftrimatsolve.o
14 ${GPP} $^ -o ${BIN} ${FLAGS} ${LIBS} ${OPTI}
15
16 main.o: main.cpp experiments.h gslvec.h diftrimat.h
17 ${GPP} -c $< -o $@ ${COMPFLAGS} ${CFLAGS} ${OPTI}
18
19 gslvec.o: gslvec.cpp gslvec.h
20 ${GPP} -c $< -o $@ ${COMPFLAGS} ${CFLAGS} ${OPTI}
21
22 diftrimat.o: diftrimat.cpp diftrimat.h gslvec.h
23 ${GPP} -c $< -o $@ ${COMPFLAGS} ${CFLAGS} ${OPTI}
24
25 diftrimatsolve.o: diftrimatsolve.cpp diftrimat.h gslvec.h
26 ${GPP} -c $< -o $@ ${COMPFLAGS} ${CFLAGS} ${OPTI}
27
28 clean: cleanish
29 rm -f ${BIN}
30
31 cleanish:
32 rm -f *.o
33 rm -f *.dat
34 rm -f *.aux
35 rm -f *.log
36 rm -f *.sty
37 rm -f *.eps
∗Archive of source code:
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38 rm -f *.tex
39 rm -f *.pdf
40
41 run: all
42 ./${BIN}
43
44 runtime: all
45 time ./${BIN}
A.4.2 main.cpp
1 #include <cmath>
2 #include <iostream>
3 #include <omp.h>
4
5 #include "diftrimat.h"
6 #include "gslvec.h"
7
8 // Experiment number
9 #define EXPT 2
10 #include "experiments.h"
11
12 using namespace std;
13
14
15 int main() {
16 //Simulation Parameters
17 const int numRPoints = 2000000,
18 timeSteps = 2000;
19
20 const double maxR = 400000, // in nanometers
21 dr = maxR / numRPoints; //dr = maxR / numRPoints;
22
23 const double maxT = 1e7, // in microseconds
24 t1 = 0.001; // initial time point
25
26 const double pulseRate = 1e6/maxT,// in Hz
27 pulsePeriod = 1e6/pulseRate, // in microseconds
28 numPulses = (maxT-t1)/pulsePeriod;
29 const int stepsPerPulse = timeSteps/numPulses;
30
31 // Get Array of solution components under intial conditions
32 auto l = makel(numRPoints, dr);
33
34 #pragma omp parallel for
35 for(size_t i = 0; i < l.size(); ++i){
36 auto &a = l[i];
37 *a.fout << "# numRPoints: " << numRPoints
38 << ", timeSteps: " << timeSteps
39 << ", maxR: " << maxR
40 << ", maxT: " << maxT
41 << ", pulseRate: " << pulseRate
42 << '\n';
43 *a.fout << "#t\tr\tConcentration\n";
44 }
45
46 // Simulation
47 double lastt = 0;
48 for (int t=0; t != timeSteps; ++t){
49 //Formula for next exponentially increasing time step
50 const double thist = (t / stepsPerPulse) * pulsePeriod
51 +pow(10,((double)(t%stepsPerPulse)/(stepsPerPulse-1)*log10(pulsePeriod/
t1))) * t1;
52 const double dt = thist-lastt;
53
54 // Pulse
55 if (t%stepsPerPulse == 0)
56 pulse(l,dr);
57
58 // Reaction
59 #pragma omp parallel for
60 for (int i = 0; i < numRPoints; ++i)
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61 reaction(l, i, dt);
62
63 // Diffusion
64 #pragma omp parallel for
65 for(size_t i = 0; i < l.size(); i++){
66 auto &a = l[i];
67 a.rDiff(a.D, dr, dt);
68 }
69
70 // Save to File
71 #pragma omp parallel for
72 for(size_t i = 0; i < l.size(); ++i){
73 auto &a = l[i];
74 diftrimatsolve(a.rDiff, a.r, a.outr);
75
76 for (double i=1; i < numRPoints; i*=1.1){
77 const double r = double(i) * dr;
78 *a.fout << thist << '\t'
79 << double(r) << '\t'
80 << a.outr.get(i)<< '\n';
81 }
82 *a.fout << '\n'; // Newline for gnuplot
83 }
84
85 //Set last outr to inr
86 #pragma omp parallel for
87 for(size_t i = 0; i < l.size(); ++i){
88 auto &a = l[i];
89 swap(a.r, a.outr);
90 }
91
92 // Set this time to previous
93 lastt=thist;
94
95 cout << '\r' << "Done: " << (double)t / timeSteps *100 << "% "; // <<
flush
96 }
97
98 cout << endl;
99 for(size_t i = 0; i < l.size(); ++i){
100 auto &a = l[i];
101 delete a.fout; // Close files
102 }
103
104 return 0;
105 }
A.4.3 experiments.h
1 #ifndef __Experiments__
2 #define __Experiments__
3
4 #include <array>
5 #include <fstream>
6 #include <iostream>
7 #include <memory>
8
9 using namespace std;
10
11 #include "gslvec.h"
12
13 struct T {
14 std::ofstream *fout; // Output file
15 diftrimat rDiff; // Tridiagonal matrix
16 const double D; // Diffusion constant in nm^2 /us
17 gslvec r; // Vector of r points
18 gslvec outr; // Tmp output vector of r points
19 };
20
21 const double Dzn = 650; //Diffusion Coefficient in (nm)^2 / us
22 const double Dcu = 650;
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23 const double DAB = 304; // martin
24 const double DHSA = 61; // http://bionumbers.hms.harvard.edu//bionumber.aspx?id
=100612&ver=6
25
26 const double ABCukon = 3.0e8 * 1e-12;// in (uM us)^-1
27 const double ABCukoff = 0.8 * 1e-6; // in us^-1
28 const double ABCu12 = 0.9 * 1e-6; // in us^-1
29 const double ABCu21 = 2.22 * 1e-6; // in us^-1
30 const double ABCu13 = 4.2e5 * 1e-12;// in (uM us)^-1
31 const double ABCu32 = 1.7 * 1e-6; // in us^-1
32
33 const double ABZnkon = 1.9e6 * 1e-12;// in (uM us)^-1
34 const double ABZnkoff = 110 * 1e-6; // in us ^-1
35
36 const double HSACukon = 1.0e8 * 1e-12;// in (uM us)^-1
37
38 inline double defpos (double in){return (in<0)?0:in;}
39
40 #if EXPT == 1 // Diffusion of Zn and Cu
41 std::array<T,2> makel(const int nr, const double dr){
42 gslvec rZn(nr), rCu(nr);
43
44 // Initial conditions
45 for (int i = 0; i <nr; ++i){// vesicle diameter = 40nm
46 const double r = i * dr;
47 rZn.set( i, ((20>r)? 300: 0) ); // concentration in uM
48 rCu.set( i, ((20>r)? 30 : 0) ); // concentration in uM
49 }
50 return std::array<T,2>
51 { T{new std::ofstream("1-Zn.dat"), diftrimat(nr), Dzn, rZn, gslvec(nr)}
52 , T{new std::ofstream("1-Cu.dat"), diftrimat(nr), Dcu, rCu, gslvec(nr)}
53 };
54 }
55
56 inline void reaction (std::array<T,2> &, const size_t, const double){}
57
58 inline void pulse (std::array<T,2> &, const double){}
59
60 #elif EXPT == 2 // Reaction of Cu with AB
61 std::array<T,5> makel(const int nr, const double dr){
62 gslvec rCu(nr), rAB(nr), rABCu1(nr), rABCu2(nr),rABCu3(nr);
63
64 // Initial conditions
65 for (int i = 0; i <nr; ++i){// vesicle diameter = 40nm
66 const double r = i * dr;
67 rCu.set( i, ((20>r)? 30 : 0) ); // concentration in uM
68 rAB.set( i, 0.003); // concentration in uM
69 rABCu1.set( i, 0); // concentration in uM
70 rABCu2.set( i, 0); // concentration in uM
71 rABCu3.set( i, 0); // concentration in uM
72 }
73 return std::array<T,5>
74 { T{new std::ofstream("2-Cu.dat") , diftrimat(nr), Dcu, rCu , gslvec(nr
)}
75 , T{new std::ofstream("2-AB.dat") , diftrimat(nr), DAB, rAB , gslvec(nr
)}
76 , T{new std::ofstream("2-ABCu1.dat"), diftrimat(nr), DAB, rABCu1, gslvec(nr
)}
77 , T{new std::ofstream("2-ABCu2.dat"), diftrimat(nr), DAB, rABCu2, gslvec(nr
)}
78 , T{new std::ofstream("2-ABCu3.dat"), diftrimat(nr), DAB, rABCu3, gslvec(nr
)}
79 };
80 }
81
82 inline void reaction (std::array<T,5> & l , const size_t i , const double dt){
83 const double
84 Cu = l[0].r.get(i) , AB = l[1].r.get(i)
85 , ABCu1 = l[2].r.get(i) , ABCu2 = l[3].r.get(i)
86 , ABCu3 = l[4].r.get(i) ;
87
88 const double dCu = -ABCukon*AB*Cu + ABCukoff*ABCu1
89 + -ABCu13*ABCu1*Cu + ABCu32*ABCu3;
90 const double dAB = -ABCukon*AB*Cu + ABCukoff*ABCu1;
91 const double dABCu1 = ABCukon*AB*Cu - ABCukoff*ABCu1
254
92 + -ABCu13*ABCu1*Cu
93 + -ABCu12*ABCu1 + ABCu21*ABCu2;
94 const double dABCu2 = ABCu12*ABCu1 - ABCu21*ABCu2
95 + ABCu32*ABCu3;
96 const double dABCu3 = ABCu13*ABCu1*Cu - ABCu32*ABCu3;
97
98 l[0].r.set(i,Cu + dt * dCu );
99 l[1].r.set(i,AB + dt * dAB );
100 l[2].r.set(i,ABCu1 + dt * dABCu1);
101 l[3].r.set(i,ABCu2 + dt * dABCu2);
102 l[4].r.set(i,ABCu3 + dt * dABCu3);
103 }
104
105 inline void pulse (std::array<T,5> &, const double){}
106
107 #elif EXPT == 3 // Reaction of Zn with AB
108 std::array<T,3> makel(const int nr, const double dr){
109 gslvec rZn(nr), rAB(nr), rABZn(nr);
110
111 // Initial conditions
112 for (int i = 0; i <nr; ++i){// vesicle diameter = 40nm
113 const double r = i * dr;
114 rZn.set( i, ((20>r)? 300 : 0) ); // concentration in uM
115 rAB.set( i, 0.003); // concentration in uM
116 rABZn.set( i, 0); // concentration in uM
117 }
118 std::ofstream * fout = new std::ofstream("3-AB.dat");
119 fout->precision(8);
120 return std::array<T,3>
121 { T{new std::ofstream("3-Zn.dat") , diftrimat(nr), Dzn, rZn , gslvec(nr)
}
122 , T{fout , diftrimat(nr), DAB, rAB , gslvec(nr)
}
123 , T{new std::ofstream("3-ABZn.dat") , diftrimat(nr), DAB, rABZn, gslvec(nr)
}
124 };
125 }
126
127 inline void reaction (std::array<T,3> & l , const size_t i , const double dt){
128 const double Zn = l[0].r.get(i);
129 const double AB = l[1].r.get(i);
130 const double ABZn = l[2].r.get(i);
131
132 const double dZn = ABZnkoff*ABZn - ABZnkon*Zn*AB;
133 const double dAB = dZn;
134 const double dABZn = -dZn;
135
136 // negative concentrations start at 145839, 145053
137 // therfore using long double
138
139 l[0].r.set(i,defpos(Zn + dt * dZn ));
140 l[1].r.set(i,defpos(AB + dt * dAB ));
141 l[2].r.set(i,defpos(ABZn + dt * dABZn ));
142 }
143
144 inline void pulse (std::array<T,3> &, const double){}
145
146 #elif EXPT==4 // Reaction of AB.Cu with Cu
147 std::array<T,4> makel(const int nr, const double dr){
148 gslvec rCu(nr), rAB(nr), rABCu1(nr), rABCu2(nr),rABCu3(nr);
149
150 // Initial conditions
151 for (int i = 0; i <nr; ++i){// vesicle diameter = 40nm
152 const double r = i * dr;
153 rCu.set( i, ((20>r)? 30 : 0) ); // concentration in uM
154 rABCu1.set( i, 0.003*ABCu21/(ABCu12+ABCu21)); // concentration in uM
155 rABCu2.set( i, 0.003*ABCu12/(ABCu12+ABCu21)); // concentration in uM
156 rABCu3.set( i, 0); // concentration in uM
157 }
158 return std::array<T,4>
159 { T{new std::ofstream("4-Cu.dat") , diftrimat(nr), Dcu, rCu , gslvec(nr
)}
160 , T{new std::ofstream("4-ABCu1.dat"), diftrimat(nr), DAB, rABCu1, gslvec(nr
)}
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161 , T{new std::ofstream("4-ABCu2.dat"), diftrimat(nr), DAB, rABCu2, gslvec(nr
)}
162 , T{new std::ofstream("4-ABCu3.dat"), diftrimat(nr), DAB, rABCu3, gslvec(nr
)}
163 };
164 }
165
166 inline void reaction (std::array<T,4> & l , const size_t i , const double dt){
167 const double
168 Cu = l[0].r.get(i)
169 , ABCu1 = l[1].r.get(i) , ABCu2 = l[2].r.get(i)
170 , ABCu3 = l[3].r.get(i) ;
171
172 const double dCu = -ABCu13*ABCu1*Cu + ABCu32*ABCu3;
173 const double dABCu1 = -ABCu13*ABCu1*Cu
174 + -ABCu12*ABCu1 + ABCu21*ABCu2;
175 const double dABCu2 = ABCu12*ABCu1 - ABCu21*ABCu2
176 + ABCu32*ABCu3;
177 const double dABCu3 = ABCu13*ABCu1*Cu - ABCu32*ABCu3;
178
179 l[0].r.set(i,Cu + dt * dCu );
180 l[1].r.set(i,ABCu1 + dt * dABCu1);
181 l[2].r.set(i,ABCu2 + dt * dABCu2);
182 l[3].r.set(i,ABCu3 + dt * dABCu3);
183 }
184
185 inline void pulse (std::array<T,4> &, const double){}
186
187 #elif EXPT==5 // AB + Cu + HSA
188 std::array<T,7> makel(const int nr, const double dr){
189 gslvec rCu(nr),rAB(nr),rABCu1(nr),rABCu2(nr),rABCu3(nr),rHSA(nr),rHSACu(nr);
190
191 // Initial conditions
192 for (int i = 0; i <nr; ++i){// vesicle diameter = 40nm
193 const double r = i * dr;
194 rCu .set( i, ((20>r)? 30 : 0) ); // concentration in uM
195 rAB .set( i, 0.003); // concentration in uM
196 rABCu1.set( i, 0); // concentration in uM
197 rABCu2.set( i, 0); // concentration in uM
198 rABCu3.set( i, 0); // concentration in uM
199 rHSA .set( i, 5); // concentration in uM
200 rHSACu.set( i, 0); // concentration in uM
201 }
202 return std::array<T,7>
203 { T{new std::ofstream("5-Cu.dat") , diftrimat(nr), Dcu, rCu , gslvec(
nr)}
204 , T{new std::ofstream("5-AB.dat") , diftrimat(nr), DAB, rAB , gslvec(
nr)}
205 , T{new std::ofstream("5-ABCu1.dat"), diftrimat(nr), DAB, rABCu1, gslvec(
nr)}
206 , T{new std::ofstream("5-ABCu2.dat"), diftrimat(nr), DAB, rABCu2, gslvec(
nr)}
207 , T{new std::ofstream("5-ABCu3.dat"), diftrimat(nr), DAB, rABCu3, gslvec(
nr)}
208 , T{new std::ofstream("5-HSA.dat") , diftrimat(nr), DHSA, rHSA , gslvec(
nr)}
209 , T{new std::ofstream("5-HSACu.dat"), diftrimat(nr), DHSA, rHSACu, gslvec(
nr)}
210 };
211 }
212
213 inline void reaction (std::array<T,7> & l , const size_t i , const double dt){
214 const double
215 Cu = l[0].r.get(i) , AB = l[1].r.get(i)
216 , ABCu1 = l[2].r.get(i) , ABCu2 = l[3].r.get(i)
217 , ABCu3 = l[4].r.get(i) , HSA = l[5].r.get(i)
218 , HSACu = l[6].r.get(i);
219
220 const double dCu = -ABCukon*AB*Cu + ABCukoff*ABCu1
221 + -ABCu13*ABCu1*Cu + ABCu32*ABCu3
222 + -HSACukon*HSA*Cu;
223 const double dAB = -ABCukon*AB*Cu + ABCukoff*ABCu1;
224 const double dABCu1 = ABCukon*AB*Cu - ABCukoff*ABCu1
225 + -ABCu13*ABCu1*Cu
226 + -ABCu12*ABCu1 + ABCu21*ABCu2;
256
227 const double dABCu2 = ABCu12*ABCu1 - ABCu21*ABCu2
228 + ABCu32*ABCu3;
229 const double dABCu3 = ABCu13*ABCu1*Cu - ABCu32*ABCu3;
230 const double dHSA = -HSACukon*HSA*Cu;
231 const double dHSACu = +HSACukon*HSA*Cu;
232
233 l[0].r.set(i,defpos(Cu + dt * dCu ));
234 l[1].r.set(i,defpos(AB + dt * dAB ));
235 l[2].r.set(i,defpos(ABCu1 + dt * dABCu1));
236 l[3].r.set(i,defpos(ABCu2 + dt * dABCu2));
237 l[4].r.set(i,defpos(ABCu3 + dt * dABCu3));
238 l[5].r.set(i,defpos(HSA + dt * dHSA ));
239 l[6].r.set(i,defpos(HSACu + dt * dHSACu));
240 }
241
242 inline void pulse (std::array<T,7> &, const double){}
243
244 #elif EXPT == 6 // HSA + Cu
245 std::array<T,3> makel(const int nr, const double dr){
246 gslvec rCu(nr),rHSA(nr),rHSACu(nr);
247
248 // Initial conditions
249 for (int i = 0; i <nr; ++i){// vesicle diameter = 40nm
250 const double r = i * dr;
251 rCu .set( i, ((20>r)? 30 : 0) ); // concentration in uM
252 rHSA .set( i, 5); // concentration in uM
253 rHSACu.set( i, 0); // concentration in uM
254 }
255 return std::array<T,3>
256 { T{new std::ofstream("6-Cu.dat") , diftrimat(nr), Dcu, rCu , gslvec(
nr)}
257 , T{new std::ofstream("6-HSA.dat") , diftrimat(nr), DHSA, rHSA , gslvec(
nr)}
258 , T{new std::ofstream("6-HSACu.dat"), diftrimat(nr), DHSA, rHSACu, gslvec(
nr)}
259 };
260 }
261
262 inline void reaction (std::array<T,3> & l , const size_t i , const double dt){
263 const double Cu = l[0].r.get(i), HSA = l[1].r.get(i)
264 , HSACu = l[2].r.get(i);
265
266 const double dCu = -HSACukon*HSA*Cu;
267 const double dHSA = dCu;
268 const double dHSACu = -dCu;
269
270 l[0].r.set(i,defpos(Cu + dt * dCu ));
271 l[1].r.set(i,defpos(HSA + dt * dHSA ));
272 l[2].r.set(i,defpos(HSACu + dt * dHSACu));
273 }
274
275 inline void pulse (std::array<T,3> &, const double){}
276
277 #elif EXPT == 7
278 std::array<T,2> makel(const int nr, const double dr){
279 gslvec rZn(nr), rCu(nr);
280
281 // Initial conditions
282 for (int i = 0; i <nr; ++i){// vesicle diameter = 40nm
283 const double r = i * dr;
284 rZn.set( i, ((20>r)? 300: 0) ); // concentration in uM
285 rCu.set( i, ((20>r)? 30 : 0) ); // concentration in uM
286 }
287 return std::array<T,2>
288 { T{new std::ofstream("7-Zn.dat"), diftrimat(nr), Dzn, rZn, gslvec(nr)}
289 , T{new std::ofstream("7-Cu.dat"), diftrimat(nr), Dcu, rCu, gslvec(nr)}
290 };
291 }
292
293 inline void reaction (std::array<T,2> &, const size_t, const double){}
294
295 inline void pulse (std::array <T,2> & l, const double dr){
296 for (int i = 0; i*dr <300; ++i){// vesicle diameter = 40nm
297 l[0].r.set( i, 300); // concentration in uM
298 l[1].r.set( i, 30 ); // concentration in uM
257
299 }
300 }
301
302 #elif EXPT == 8 // pulse AB + Cu
303 std::array<T,5> makel(const int nr, const double dr){
304 gslvec rCu(nr), rAB(nr), rABCu1(nr), rABCu2(nr),rABCu3(nr);
305
306 // Initial conditions
307 for (int i = 0; i <nr; ++i){// vesicle diameter = 40nm
308 const double r = i * dr;
309 rCu.set( i, ((20>r)? 30 : 0) ); // concentration in uM
310 rAB.set( i, 0.003); // concentration in uM
311 rABCu1.set( i, 0); // concentration in uM
312 rABCu2.set( i, 0); // concentration in uM
313 rABCu3.set( i, 0); // concentration in uM
314 }
315 return std::array<T,5>
316 { T{new std::ofstream("8-Cu.dat") , diftrimat(nr), Dcu, rCu , gslvec(nr
)}
317 , T{new std::ofstream("8-AB.dat") , diftrimat(nr), DAB, rAB , gslvec(nr
)}
318 , T{new std::ofstream("8-ABCu1.dat"), diftrimat(nr), DAB, rABCu1, gslvec(nr
)}
319 , T{new std::ofstream("8-ABCu2.dat"), diftrimat(nr), DAB, rABCu2, gslvec(nr
)}
320 , T{new std::ofstream("8-ABCu3.dat"), diftrimat(nr), DAB, rABCu3, gslvec(nr
)}
321 };
322 }
323
324 inline void reaction (std::array<T,5> & l , const size_t i , const double dt){
325 const double
326 Cu = l[0].r.get(i) , AB = l[1].r.get(i)
327 , ABCu1 = l[2].r.get(i) , ABCu2 = l[3].r.get(i)
328 , ABCu3 = l[4].r.get(i) ;
329
330 const double dCu = -ABCukon*AB*Cu + ABCukoff*ABCu1
331 + -ABCu13*ABCu1*Cu + ABCu32*ABCu3;
332 const double dAB = -ABCukon*AB*Cu + ABCukoff*ABCu1;
333 const double dABCu1 = ABCukon*AB*Cu - ABCukoff*ABCu1
334 + -ABCu13*ABCu1*Cu
335 + -ABCu12*ABCu1 + ABCu21*ABCu2;
336 const double dABCu2 = ABCu12*ABCu1 - ABCu21*ABCu2
337 + ABCu32*ABCu3;
338 const double dABCu3 = ABCu13*ABCu1*Cu - ABCu32*ABCu3;
339
340 l[0].r.set(i,Cu + dt * dCu );
341 l[1].r.set(i,AB + dt * dAB );
342 l[2].r.set(i,ABCu1 + dt * dABCu1);
343 l[3].r.set(i,ABCu2 + dt * dABCu2);
344 l[4].r.set(i,ABCu3 + dt * dABCu3);
345 }
346
347 inline void pulse (std::array<T,5> & l, const double dr){
348 for (int i = 0; i*dr<20; ++i){// vesicle diameter = 40nm
349 l[0].r.set( i, 30); // concentration in uM
350 }
351 }
352
353
354 #else
355 #error "No experiment (EXPT) defined"
356 #endif
357
358 #endif
A.4.4 gslvec.h
1 #ifndef __gslvec__
2 #define __gslvec__
3
258
4 #include <gsl/gsl_vector.h>
5
6 class diftrimat;
7
8 class gslvec {
9 public:
10 gslvec(size_t n);
11 gslvec(gslvec&&);
12 gslvec(const gslvec&);
13 gslvec& operator=(gslvec&&);
14 ~gslvec();
15
16 gslvec& operator<<= (gslvec& a);
17 inline double get(const size_t& i){return gsl_vector_get(vec, i);}
18 inline void set(const size_t& i, const double& num){gsl_vector_set(vec, i, num
);}
19
20 friend void diftrimatsolve(diftrimat&, gslvec& in , gslvec& out);
21 private:
22 gsl_vector *vec;
23 };
24
25 #endif // __gslvec__
A.4.5 gslvec.cpp
1 #include <algorithm>
2
3 #include "gslvec.h"
4
5 using namespace std;
6
7 gslvec::gslvec(size_t n){
8 vec = gsl_vector_calloc(n);
9 }
10
11 gslvec::gslvec(gslvec && from){
12 vec = from.vec;
13 from.vec = 0;
14 }
15 gslvec& gslvec::operator=(gslvec&& from){
16 swap(vec, from.vec);
17 return *this;
18 }
19
20 gslvec::gslvec(const gslvec& from)
21 :gslvec(from.vec->size)
22 {
23 gsl_vector_memcpy(vec, from.vec);
24 }
25
26 gslvec::~gslvec(){
27 if(vec!= 0){
28 gsl_vector_free(vec);
29 }
30 }
31
32 gslvec& gslvec::operator<<= ( gslvec& b){
33 gsl_vector_free(vec);
34 vec = b.vec;
35 b.vec = 0;
36 return *this;
37 }
A.4.6 diftrimat.h
1 #ifndef __diftrimat__
2 #define __diftrimat__
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3
4 #include "gslvec.h"
5 #include "diftrimatsolve.h"
6
7 class diftrimat{
8 public:
9 diftrimat(size_t n);
10 diftrimat(size_t n, double D, double dr, double dt);
11 void operator()(double D, double dr, double dt);
12 friend void diftrimatsolve(diftrimat&, gslvec& in , gslvec& out);
13
14 private:
15 const size_t Size;
16 gslvec diag;
17 gslvec upper;
18 gslvec lower;
19 };
20
21
22 #endif //__diftrimat__
A.4.7 diftrimat.cpp
1 #include "diftrimat.h"
2
3 #include <cmath>
4 using namespace std;
5
6 diftrimat::diftrimat(size_t n): Size(n), diag(n), upper(n-1), lower(n-1){}
7
8 diftrimat::diftrimat(size_t n, double D, double dr, double dt)
9 : diftrimat(n){
10 operator()(D, dr, dt);
11 }
12
13 void diftrimat::operator()(double D, double dr, double dt){
14 const double diagelm = 1+2*dt*D/(dr*dr);
15 const double dr2 = dr*dr;
16
17 for(size_t i = 0; i != Size-1; ++i){
18 diag .set(i, diagelm);
19 lower.set(i, dt*D*( 1/(2*(i+1.5))-1) / dr2);
20 upper.set(i, dt*D*(-1/(2*(i+0.5))-1) / dr2);
21 }
22
23 diag.set(Size-1, diagelm);
24 lower.set(Size-2,-2*dt*D/dr2);
25 }
A.4.8 diftrimatsolve.h
1 #ifndef __diftrimatsolve__
2 #define __diftrimatsolve__
3
4 #include "gslvec.h"
5 #include "diftrimat.h"
6
7
8 void diftrimatsolve(diftrimat&, gslvec& in , gslvec& out);
9
10 #endif
A.4.9 diftrimatsolve.cpp
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1 #include "diftrimatsolve.h"
2
3 #include <gsl/gsl_linalg.h>
4
5 #include "diftrimat.h"
6 #include "gslvec.h"
7
8 void diftrimatsolve(diftrimat &trimat, gslvec &in, gslvec &out){
9 const int err =
10 gsl_linalg_solve_tridiag(
11 trimat.diag.vec,
12 trimat.upper.vec,
13 trimat.lower.vec,
14 in.vec,
15 out.vec
16 );
17 if (err != 0)
18 throw err;
19 else
20 return;
21 }
A.4.10 getr.hs
1 {-# LANGUAGE ScopedTypeVariables #-}
2 import Control.Applicative
3 import Data.List (elemIndex, transpose)
4 import Data.List.Split (splitOn)
5 import Data.Maybe
6 import Data.Traversable
7 import Control.Monad
8 import Prelude
9 import System.Environment (getArgs)
10
11 main :: IO()
12 main = do
13 file <- head <$> getArgs :: IO(String)
14 radii <- map read . tail <$> getArgs :: IO ([Double])
15
16 contents <- filter (/= [])
17 . map (map (map read)) . map (map words)
18 . splitOn [""]
19 . lines
20 <$> readFile file :: IO([[[Double]]])
21
22 let times = map head.head.transpose $ contents
23 let rs = map (!!1) . head $ contents
24 let wantrs= catMaybes . map (flip find' rs) $ radii
25 let getrs = [flip (!!)] <*> map snd wantrs
26 let vals = map (map (!!2))$ foreach getrs $ transpose contents
27 let ys = transpose $ times : vals
28
29 writeFile (file ++".r.dat") . (++) "#time "
30 . unlines . map (unwords . map show)
31 $ map fst wantrs : ys
32
33 find' :: Ord a => a -> [a] -> Maybe (a, Int)
34 find' _ [] = Nothing
35 find' x xs = sequenceT (e,join n)
36 where
37 e = listToMaybe . dropWhile (<x) $ xs
38 n = flip elemIndex xs <$> e
39
40 sequenceT :: (Maybe a, Maybe b) -> Maybe (a,b)
41 sequenceT (Just a, Just b) = Just (a,b)
42 sequenceT _ = Nothing
43
44 foreach :: [[a]->b] -> [a] -> [b]
45 foreach [] _ = []
46 foreach (f:fs) a = f a : foreach fs a
261
262
Appendix B
Other Information
This thesis∗ was written using LATEX using many LATEX packages (see source in
footnote). The graphs where generated using gnuplot. GNU Parallel was use to
parallelize the compilation of the gnuplot graphs, Zsh was used to locate files via
globbing, GNU Core Utils were used to edit strings in pipes.
B.1 Raw Data and Source Code for Listings
The raw data for each figure† may be accessed from within the pdf version of the
thesis by clicking the images. This requires a pdf reader that is capable of accessing
embeded files. When multiple files are attached to single image, they are bound in
a single file using tar, and then compressed using xz compression. The files can be
extracted using GNU Tar via ‘tar -xJf filename.tar.xz’, or equivalent utility.
The source code for each code listing is attached to the hyperlink in the footnote
of the section heading. All files in each section are compressed into a single file
using tar xz, as described above.
∗ Archive of partial source code:
†Excluding figures 6.9, 6.11 & 6.12, due to the file size of the raw data
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